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Abstract 
The lack of new drugs coming through to the market, to add to those few 
available, for use against diseases caused by trypanosomatids, calls for ways of 
safe-guarding the use of the current drugs to prolong their usefulness. This can 
be achieved by studying mechanisms of resistance to the drugs currently in use. 
In this thesis, the complementary use of untargeted metabolomic and whole 
genome sequence analyses was applied to elucidate the mechanisms of 
amphotericin B (AmB) resistance in L. mexicana promastigotes and 
isometamidium (ISMM) resistance in bloodstream forms of T. brucei. 
 
Resistance to AmB and ISMM was induced by step-wise increase of the drug 
concentration in the growth medium of L. mexicana promastigotes and 
bloodstream forms of T. brucei, respectively.  
 
Untargeted metabolomics results were used to link a single SNP in the lanosterol 
14α-demethylase (CYP51) gene of the sterol (ergosterol) biosynthetic pathway 
from a multitude of SNPs that were found in generated AmB resistant cells as 
compared to the parental wild-type cells. The identified SNP was found to be a 
non-synonymous mutation, causing the change N176I, outside the active sites of 
CYP51 and was accompanied by accumulation of the enzyme’s product, 4, 4-
dimethylcholesta-8, 14, 24-trien-3β-ol. These results suggested a break down in 
a possible protein-protein interaction of CYP51 with the next enzyme in the 
pathway, sterol C14-reductase, for efficient flow of the metabolite. Although 
the main subcellular localisation is different for these enzymes, they had a 
common localisation in the ER. AmB resistance was accompanied by depleted 
levels of ergosterol in AmB resistant cells. Expression of the wild-type CYP51 in 
AmB resistant cells restored ergosterol levels to those of the parental wild-type. 
Associated with restoration of ergosterol synthesis was reversal of resistance to 
AmB and susceptibility to pentamidine observed in AmB resistant cells. Thus 
N176I mutation in CYP51 underlies resistance to AmB in L. mexicana 
promastigotes.  
 
T. brucei resistance to isometamidium was accompanied by loss of the 
kinetoplast and maintenance of a much reduced mitochondrial membrane 
iii 
 
potential as compared to the parental wild-type cells. Reduction of the 
mitochondrial membrane potential was not connected to any apparent alteration 
of the energy metabolism of related metabolites. However, a perturbation in 
sphingolipid metabolism was observed to lead to depletion of sphingomyelin and 
accumulation of its precursor ceramide in the resistant cells. The responsible 
reaction enzyme, choline phosphorylceramide synthase (SLS4), was found to 
have 4 non-synonymous mutations which were outside the active site. The ISMM 
resistant cells exhibited a slow growth phenotype which has also been associated 
with perturbation of the sphingolipid synthesis pathway. ISMM resistant cells also 
showed cross resistance to diminazene aceturate and ethidium bromide used for 
control of African animal trypanosomiasis.   
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Chapter One 
1 General Introduction 
Kinetoplastid protozoa are characterised by the presence of a flagellum and a 
network of circular DNA organized as an organelle called the kinetoplast. They 
cause some of the most debilitating neglected diseases in humans and animals. 
The Leishmaniases caused by Leishmania species and trypanosomiases caused by 
Trypanosoma species, respectively, are examples of such diseases. These 
diseases are controlled primarily by chemotherapy although there are few 
effective drugs and there is no known vaccine. The shortage of drugs for treating 
these diseases and their well-known shortcomings inspired this study to assess 
possible ways of prolonging the use of two anti-kinetoplastid drugs by identifying 
molecular markers of resistance and the possible mechanisms, and how to 
circumvent resistance should it arise. 
 
1.1 African trypanosomiases 
African trypanosomiases are infectious diseases that affect both humans and 
animals and are caused by species of Trypanosoma. Two broad types of African 
trypanosomiasis can be distinguished based on the hosts of the causative agents. 
The type affecting humans as hosts is referred to as Human African 
Trypanosomiasis (HAT) also commonly called African sleeping sickness. The 
second type affects animals as hosts and is called African Animal 
Trypanosomiasis (AAT).  
 
1.1.1 Human African Trypanosomiasis 
HAT affects the populations of poor remote rural parts of Africa more than the 
urban or peri-urban area populations (Brun et al., 2010). Sleeping sickness 
occurs in about 36 sub-Saharan African countries (Figure 1.1), putting 60 million 
people at risk of contracting the disease (Fairlamb, 2003). The distributions of 
the diseases overlap with the distribution of the vector, the tsetse flies of the 
genus Glossina (Barrett et al., 2003). It was estimated that 300, 000 – 500, 000 
people were infected with the disease in the year 1998 while in 2001, 50, 000 
deaths were recorded (Barrett et al., 2003; Fairlamb, 2003). The disease 
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statistics have been thought to be underestimates because the disease occurs in 
the rural remote areas where not all cases can be diagnosed and hence 
unreported (Barrett et al., 2003). In recent years, incidence has declined to less 
than 10, 000 reported in 2011 (Simarro et al., 2011). HAT is caused by two 
distinct subspecies of Trypanosoma brucei or T. brucei, occurring in separate 
geographical foci of the African continent. In West and Central Africa, T. b. 
gambiense causes the chronic form of the disease while in east and southern 
Africa, the predominant T. b. rhodesiense causes the acute form of the disease 
(Figure 1.1). HAT is zoonotic with the humans acting as the main reservoirs of T. 
b. gambiense, while the major reservoirs of T. b. rhodesiense are wild and 
domestic animals, especially cattle (Brun et al., 2010; Simarro et al., 2008; 
Wilkinson and Kelly, 2009). 
 
 
Figure 1.1 Distribution of reported cases of Human African Trypanosomiasis. 
The two areas of the continent in which distribution of HAT caused by T. b. gambiense and 
T. b. rhodesiense is divided by the black line. Adapted from Simarro et al., 2008 with the 
Creative Commons Attribution License authorisation. 
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1.1.2 African Animal Trypanosomiasis 
African Animal Trypanosomiasis is endemic in 37 African countries where it is 
estimated that about 50 – 70 million animals are at risk from trypanosomiasis. 
AAT is common in domesticated animals. T. congolense, T. vivax and, to a lesser 
extent, T. b. brucei are the causative agents of the disease in domestic animals 
(Geerts et al., 2001). There have been reports of these three non-human 
pathogens causing trypanosomiasis in man (Brun et al., 2010). 
 
1.1.3 Burden (Economic) of African Animal trypanosomiases 
Human African trypanosomiasis and African Animal trypanosomiasis are a major 
cause of underdevelopment in the sub-Saharan rural areas (Brun et al., 2010; 
Welburn et al., 2006). AAT results in estimated annual economic losses of USA 
$1.340 billion (Kristjanson et al., 1999). Livestock, especially cattle, provide 
food, transport, manure and draught power, for the rural population. However, 
AAT has been reported to reduce animal numbers and those that survive are too 
weak and ill to provide even the basic of benefits (Welburn et al., 2006).This 
deprives people a way out of poverty by reducing what could have been realised 
from the sale of animal meat and other products. 
 
1.1.4 Trypanosomiases in Zambia 
Zambia is located at latitude 15° 0’ South and 30° 0’ East in the Southern 
African region (Figure 1.1). It lies in the common (tsetse) fly belt region covering 
Zambia, Zimbabwe, Mozambique and Malawi. The common fly belt is mostly 
centred in the eastern part of Zambia that is drained by the Zambezi and the 
Luangwa rivers (Figure 1.2). Within this belt, the highest tsetse densities are 
situated around the two river valleys. Glossina morsitans morsitans (Westwood) 
and Glossina pallidipes (Austen) are the most common species of tsetse fly in 
this region (Munang'andu et al., 2012). The proliferation of the tsetse in the 
river valleys seems to be supported by the conducive climate, the relative 
abundance and wide range of hosts from which the flies take blood meals. 
Despite various strategies aimed at tsetse fly control or elimination as well as 
wild animal conservation being put in place, dating as far back as the pre-
colonial era and on into the young Zambian nation, there seem to have been a 
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sustained infestation and confinement of the vector to the Luangwa and Zambezi 
valley. Eastern Zambia will continue to harbour trypanosomiases because of the 
close interactions between the vectors, the two hosts and the causative 
parasites (Munang'andu et al., 2012). To reduce these interactions the 
government of Zambia established national parks, around which are game 
management areas which act as buffer zones between wild-life and humans. 
Sustained tsetse fly infestation of parts of eastern Zambia could be the reason 
why the transmission foci of HAT have remained in this part of the country while 
it has since been reported to have disappeared from most parts of the country 
even in the absence of active control strategies (Figure 1.2). The disappearance 
of HAT has so far been attributed mostly to anthropogenic activities. HAT in 
Zambia is caused by T. b. rhodesiense and is zoonotic (Mwanakasale and 
Songolo, 2011). The first recorded case of HAT in Zambia was in 1908 when it 
was diagnosed in a European mineral explorer who travelled in the area 
prospecting for minerals (Stephens and Fantham, 1910). 
 
 
Figure 1.2 The distribution of tsetse flies in Eastern Zambia and occurrence of clinical HAT. 
Insert map shows the position of eastern Zambia. Adapted from Munang’andu et al., 2012 
with the Creative Commons Attribution License authorisation.  
 
5 
 
The main causative agent of AAT in Zambia is T. congolense while T. vivax is 
responsible for a few infections in cattle. Cattle are the most affected by AAT 
with a monthly risk of infection at 6% on the plateau area of eastern Zambia 
(Simukoko et al., 2007; Simukoko et al., 2011). The highest prevalence of AAT 
affecting cattle was in 1992 but varies from year to year, with 25, 000 animals 
reportedly affected in the Eastern province of Zambia for the period from 1988 
to 2008. The various intervention strategies instituted from then on has 
precipitated a decline in the prevalence of the disease. These strategies 
included use of isometamidium chloride every four months for prophylaxis and 
diminazene aceturate for the treatment of infected animals. This regimen is still 
in use for controlling the disease. Insecticide based techniques targeting the 
tsetse flies have also been used to control AAT (Mubamba et al., 2011). 
 
1.2 Life cycle of Trypanosoma brucei 
Trypanosomes undergo differentiation in two different hosts; namely mammals 
and tsetse flies. The two hosts present distinct environments with different 
nutrients available to the trypanosomes as a consequence the parasites assume 
different forms to adapt to the environment and this results in their having a 
complex life cycle (Figure 1.3). A bite of the mammalian host by an infected 
tsetse fly during a blood meal leads to delivery of metacyclic forms of 
trypanosomes. The metacyclic forms transform into the replicative long slender 
trypomastigotes or bloodstream forms, which multiply by binary fission with a 
doubling time of about six hours (Vickerman, 1985). The long slender 
trypomastigotes express variant surface glycoproteins (VSG) on their surface. 
The VSGs are recognised by the host (mammal) immune system which leads to 
production of IgM and IgG antibodies that neutralise the trypanosomes. This 
results in a reduction in parasitaemia. The surviving trypanosomes, however, 
avoid the host immune response against them by producing different VSGs from 
the ones that were initially recognised leading to an increase in parasitaemia. 
The long slender trypomastigotes then transform into non - dividing stumpy 
trypomastigotes which have altered their biochemical physiology as a pre-
adaptation for the tsetse fly (Vickerman, 1985).  
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Figure 1.3 The life cycle of African trypanosomes.  
(Source; Blum, et al., 2008). 
 
The next bite of an infected mammal by the tsetse fly leads to transmission of 
the stumpy trypomastigotes, which are able to continue the life cycle in the 
vector. When the infected blood is ingested by the tsetse fly and upon reaching 
the lumen of the midgut, the stumpy trypanosomes transform into the procyclic 
trypanosomes (Vickerman, 1985). The procyclic trypanosomes increase in body 
length and the mitochondrion becomes more elaborate. The procyclic forms 
transform into the proliferative epimatigotes in the salivary glands. The 
epimastigotes transform into the non-proliferative metacyclics that are ready for 
injection into the mammals at the next infected tsetse fly blood meal 
(Vickerman, 1985; Wheeler, 2010). 
 
1.2.1 Cellular organization - Glycosome, mitochondrion, 
kinetoplast 
Trypanosomes are single celled organisms measuring 15 to 30 µm in length and 
possess a flagellum (Brun et al., 2010) which is involved in several cell processes 
including cell motility, cytokinesis, cell morphogenesis, host immune evasion and 
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host cell attachment in T. brucei (Ralston and Hill, 2008). They are obligate 
parasites with a eukaryotic cellular organization (Figure 1.4). However, some of 
their organelles possess unique features compared to those of the other 
eukaryotes (Brun et al., 2010). 
 
 
Figure 1.4 Schematic representation of the organisation of major organelles of bloodstream 
form of Trypanosoma brucei. 
Adapted from http://www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad88/Trypanosomiasis.htm 
 
Trypanosomes possess a single large mitochondrion spanning the entire cell 
length. The mitochondria assume different forms at different stages of the 
trypanosomes’ life cycle. It changes from the simple tubular form in the 
bloodstream forms to a branched network having prominent well developed 
discoid or plate-like cristae in the procyclic forms (Opperdoes, 1987; Vickerman, 
1985). The mitochondrion contains DNA called kinetoplast DNA. It forms a disk-
like structure in the mitochondrial matrix and is located adjacent to the 
flagellum basal body (Simpson, 1987). kDNA is a network of DNA circles called 
minicircles and maxicircles (Shapiro and Englund, 1995). The minicircles encode 
small guide RNA (gRNA) that are used for editing transcripts of the maxicircles in 
a process that involves insertion or deletion of uridine residues to form 
functional mRNAs (Aphasizhev and Aphasizheva, 2011). The maxicircles of T. 
brucei are the equivalents of the mitochondrial genome in other eukaryotic cells 
and encode the ribosomal RNA namely the 9S and 12S subunit genes and a 
ribosomal protein called RPS12. The maxicircle genes also encode subunits or 
protein subunits of the electron transport chain and these include the ATPase A6 
8 
 
subunit, six subunits of complex I, apocytochrome b of complex III and three 
subunits of complex IV (Schnaufer et al., 2002). 
  
The cytoplasm contains many spherical or ellipsoidal peroxisome-like organelles 
called glycosomes. There is an average of 230 glycosomes per cell, each of which 
is bound by a single membrane and they occupy about 4.3% of the total cell 
volume in T. brucei (Opperdoes et al., 1984). They contain most of the 
glycolytic enzymes which earned peroxisomes in these protozoa the name, 
glycosomes (Opperdoes and Borst, 1977). Glycosomes change in shape from 
being spherical to a bacilliform or rod-shaped organelles as the trypanosome 
transforms from bloodstream forms into procyclic forms (Vickerman, 1985). 
 
1.2.2 Energy metabolism in T. b. brucei 
The complexity of the life cycle of the T. brucei parasites makes them adopt 
different metabolic patterns at different stages of their life cycles as their 
differentiation alternates between the blood stream forms and the procyclic 
forms. This is due to the different carbon sources found in the two hosts 
(Bringaud et al., 2006; van Hellemond et al., 2005a).  
 
The bloodstream form trypanosome has the simplest energy metabolism which is 
based on glycolysis because of the high concentration of glucose (5 mM) in the 
vertebrate hosts, as compared to the procyclic form. The procyclic forms 
depend on amino acid catabolism, in particular L-proline, which is among the 
prominent constituents of insect’s hemolymph and tissue fluids, and L-threonine 
(Bringaud et al., 2006) which is the main carbon source in the fatty acid and 
sterol biosynthetic pathways (Millerioux et al., 2013). The prominence of proline 
in the insect is due to the fact that it is used by tsetse flies as an energy source 
for flight (Vickerman, 1985). However, procyclic forms of T. brucei, 
preferentially use glucose when both glucose and amino acids are available, but 
use proline in glucose diminished environments (Lamour et al., 2005). 
 
1.2.2.1 The Glycolytic pathway 
Carbohydrate energy metabolism in trypanosomes is said to be 
compartmentalised as it occurs in the glycosome, the cytosol and the 
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mitochondrion (Opperdoes, 1987). In procyclic forms of T. brucei the first seven 
reactions of the glycolytic pathway, converting glucose to 3-phosphoglycerate, 
occur in the glycosome. The last three of the ten classical glycolytic reactions, 
involving conversion of 3-phosphoglycerate into pyruvate, take place in the 
cytosol (van Hellemond et al., 2005a). Part of the phosphoenolpyruvate 
produced in these last three reactions is imported from the cytosol into the 
glycosome and subsequently metabolized in four reactions to succinate (Figure 
1.4) (Besteiro et al., 2005). The remaining phosphoenolpyruvate, in the cytosol, 
is converted to the end-product of glycolysis, pyruvate. 
 
In bloodstream forms of T. brucei, glucose is classically believed to be 
catabolised as far as pyruvate which is secreted from the cell (Besteiro et al., 
2005; van Hellemond et al., 2005a). However, recently it has become clear that 
a more extensive metabolism of glucose occurs in bloodstream forms 
(Kerkhoven, 2013 - In Press). Although the primary flux does end in pyruvate, 
many of the pathways present in procyclic forms also occur in bloodstream forms 
(Creek and Barrett, Unpublished). Indeed it has also been shown that glucose is 
also catabolised to acetate. Acetate derived from glucose catabolism and that 
from threonine is said to be essential for cell viability and is used for fatty acid 
synthesis by the bloodstream forms of T. brucei (Mazet et al., 2013). 
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Figure 1.5 Trypanosoma brucei procyclic form energy metabolism. 
Representation of parasite grown in an environment with an abundance of glucose. 
Glucose, proline and threonine catabolism excreted end products are shown with a grey 
background. Reactions with uncertain occurrence under standard growth conditions are 
indicated by dashed arrows. Occurrence of succinate fermentation pathways in the 
glycosome and mitochondria are shadowed. Substrate level phosphorylation and oxidative 
phosphorylation ATP yield are boxed and circled, respectively. 1,3BPGA = 1,3-
bisphosphoglycerate; c = cytochrome c; CIT = citrate ;DHAP = dihydroxyacetone 
phosphate; e
-
 = electrons; FBP = fructose 1,6-bisphosphate; G3P = glycerol-3-phosphate; 
GAP = glyceraldehyde-3-phosphate; Fd = ferredoxin; FUM = fumarate; GLUT = glutamate; 
ISC = isocitrate ; KET = 2-ketoglutarate ; MAL = malate; MCoA = methylmalonyl-CoA; OAA = 
oxaloacetate; PCoA = propionyl-CoA; PEP = phosphoenolpyruvate; PPi = inorganic 
pyrophosphate; PYR = pyruvate; SCoA = succinyl-CoA; SUC = succinate. Numbered 
enzymes are: 1 = hexokinase: 2 = glucose-6-phosphate isomerase; 3a = ATP-dependent 
phosphofructokinase (ATP-PFK); 3b = PPi-dependent phosphofructokinase (PPi-PFK); 4 = 
aldolase; 5 = triose-phosphate isomerase; 6 = glycerol-3-phosphate dehydrogenase; 7a = 
glycerol-3-phosphatase; 7b = glycerol kinase; 8 = glyceraldehyde-3-phosphate 
dehydrogenase; 9 = phosphoglycerate kinase; 10 = phosphoglycerate mutase; 11 = enolase; 
12a = pyruvate kinase (PYK); 12b = pyruvate phosphate dikinase (PPDK); 13a = 
phosphoenolpyruvate carboxykinase (PEPCK); 13b = phosphoenolpyruvate 
carboxytransphosphorylase; 14 = malate dehydrogenase; 15a = malic enzyme; 15b = malate 
dehydrogenase (decarboxylating) ; 16a = pyruvate:ferredoxin oxidoreductase; 16b = 
pyruvate dehydrogenase complex; 17 = ferredoxin:NAD oxidoreductase; 18 = hydrogenase; 
19a = Acetyl-CoA synthetase ‘ADP forming’ (‘ADP forming’ AceCS); 19b = acetate:succinate 
CoA-transferase (ASCT); 20 = succinyl-CoA synthetase (SCoAS); 21 = unknown enzyme; 22 
= bifunctional acetyl-CoA reductase/alcohol dehydrogenase; 23a = lactate dehydrogenase; 
11 
 
23b = unknown enzyme; 24 = fumarase, 25a, membrane-bound fumarate reductase (FRD); 
25b = NADH-dependent fumarate reductase (NADH-FRD); 26 = propionate:succinate CoA-
transferase; 27 = methylmalonyl-CoA mutase; 28 = methylmalonyl-CoA racemase; 29 = 
propionyl-CoA carboxylase; 30 = citrate synthase; 31 = aconitase; 32 = citrate lyase; 33 = 
isocitrate dehydrogenase; 34 = acetyl-CoA synthetase ‘AMP forming’ (‘AMP forming’ 
AceCS); 35 = L-proline dehydrogenase; 36 = pyrroline-5 carboxylate dehydrogenase; 37 = 
alanine aminotransferase; 38 = 2-ketoglutarate dehydrogenase complex; 39 = L-threonine 
dehydrogenase; 40 = acetyl-CoA:glycine C-acetyltransferase; 41a = rotenone-sensitive 
NADH dehydrogenase (complex I of the respiratory chain); 41b = rotenone-insensitive NADH 
dehydrogenase; 42 = FAD-dependent glycerol-3-phosphate dehydrogenase (FAD-GPDH); 
43a = rhodoquinone, such as menaquinone; 43b = ubiquinone; 44 = SHAM-sensitive 
alternative oxidase; 45 = complex III of the respiratory chain; 46 = complex IV of the 
respiratory chain; 47 = F0F1-ATP synthase. (Source: Bringaud, et al., 2010) 
 
The glycolytic pathway in trypanosomes is regulated by the compartmentation of 
the glycolytic pathway to the glycosomes instead of by the typical allosteric 
regulation of enzymes as is in mammals and many other species (Haanstra et al., 
2008; Tielens and van Hellemond, 2009). 
  
1.2.2.2 The Kreb’s Cycle 
The fate of pyruvate under certain conditions is different in different species of 
trypanosomes. It is converted to L-lactate instead of D-lactate anaerobically in 
T. b. gambiense procyclic forms by an unknown enzyme (Darling et al., 1988). 
The procyclic forms of T. brucei do not excrete pyruvate but take it up into the 
mitochondrion where it is further degraded by pyruvate dehydrogenase to 
acetyl-CoA. Acetyl-CoA is not degraded in the usual way of the Kreb's cycle but 
into acetate. The conversion of acetyl-CoA to acetate is catalysed by 
acetate:succinate transferase which transfers the CoA from acetyl-CoA to 
succinate to yield succinyl-CoA which is converted back to succinate by succinyl-
CoA synthetase to produce ATP (van Hellemond et al., 2005a). The combined 
action of succinyl-CoA synthetase and acetyl CoA thioesterase results in acetate 
being produced and excreted to the cytosol (Bringaud et al., 2010; van 
Hellemond et al., 2005a). As a result procyclics do not use a complete Kreb’s 
cycle to generate energy (van Grinsven et al., 2009; van Hellemond et al., 
2005a; van Weelden et al., 2003). This happens despite all the Kreb's cycle 
enzyme genes being present in the genome and are expressed in the procyclic 
forms of T. brucei (Tielens and van Hellemond, 2009). The acetate formed in the 
mitochondrion is also exported to the cytosol where the essential cytosolic 
acetyl-CoA synthetase converts it into acetyl-CoA which is used in the 
biosynthesis of lipids (Riviere et al., 2009). 
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A part of the Krebs cycle is used when proline happens to be the main carbon 
source for the procyclics and is degraded to succinate as the major end product 
through α – ketoglutarate (van Weelden et al., 2005). The first two reactions of 
the cycle have been assumed to be involved in metabolism in the wild-type 
strains of procyclic T. brucei as was shown in the accumulation of citrate in 
aconitase knockout procyclic T. brucei (van Weelden et al., 2003). The presence 
of the Krebs cycle enzymes in the mitochondrion of these parasites led to the 
interpretation that the Krebs cycle may have a role to play in energy generation 
or metabolism of the parasite’s life cycle stages in the salivary glands of the 
tsetse fly (van Weelden et al., 2003). The phosphoenolpyruvate produced from 
the glycolytic pathway can be re-exported back into the glycosomes where it is 
converted to malate through oxaloacetate. The malate may also be exported to 
the mitochondrion where it is converted through fumarate to succinate in a 
similar reaction to the one which occurs in the glycosome. This conversion is 
believed to be part of the Krebs cycle that is utilised by the procyclic forms of T. 
brucei (Figure 1.5). In the glycosome and mitochondrion the produced succinate 
is excreted (Tielens and van Hellemond, 2009). The bloodstream forms of T. 
brucei lack most of the Kreb's cycle enzymes (van Hellemond et al., 2005a).  
 
1.2.2.3 The Electron Transport Chain 
The procyclic forms of T. brucei have a fully functional branched electron-
transport chain (van Hellemond et al., 2005a; van Hellemond et al., 2005b). The 
flow of electrons in complex I, complex III and complex IV leads to translocation 
of protons from the mitochondrial matrix into the mitochondrial intermembrane 
space thereby producing a proton gradient that leads to generation of a proton 
motive force (van Hellemond et al., 2005b). The proton motive force is used for 
generating ATP by ATP synthase or ATPase. Oxygen is the final acceptor of the 
electrons leading to the formation of water (van Hellemond et al., 2005b). The 
proton gradient is responsible for the generation of the mitochondrial membrane 
potential which in turn is also important in the importation of proteins and key 
metabolites from the cytosol into the mitochondrion (Besteiro et al., 2005; 
Jensen et al., 2008). Therefore, both substrate-level and oxidative 
phosphorylation contribute to ATP generation in procyclic trypanosomes. ATP 
generation by oxidative phosphorylation is essential in the presence of lower 
concentrations of glucose when metabolism shifts to use of amino acids while 
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generation of ATP by substrate-level phosphorylation dominates in the presence 
of high concentrations of glucose (Besteiro et al., 2005; Bringaud et al., 2010). 
However, ATP generation by oxidative phosphorylation in procyclic T. brucei was 
shown not to be essential while ATP generation through substrate level 
phoshorylation in the cytosol was indicated to be essential (Coustou et al., 
2003). 
 
The branching of the electron transport chain of procyclic T. brucei (Figure 1.5) 
is due to the presence of the plant like alternative oxidase (AOX) (van 
Hellemond et al., 2005b). The plant like alternative oxidase is sometimes 
referred to, in bloodstream forms of the African trypanosomes, as trypanosome 
alternative oxidase (TAO) and its activity is maintained at relatively low levels in 
procyclic T. brucei. The flow of electrons obtained from the oxidation of the 
reduced ubiquinol pool through the plant-like alternative oxidase does not result 
in ATP synthesis. The AOX has been assumed to be involved in control of proton 
gradient generation as a means of regulating oxidative phosphorylation or as a 
reduction-oxidation dissipating system for trypanosomes (Bringaud et al., 2006). 
The trypanosomal alternative oxidase in the procyclic form of trypanosomes 
seems to help the parasites tolerate the non-constant supply of oxygen and 
nutrients in the insect’s alimentary canal and salivary glands (Chaudhuri et al., 
2006). 
 
The bloodstream forms of the T. brucei family and T. evansi have a relatively 
simple mitochondrion. Among other things they have a glycerol-3-phosphate 
dehydrogense, ubiquinol pool and a plant-like alternative oxidase but lack the 
cytochromes and hence the full complement electron transport chain (van 
Hellemond et al., 2005a). Electrons from glycosomal NADH are transported to 
the mitochondria by the glycerol-3-phosphate/dihydroxyacetone phosphate 
shuttle where the electrons are donated to the ubiquinone/ubiquinol pool 
through the FAD-linked glycerol-3-phosphate dehydrogenase. The plant-like 
alternative oxidase is the final acceptor of the electrons from the reduced 
ubiquinol. This flow of electrons does not result in ATP synthesis as no proton 
translocation is involved although the mitochondrion contains the F0F1-H
+-ATPase 
which is expressed at lower levels than in the procyclic forms (van Hellemond et 
al., 2005a). The F0F1-H
+-ATPase is used for the generation of the mitochindrial 
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membrane potential through its reverse function of ATP breakdown and leads to 
translocation of protons (Brown et al., 2006). The mitochondria of bloodstream 
forms of T. brucei also contain the subunits of NADH dehydrogenase or complex I 
which are assembled into α and β sub-complexes, although the complex has 
been found not to be important for the bloodstream stages of T. brucei (Surve et 
al., 2012). 
 
The main excretory products of glucose metabolism in procyclic T. brucei are 
acetate and succinate, while those of L-proline and threonine metabolism are 
succinate/alanine and acetate, respectively (Bringaud et al., 2010). This kind of 
metabolism where substrates are partially oxidised to fermentation products like 
acetate and succinate which are excreted with oxygen acting as the final 
electron acceptor during oxidation of NADH in the electron transport chain is 
referred to as aerobic fermentation. This process in procyclics of T. brucei is 
accompanied by oxidative phosphorylation (Cazzulo, 1992; Tielens and van 
Hellemond, 2009). 
 
The procyclic forms of T. brucei maintain a redox and ATP balance in their 
glycosomes through re-oxidation of the generated NADH into NAD+ (Bringaud et 
al., 2006; van Hellemond et al., 2005a). The wild-type procyclic T. brucei 
glycosomal redox balance is adequately maintained by glycosomal succinate 
fermentation alone. The glycosomal succinate fermentation involves the 
conversion of phosphoenolpyruvate imported from the cytosol through 
oxaloacetate, malate and fumarate to succinate. Alternatively, the redox 
balance can be maintained by either the glycerol-3-phosphate/dihydroxyacetone 
phosphate shuttle or down-regulation of glucose metabolism or switch the 
energy metabolism to that of proline as the main substrate (Ebikeme et al., 
2010). This ability of procyclic T. brucei to easily shift its energy metabolism is 
assumed to allow for adaptation to rapid environmental changes in nutrient 
supply (Bringaud et al., 2006; Ebikeme et al., 2010). 
  
The degradation of glucose and/or glycerol, and amino acids like proline leads to 
generation of large amounts of reducing equivalents namely FADH2 and NADH + 
H+ in procyclic T. brucei mitochondria. These reducing equivalents are further 
metabolized in the electron transport chain, highlighting the importance and 
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ultimately the essentiality of the electron transport chain to the parasites’ 
energy metabolism (Coustou et al., 2003; Tielens and van Hellemond, 2009; van 
Weelden et al., 2003; van Weelden et al., 2005). The essentiality of the 
respiratory chain in procyclic forms of T. brucei was demonstrated by the 
simultaneous inhibition of both complex IV and plant like alternative oxidase 
with potassium cyanide (KCN) and Salicylhydroxamic acid (SHAM) respectively, 
which led to the rapid death of the procyclic T. brucei cells (Coustou et al., 
2003; van Weelden et al., 2003). 
 
1.3 Leishmaniasis 
The Leishmaniases are a complex of diseases caused by intracellular 
trypanosomatid protozoa parasites called Leishmania. Over 21 species of 
Leishmania cause the diseases (Ouellette et al., 2004). The diseases occur in 
various forms depending on the clinical symptom presentations. The three main 
forms of the diseases are cutaneous, mucocutaneous and visceral leishmaniasis. 
The cutaneous form is caused by L. braziliensis, L. major, L. guyanensis, L. 
tropica, L. panamensis, L. aethiopica, L. mexicana, L. amazonensis, L. 
donovani, L. aethiopica, L. pifanoi and L. infantum in various geographical 
regions, presents with ulcers on the exposed parts of the body. While the lesions 
in the mucocutaneous form affect the mucous membranes of the throat, nose 
and the mouth which may lead to partial or total destruction of the tissues of 
the affected part of the body. It is caused by L. braziliensis and L. panamensis. 
Visceral leishmaniasis affects the organs like the liver and spleen and may lead 
to their swelling and can be fatal if left untreated (Grevelink and Lerner, 1996). 
The other characteristics of visceral leishmaniasis are irregular fevers and 
weight loss. It is caused by L. donovani, L. infantum and L. tropica and each of 
these causes the disease in different parts of the world (http://www.who.int/ 
leishmaniasis/disease_epidemiology/en/). 
 
1.3.1 Distribution of the Leishmaniases 
The Leishmaniases are endemic in 98 countries covering five continents putting 
350 million people at risk of contracting the diseases (Figure1.6). The estimated 
incidences of new cases of visceral and cutaneous leishmaniases stand at 0.5 and 
1.5 million, respectively, per annum. Visceral leishmaniasis is known to cause an 
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estimated 50, 000 deaths annually. Leishmaniasis is an opportunistic infection in 
HIV positive individuals. The severity of the leishmaniases is enhanced by co-
infection with HIV and management of such infections are difficult (WHO, 2010). 
Visceral leishmaniasis occurs more often in the co-infections with HIV than the 
other forms of leishmaniasis. Leishmaniasis co-infection with HIV was reported in 
35 countries by 2010 (WHO, 2010). The increased infections of HIV and its spread 
into rural areas has led to increased transmission and spread of leishmaniasis 
into the urban areas resulting in geographical overlap of the two diseases (WHO, 
2010). 
 
 
Figure 1.6 Global distribution of leishmaniasis and Leishmania/HIV co-infection, 1990-1998. 
(http://www.who.int/csr/resources/publications/CSR_ISR_2000_1leish/en/) 
 
1.3.2 Life cycle of Leishmania 
The life cycle of Leishmania species is complex (Figure 1.7). Like that of the 
other trypanosomatids, it involves vertebrate and invertebrate hosts. In the 
vertebrate hosts they exist as intracellular parasites while in the invertebrate 
they exist as extracellular organisms. The invertebrate hosts are sand flies of 
two important genera, Phlebotomus found in the new world and Lutzomya which 
occur in the old world (Banuls et al., 2007). The cycle starts with the bite of an 
infected female sand fly that needs the blood meal for egg development. During 
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feeding the metacyclic promastigotes are deposited into the mammal through 
the skin. The metacyclic promastigotes have small slender bodies and possess  
 
 
Figure 1.7 Life cycle of leishmania in mammals and sandfly.  
(Source: Handman, 2001). 
 
 
long free flagella. The presence of the flagella makes these cells very motile. 
The promastigotes are then taken up by macrophages through phagocytosis and 
they metamorphose into amastigotes. The amastigotes reside within the 
parasitophorous vacuole of macrophages of the host. The amastigotes are ovoid 
in shape with a diameter of about 2.5 – 5 µm. They do not possess free flagella 
and therefore they are not motile. The amastigotes divide by binary fission and 
as they increase in number this leads to rupture of the infected macrophage and 
resulting in release of the amastigotes that infect neighbouring macrophages 
(Banuls et al., 2007). The amastigotes are transported to the draining lymph 
nodes from the site of bite by the dendritic cells (Moll et al., 1993). A bite of 
the infected vertebrate by the sand fly during a blood meal leads to taking up of 
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macrophages infected with amastigotes. These amastigotes transform into 
procyclic promastigotes in the sand fly’s intestines. Cultured late log phase 
promastigotes have an average body length of 15.22 ± 3.49 µm (Bates, 1994). 
The division of the procyclic promastigotes is rapid resulting in their increased 
numbers. Procyclic promastigotes mature and differentiate into metacyclic 
promastigotes (Banuls et al., 2007). The bite of a mammal by an infected sand 
fly leads to delivery of the metacyclic promastigotes thereby completing and 
starting the life cycle. 
 
1.4 Biochemistry of Leishmania 
Leishmania species are known to have the most extensive metabolic network 
compared to trypanosomes and enzymes of the major metabolic pathways are 
known to be encoded by about 400 genes (Opperdoes and Coombs, 2007). The 
digenetic life cycle involving two different hosts have made the Leishmania 
species develop means and ways of adapting to the two environments. The two 
hosts provide environment with different nutrients. As a result, the biochemistry 
of leishmania species is influenced by not only how these parasites acquire the 
nutrients but also how they compete for the nutrients with the host (Burchmore 
and Barrett, 2001; Landfear, 2000). Leishmania use surface membrane protein 
transporters to take up the nutrients and to compete for these nutrients, usually 
each transporter is able to transport more than one substrate. Thus, the three 
glucose transporters of L. mexicana have an overlapping transportation of 
mannose, glucose, galactose, fructose and ribose (Naula et al., 2010; Rodriguez-
Contreras et al., 2007).  
 
Leishmania energy metabolism is similar to that of T. brucei (section 1.2.2). 
However, there are differences between the two. Leishmania promastigotes are 
able to utilise disaccharides and plant starch found in nectar which is fed on by 
sand flies, as sources of glucose. Excess glucose, as glucose 6-phosphate, is 
converted to a potential energy store mannogen although its utilisation is not 
well understood (Opperdoes and Coombs, 2007; Saunders et al., 2010). All the 
Kreb’s cycle enzymes are present but it is not known whether the cycle proceeds 
as a cyclic pathway. Generally there is no difference in the expression of central 
carbon metabolism enzymes at various stages of the life cycle of Leishmania 
(Saunders et al., 2010). The presence of a full-complement electron transport 
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chain which is functional throughout the life cycle is without the alternative 
oxidase (Opperdoes and Coombs, 2007; Saunders et al., 2010). While inhibition 
of the electron transport chain leads to cell death in T. brucei, it only leads to 
reversible effects on metabolism in Leishmania (Opperdoes and Coombs, 2007).  
Gluconeogenesis is operational in Leishmania and derives its carbon skeleton 
mostly from the amino acids. Regulatory mechanisms of gluconeogenesis which 
are supposed to prevent futile operation of the glycolytic pathway are not 
known (Saunders et al., 2010). 
 
Leishmania parasites do not have a de novo purine synthesizing mechanism, 
therefore they rely on the host for purine substrates for their purine salvage 
pathway, making the pathway a probable drug target (Carter et al., 2008; 
Landfear et al., 2004). The pyrimidine biosynthesis of Leishmania proceeds as in 
the mammalian cells and as a result it has always been thought to be a less 
likely target for drugs (Carter et al., 2008). This view about the pathway is likely 
to change as it has been shown to be essential to promastigotes and together 
with the pyrimidine salvage pathway contribute to an effective amastigote 
infectivity of the mammalian cells (Wilson et al., 2012). Leishmania use 
nucleoside transporters to acquire purine substrates. Although the L. donovani 
nucleoside transporters do not have a broad and overlapping specificity for their 
substrate, each is able to transport more than one substrate. The high affinity 
nucleoside transporters, LdNT1 transports adenosine, uridine, thymidine and 
cytidine, and LdNT2 transports inosine and guanosine (Aronow et al., 1987). Two 
more nucleobase transporters exist in L. major and these are high affinity NT3 
and low affinity NT4 whose substrates are xanthine, hypoxanthine, adenine and 
guanine, and adenine, respectively (Ortiz et al., 2007; Sanchez et al., 2004). 
These transporters actively transport their substrates into the cells and they are 
known to be concentrative transporters that help the parasites accumulate 
substrates in competition with the host cells. The challenge posed by the 
difference in pH between the parasites' environments in terms of nutrient 
acquisition is overcome by having transporters which function optimally at given 
pH points. For example, L. major NT4 functions optimally at acidic pH and 
therefore suited to function in amastigotes that reside in macrophages’ acidic 
parasitophorous vacuoles while NT3 optimal pH is neutral and is thought to be 
suited for transportation of substrates in the promastigotes (Ortiz et al., 2009). 
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Polyamine transporters have been reported in L. donovani, L. mexicana and L. 
major. These are the putrescine and spermidine transporters and are high 
affinity transporters that function at neutral and acidic optimal pH for 
promastigotes and amastigotes, respectively (Basselin et al., 2000; Hasne and 
Ullman, 2005). Spermidine and putrescine transported across the membrane by 
these transporters serve as the salvage source of these metabolites. However, 
Leishmania parasites have a fully functional polyamine biosynthetic pathway 
which provides for the cell’s polyamine requirements (Colotti and Ilari, 2011). 
One important function of the polyamine pathway to the parasites is the 
generation of trypanothione, a molecule which is unique to Leishmania and 
trypanosomes and therefore is regarded as a possible drug target (Fairlamb et 
al., 1985). Trypanothione functions in the cell are equivalent to those of 
glutathione in other eukaryotic cells although trypanothione is more reactive 
hence more efficient than glutathione. Apart from functioning as a reductant in 
the cells trypanothione is more efficient at nitric oxide neutralisation than 
glutathione (Bocedi et al., 2010; Krauth-Siegel et al., 2003).  
 
1.4.1 Sterol biosynthesis 
Sterols are constituents of the cell membrane where they render a structural 
function, contribute to membrane fluidity and permeability, and exert an 
indirect influence on the functionality of integral membrane proteins like 
enzymes and ion channels. They also play a role in cell cycle regulation 
(Dufourc, 2008; Lepesheva and Waterman, 2007; Roberts et al., 2003). Sterol 
synthesis and composition of Leishmania species is similar to that of fungi 
because Leishmania sterols are dominated by the ergostane (C28) sterols 
including ergosterol and ergosterol-like sterols that are typical sterols of fungi 
(Berman, 1988). This has been supported by the sensitivity of Leishmania species 
to antifungal drugs that target the sterol biosynthetic pathway (Roberts et al., 
2003). Sterols, sterol esters and triacylglycerols make up about 14 – 55% of the 2 
– 5% total lipids of dry weight of Leishmania promastigotes (Berman, 1988). The 
major sterol of Leishmania promastigotes and amastigotes is ergosta-5,7,24 (28)-
trien-3-ol and makes up about 85% of the total sterols in L. mexicana (Al-
Mohammed et al., 2005) while ergosta-5,7,22-trien-3-ol or ergosterol the major 
sterol of fungi, occurs in smaller amounts. Leishmania promastigotes contain 
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about 5% stigmastane (C29) related sterols of the total sterols. For example 
stimasta-5, 7, 24(28)-trien-3β-ol is present in small amounts in promastigotes. 
Amastigotes of some species of Leishmania can contain as much as 20% of 
stigmastane-related sterols (Roberts et al., 2003). Cholesterol from the culture 
medium or of host animal origin is present in variable amounts of not less than 
10% of the total sterols in various species of Leishmania (Roberts et al., 2003).  
 
The sterols of Leishmania are mainly synthesized from L-leucine which provides 
up to about 80% of the carbon in sterols while the rest of the carbon atoms may 
be derived from isoleucine, glucose, threonine and acetate (Ginger et al., 1996; 
Ginger et al., 1999). There are variations in the extent of utilization of leucine 
for sterol biosynthesis among Leishmania species studied so far. L. mexicana, L. 
major and L. amazonensis seem to utilize more leucine for sterol biosynthesis 
than L. donovani, L. tropica and L. braziliensis (Ginger et al., 2000). However, it 
was later shown that the entire leucine carbon skeleton is incorporated into the 
sterols through the formation of 3-hydroxy-3–methyl-glutaryl-CoA (HMG-CoA), 
which is subsequently converted to mevalonate by HMG-CoA reductase in L. 
mexicana (Ginger et al., 2001). However, isoleucine, glucose, threonine and 
acetate are the major contributors of carbon atoms in triacylglycerols and 
phospholipids while leucine is a minor contributor to synthesis of triacylglycerols 
and phospholipids (Ginger et al., 1996; Ginger et al., 1999). 
 
The sequence of reactions in the sterol biosynthetic pathway (Figure 1.8) in 
trypanosomatidae starting from acetyl-CoA up to lanosterol is well known. 
However, the reaction sequences from lanosterol to ergosterol are yet to be 
clarified (Lepesheva and Waterman, 2011a). This could partly be the reason why 
little is known about enzyme localization after the lanosterol synthesis reaction. 
The sterol biosynthetic pathway occurs in more than one cellular compartment 
as the enzymes catalyzing the reactions characterised so far have been indicated 
to localise to various sub-cellular compartments. The reason for the occurrence 
of the biosynthetic pathway in various sub-cellular compartments is not known 
although there are speculations of a possible role in regulation of the 
trypanosomatidae’s utilisation of sterols (Lepesheva and Waterman, 2011a).  
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The enzymes of the mevalonate or isoprenoid part of the sterol biosynthetic 
pathway have been indicated to be found mainly in the mitochondria and the 
glycosomes. The synthesis of HMG-CoA from condensation of acetoacetyl-CoA 
and acetyl-CoA is catalyzed by 3-hydroxy-3 –methyl-glutaryl-CoA synthase, which 
has been shown to localise to the mitochondria (Carrero-Lerida et al., 2009). 
The subsequent reaction involving conversion of HMG-CoA to mevalonate is 
catalyzed by 3-hydroxy-3 –methyl-glutaryl-CoA reductase which is also localised 
in the mitochondria in L. major (Pena-Diaz et al., 2004). Earlier reports 
associated 3-hydroxy-3 –methyl-glutaryl-CoA reductase with mainly the 
glycosome and its minor activity with the mitochondria/microsome compartment 
in L. mexicana (Urbina et al., 2002). The next enzyme mevalonate kinase in L. 
major, catalysing the formation of mevalonate phosphate from mevalonate is 
localised in the glycosome (Carrero-Lerida et al., 2009). 
 
Enzymes of the pathway downstream the mevalonate pathway have also been 
reported to localise to different subcellular compartments of the cells of 
leishmania. Farnesyl diphosphate synthase of L. major is localised in the cytosol 
and converts geranyl diphosphate to farnesyl diphosphate (Ortiz-Gomez et al., 
2006). Squalene synthase, a membrane bound enzyme of L. mexicana, is found 
in two compartments, the glycosome and the mitochondria/microsomal vesicle 
(Urbina et al., 2002). Sterol C24 methyl transferase further downstream in the 
pathway catalysing the introduction of a double bond between carbon atom 
number 24 and carbon atom number 241 on fecosterol from zymosterol, is 
localised mainly in the endoplasmic reticulum in L. major (Jimenez-Jimenez et 
al., 2008).
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Figure 1.8 Simplified Leishmania major sterol biosynthetic pathway  
(Adapted from biocyc.org).
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Lanosterol 14α-demethylase for L. donovani classified as CYP5122A1 is 
reportedly a novel P450-like protein whose half knock-out led to reduced 
ergosterol synthesis in the mutant cells compared to the wild-type cells. The 
protein was found to localise to three sub-cellular compartments, the 
mitochondria, glycosome and the endoplasmic reticulum (Verma et al., 2011). 
 
Sterol (lanosterol) 14α-demethylase is a heme containing enzyme and member of 
the CYP51 gene family belonging to the Cytochrome P450 monooxygenases. In 
conjunction with NADPH cytochrome P450 reductrase, sterol 14α-demethylase 
catalyzes a three step removal of methyl groups (Figure 1.9) from position C14 
of 2, 3-epoxysqualene of the sterol biosynthetic pathway (Lepesheva and 
Waterman, 2011a; Waterman and Lepesheva, 2005). 
 
 
Figure 1.9 Sterol C14-demethylase catalyzed reaction of the sterol biosynthetic pathway. 
(Source: Waterman and lepesheva, 2005) 
Failure to remove the C14 methyl group and the presence of a methyl group at 
C4 leads to blocking of parasite growth (de Souza and Rodrigues, 2009). Although 
sterol 14-α demethylases from other organisms have a relatively broad spectrum 
of substrates, Leishmania sterol 14α-demethylase exhibit a low range of 
substrate specificity. Cloned L. infantum sterol 14α-demethylase is able to 
catalyse demethylation of C4-norlanosterol, C4-desmethylated obtusifoliol, and 
14-methylzymosterol, although it exhibits high specificity for C4-norlanosterol 
and obtusifoliol (Hargrove et al., 2011). There are very few sequence similarities 
in the enzyme primary structure between trypanosomatidae and human enzyme, 
offering possibilities of development of inhibitors that are selective for the 
parasite (Lepesheva and Waterman, 2011a). Leishmania lanosterol 14α-
demethylase is targeted for inhibition by azoles like ketoconazole (de Souza and 
Rodrigues, 2009; Lepesheva and Waterman, 2011a). The inhibition of sterol 14α-
demethylase leads to death of unicellular organisms due to blockage of the 
sterol biosynthetic pathway (Lepesheva and Waterman, 2007). To avoid 
ketoconazole toxicity, certain leishmania species have been reported to increase 
the intracellular drug target. Thus, in vitro ketoconazole resistance by L. 
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amazonensis was associated with up-regulation of expression of sterol 14α-
demethylase (Andrade-Neto et al., 2012). This signifies the importance of the 
enzyme to the pathway and ultimately the unicellular organisms. 
1.5 Control of the African animal trypanosomiases  
The control of trypanosomes involves the use of strategies that target the 
causative agent, the trypanosome or the vector, the tsetse fly.  
The control of trypanosomiases targeting the vector aimed at halting the 
transmission of the diseases started in the early 20th century (Schofield and 
Maudlin, 2001). A number of strategies have been used since then to try and 
eradicate the tsetse fly. 
  
The earliest was that of woodland destruction or bush clearing and wild animal 
killing. This was done to eliminate both the habitat and the animal 
reservoir/host of the vector. The method was stopped due to its negative effects 
on the environment and wild-life population. The discovery of insecticides in 
1945 led to their application in the control of the disease (Allsopp, 2001). 
Methods such as ground spraying with insecticides like 
dichlorodiphenyltrichloroethane (DDT), aerial application of residual 
insecticides, and sequential aerosol techniques (SAT) at low dosage of 
insecticides have all been employed. However, concerns over environmental 
contamination and effects on untargeted organisms have created scepticism over 
the use of insectcides. Target directed insecticide methods which do not pose 
serious risk of contaminating the environment are preferred and these include 
the odour-baited traps and targets (fabric sheets). These methods involve use of 
traps or targets impregnated with insecticides. A variant of these has been the 
dipping of animals in insecticides or use of pour-on formulations of insecticides. 
This method is called “live bait”, due to application of insecticides, mostly 
pyrethroids, on live animals. In these methods, the insecticides used are less 
toxic. The sterilization of male tsetse flies by irradiation is another method that 
has been used to control the disease and it is called the sterile insect technique 
(SIT). SIT was successfully used in Unguja Zanzibar but at a great cost (Vreysen 
et al., 2000). SIT can be used as a follow-up for eradication of the flies in 
conjunction with either dipping or use of targets (Allsopp, 2001; Schofield and 
Maudlin, 2001). 
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The technologies aimed at stopping transmission have been able to reduce the 
distribution of the tsetse flies but failed to eradicate them. In certain instances 
they reduced the use of anti-trypanosomal drugs (Hargrove et al., 2000). Various 
reasons have been cited for the failure to eradicate the tsetse fly despite it 
being susceptible to insecticides. There has been a lack of sustaining the control 
achievements due to reinvasion of the cleared areas. A large part of the African 
continent, greater than 40% of the total land area covering the 37 African 
countries affected by trypanosomiasis (Allsopp, 2001), is infested with the tsetse 
fly so huge investment would be required to cover this area. Impoverished 
African nations depend on aid to carry out these projects and often the aid for 
such comes with conditions dictated by the donor communities. Often the 
duration of these donor-financed projects is for a limited period of time. 
Trypanosomiases affect mostly poor rural communities who cannot afford the 
simplest or cheapest of these technologies (Hargrove et al., 2000; Schofield and 
Maudlin, 2001). 
 
1.5.1 Chemotherapeutic control of the trypanosomiases 
Chemotherapy has been the mainstay for the control of diseases caused by 
trypanosomes for some time (Barrett et al., 2003; Kinabo, 1993). However, 
there are only a few drugs for this purpose. There are four licensed drugs used 
for treatment of human African trypanosomiasis and whose choice of use 
depends on the subspecies of T. brucei causing the disease. These drugs are 
melarsoprol, eflornithine, pentamidine and suramin. Pentamidine and suramin 
are the first line drugs used in the early stages of the disease before the 
parasites invade the central nervous system and are used against T. b. 
gambiense and T. b. rhodesiense, respectively (Barrett et al., 2003; Brun et al., 
2010). Melarsoprol is used as a first-line drug for the treatment of the late-stage 
of the disease caused by T. b. rhodesiense. Eflornithine is only used against the 
disease caused by T. b. gambiense. Eflornithine requires large doses which 
complicates its use despite the drug having fewer side-effects as compared to 
other trypanocides. The use of eflornithine in combination with nifurtimox is 
now recommended as the overall dose and treatment duration are reduced and 
resistance selection is less likely (Priotto et al., 2009). Nifurtimox monotherapy, 
which is used against Chagas’ disease, has been used against late-stage 
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melarsoprol-refractory human African trypanosomiasis but with limited efficacy. 
Another drug that has been used occasionally to treat human African 
trypanosomiasis without a licence is diminazene (berenil), a drug which is 
indicated for veterinary use. Suramin is used effectively against the early stage 
of human African trypanosomiasis caused by T. b. rhodesiense. The drug is not 
effective against the early stage of the disease caused by T. b. gambiense and 
the late stage of human African trypanosomiasis caused by both T. b. 
rhodesiense and T. b. gambiense (Wilkinson and Kelly, 2009). Currently all of the 
drugs in use against human African trypanosomiasis are able to induce adverse 
side effects (Barrett et al., 2003). 
 
1.5.2 Chemotherapeutic control of Animal Trypanosomiasis 
Currently, there are only three drugs used for the treatment of African animal 
trypanosomiasis. These are isometamidium, homidium, and diminazene (Geerts 
et al., 2001). Isometamidium is not only active against T. congolense and T. 
vivax in domestic animals but also in T. brucei and T. evansi causing the disease 
in donkeys, horses and camels. Homidium is active against T. congolense and T. 
vivax (Kinabo, 1993). Diminazene is used against T. congolense, T. vivax and T. 
b. brucei in cattle, sheep and goats where they are the primary pathogens of the 
disease (Peregrine and Mamman, 1993). Isometamidium is mainly used for 
prophylactic purposes while homidium, which has limited prophylactic 
properties, and diminazene are both used as therapeutic agents (Delespaux et 
al., 2008; Geerts et al., 2001). 
 
Diminazene was introduced onto the market in 1955 for the treatment of 
trypanosomiasis and babesiosis in domestic livestock (Peregrine and Mamman, 
1993). It is an aromatic diamidine made up of two amidinophenyl groups that are 
joined by a triazene group (Figure 1.10A) and is commercially available as a 
diaceturate salt. It is manufactured in combination with phenyldimethyl 
pyrazolone to increase the stability of the aqueous solution of the drug from a 
few days to a couple of weeks. It is mostly sold commercially as Berenil. The 
drug is thought to have a low prophylactic activity because it is easily excreted 
and as a result is recommended for therapeutic use only. Diminazene is known to 
bind to kinetoplast DNA of trypanosomes. It has specific non-intercalating 
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interaction with adenine-thymine (A – T) rich sites in DNA. The binding of 
diminazene to kDNA leads to the accumulation of replication intermediates due 
to the inhibition of the RNA primers. Diminazene also inhibits trypanosomal 
mitochondrial topoisomerase II (Peregrine and Mamman, 1993). 
 
Homidium is a phenanthridinium compound and is commercially available as 
Novidium, the chloride salt called ethidium chloride, or ethidium, the bromide 
salt called ethidium bromide (Figure 1.10B). The drug was extensively used in 
the 1960s and 1970s, however, widespread resistance greatly limited its 
usefulness (Kinabo, 1993). Despite its being mutagenic, ethidium bromide has 
continued to be used widely for treatment of animal trypanosomiasis in many 
countries (Delespaux et al., 2008). The killing of the bloodstream form of T. 
brucei strain 427 by ethidium bromide has been reported to be through 
inhibition of the initiation of replication of free minicircles (Chowdhury et al., 
2010). It also inhibits nuclear DNA replication in dyskinetoplastic cells. The free 
minicircles were shown to be the primary targets of the drug as they were not 
shielded by the stabilising bound multiple proteins. It was concluded that the 
effective targeting of the minicircle replication by ethidium bromide could be 
due to differences in the intra-mitochondrial and extracellular concentration of 
ethidium bromide brought about by the requirement of the mitochondrial 
membrane potential to transport ethidium into the mitochondrial matrix which 
result in higher concentrations of the drug in the mitochondrial matrix 
(Chowdhury et al., 2010). 
 
Isometamidium (Figure 1.11) is a phenanthridinium compound which is 
commercially marketed as samorin or trypamidium. It was initially synthesized 
by coupling homidium (Figure 1.10B) with para-aminophenyldiazonium chloride 
(Kinabo, 1993). This synthetic route of isometamidium gives it a structure that 
differs from homidium by a meta-amidinophenyl-azo-amine moiety, a part of the 
diminazene drug (Figure 1.10A). Isometamidium is a cationic molecule and has 
hydrophobic properties due to the presence of a charged nitrogen atom in the 
phenanthridine nucleus and phenyl groups, respectively. The commercial form of 
the drug contains 70% isometamidium and 30% is made up of a mixture of its 
isomers, a bis-compound which occurs in small proportions and homidium 
(Kinabo, 1993; Kinabo and Bogan, 1988).  
  29 
 
 
Figure 1.10 Molecular structures of diminazene (A) and homidium (B). 
In A, the diminazene part which is added to homidium during synthesis of isometamedium 
is indicated (Sources/Adapted from: Peregrine and Mamman, 1993 and Kinabo, 1993, 
respectively). 
 
 
 
 
Figure 1.11 Molecular structure of isometamidium. 
The dotted line shows the two parts that make up isometamidium and their sources as 
labelled (Source/Adapted from: Kinabo, 1993). 
 
The prophylactic and therapeutic treatment of ruminants and horses against 
trypanosome infections with isometamidium chloride is done by intrasmuscular 
or subcutaneous injection at 0.5 mg/kg body weight and 1 mg/kg body weight, 
respectively (Desquesnes et al., 2013). The prophylactic treatment is done every 
three months as the drug protects the animals for at least four months 
(Mubamba et al., 2011), a period over which the drug remains detectable in the 
sera of the animals (Eisler et al., 1996). The use of isometamidium is 
recommended over the other phenanthridinium compounds which are 
carcinogenic because it does not have such a property. Isometamidium chloride 
is used with diminazene aceturate as a sanative pair, where failure of any of the 
two is replaced by the other (Desquesnes et al., 2013). 
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A number of targets and processes were indicated to be responsible for the 
antitrypanosomal activity of isometamidium and homidium. However, cleavage 
of kinetoplast DNA minicircles was one of the identified biochemical 
peculiarities of the trypanosomes that could account for selective toxicity action 
of the drugs (Kinabo, 1993). This was later found to be the action of ethidium 
bromide, a related phenanthridinium compound, in trypanosomes (Chowdhury et 
al., 2010). 
 
The other drugs that are used against animal trypanosomiasis are suramin, 
quinapyramine and cymelarsan. 
 
Quinapyramine a derivative of aminoquinaldine (Figure 1.12A), is both a 
therapeutic and prophylactic drug for animal trypanosomiasis that was 
introduced in the 1950s. It can be used in the treatment of cattle, goats and 
sheep infected with T. brucei, T. vivax, and T congolense. It was once regarded 
as a drug of choice for treatment against T. evansi, T. equiperdum and T. 
equinum infections before its eventual withdrawal from use in the 1970s due to 
widespread resistance to the drug in most parts of Africa (Kinabo, 1993). The 
continued use of quinapyramine in the wake of its lost effectiveness due to 
resistance development could have compromised the effectiveness of the other 
trypanocides like isometamidium, homidium and diminazene as quinapyramine 
cross resistance to these drugs was possible. Quinapyramine cross resistance by 
T. congolense to isometamidium, diminazene and homidium was demonstrated 
in mice and the resistant T. congolense were able to infect tsetse flies 
(Ndoutamia et al., 1993). The ease with which quinapyramine cross resistance to 
isometamidium, homidium and diminazene developed resulted in quinapyramine 
not being recommended for use in cattle (Desquesnes et al., 2013). The drug 
was later re-introduced following a change in its formulation and method of 
administration in donkeys and camels infected with T. evansi (Kinabo, 1993). A 
therapeutic and prophylactic combination of quinapyramine sulphate and 
quinapyramine chloride has since been effective in treatment and protection of 
horses and camels against T. evansi infections (Desquesnes et al., 2013). 
 
Suramin was developed around 1916 and only gained widespread use in 1923 
(Wainwright, 2010) although its use against HAT began in 1922 (Barrett and 
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Gilbert, 2006). Suramin is a colourless highly anionic polysulphonated 
naphthylamine urea compound (Figure 1.12C) which is readily soluble in water. 
Its ability to cross the blood-brain barrier is limited by its ionic nature (Fairlamb, 
2003) and that is why the drug is only used against early stage of HAT (Barrett 
and Gilbert, 2006; Brun et al., 2011; Fairlamb, 2003). The drug is administered 
intravenously in both humans and animals (Desquesnes et al., 2013; Fairlamb, 
2003), and has a long half life. The drug's mode of action is not known and 
despite resistance to the drug being easily selected in the laboratory its 
occurrence in the field is not common, in case of HAT (Brun et al., 2011). 
However, resistance to the drug in the animal form of trypanosomiasis caused by 
species of T. brucei group is known to exist. There are mixed reports on the 
stability of suramin resistance with regard to T. evansi infections. Suramin 
resistance in laboratory derived T. evansi seems to have a cost on the fitness of 
the resistant parasites while resistance in field isolates is believed to be stable 
as it persisted even after withdrawal of the drug for over two decades (Barrett 
and Gilbert, 2006). Suramin is reportedly no longer in use against T. evansi 
infections in horses and camels (Desquesnes et al., 2013). 
 
 
Figure 1.12 Molecular structures (a) Quinapyramine, (b) Cymelarsan and (c) Suramin. 
The drugs are used against animal trypanosomiasis (Source/Adapted from: Kinabo, 1993). 
 
  32 
 
Cymelarsan is a water soluble trivalent arsenical compound (Figure 1.12B) which 
was discovered in 1985 (Kinabo, 1993). It decomposes to between 33% and 42% 
melarsen oxide in aquoeus solution (Berger and Fairlamb, 1994). Therapeutic 
concentrations of melarsen oxide have been shown to penetrate the blood-brain 
barrier in mice (Keiser et al., 2000). Cymelarsan is active against T. evansi 
infections in horses, camels, cattle and buffaloes (Kinabo, 1993). Cymelarsen 
could be effective in treating goats at doses twice the recommended dosage for 
the treatment of T. evansi in horses and camels (Gutierrez et al., 2008). In the 
absence of an officially recommended drug for the treatment of T. equiperdum 
in horses, cymelarsen has been shown to be effective against both acute and 
chronic experimental infections with T. equiperdum (Hagos et al., 2010). 
 
1.6 Control of Leishmaniases 
The choice of control strategies for Leishmaniases in different geographical parts 
of the world depends on whether the disease is anthroponotic or zoonotic. 
Anthroponotic leishmaniasis involves the transmission of the disease by the 
sandfly as the vector to human hosts who also act as reservoirs of the parasite. 
The most effective control strategy of anthroponotic leishmaniasis is based on 
the treatment of the disease with an appropriate drug after its detection and 
diagnosis (WHO, 2010). Zoonotic leishmaniasis has non-human mammals, for 
example dogs, acting as reservoirs where the parasites are picked up by the 
sandfly vector, during a blood meal and transmitted to humans (Alvar et al., 
2006). Animal reservoir control is a zoonotic infection control method that 
involves the culling of dogs that show the presence of parasites in their blood 
and killing of the rodents or wild animals with poisoned baits and destruction of 
their habitats around settlement areas. Dipping of dogs in insecticides has also 
been used to reduce infection of these animals. A variant of dipping involves use 
of insecticide treated collars tied around the necks of dogs (Davies et al., 2003).  
 
Vector control aims at reducing the transmission of the disease. The control of 
leishmaniasis based on the vector is achieved through residual spraying of houses 
and animal shelters with insecticides and use of insecticide treated bednets 
(WHO, 2010). Residual house spraying, which was firstly done with DDT and later 
replaced with pyrethroids, is more widely used than bednets impregnated with 
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insecticide. Residual house spraying is useful against endophilic sand flies, i.e., 
those that rest indoors after feeding. Insecticide treated nets are best suited for 
endophagic sand flies, i.e., those that feed indoors. Residual house spraying has 
had successes in efficiently reducing fly populations. However, the extent to 
which the risk of infection can be reduced by the reduction in the insect 
population remains to be fully established. A sustained residual house spraying is 
required if the sand fly populations are to be diminished to effectively reduce 
incidence of the disease. There are various reasons for lack of sustained control 
of the vector. High cost and logistical limitations tend to curtail the application 
of sustained residual house spraying. It is also expensive and difficult to 
implement environmental management as a means of controlling the animal 
reservoir (Desjeux, 2004). Moreover, the insecticides used in residual spraying 
tend to lose their efficacy in high environmental temperatures, high radiation 
levels and in places prone to accumulation of dust (Claborn, 2010). 
 
1.6.1 Chemotherapeutic control of Leishmaniasis 
The organic antimonials’ first use as anti-leishmanial drugs is known to have 
been about 100 years ago (Ouellette et al., 2004). The trivalent forms of 
antimonials (SbIII) were initially used and later replaced by the less toxic 
pentavalent antimonials (SbV). The two pentavalent antimonials in use are 
sodium stibogluconate and meglumine antimoniate (Figure 1.13), and have been 
in use for just over 60 years (Croft and Olliaro, 2011). They are used as first line 
drugs in other parts of the world except in Bihar state of India where resistance 
to the pentavalent antimonial is wide-spread (Croft and Olliaro, 2011; Croft et 
al., 2006; Ouellette et al., 2004). 
  
Pentamidine (Figure 1.13) is an aromatic diamidine compound whose salts, 
pentamidine isethionate or pentamidine methanesulphonate, have been used as 
the second line drugs for the treatment of cutaneous leishmaniasis, 
mucocutaneous leishmaniasis and visceral leishmaniasis. It was also used to treat 
failed pentavalent antimonial treatment of visceral leishmaniasis. The drug’s 
toxicity which can lead to hypotension, hypoglycaemia, diabetes and 
nephrotoxicity coupled with its increasing treatment failure rates has limited its 
use (Ouellette et al., 2004). 
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Miltefosine is a member of the phosphocholine esters of aliphatic long chain 
alcohols classified generally as alkylphosphocholine compounds (Figure 1.13). 
Alkylphosphocholine activities against protozoan parasites and ability to kill 
cancerous cells were discovered in the early 1980s (Dorlo et al., 2012). 
However, miltefosine was approved for the treatment of visceral leishmaniasis in 
2002 in India. It is the only antileishmanial drug that is administered orally, 
although its course of treatment is relatively long, 28 days. Vomiting, diarrhoea, 
anorexia, and nausea are the common gastrointestinal side effects which are 
induced by miltefosine. Among these side effects vomiting and diarrhoea are 
observed in 38% and 20% of the treated patients, respectively (WHO, 2010). 
These side effects get resolved and treatment is continued. However, occasional 
severe side effects that prompt treatment interruption have been reported and 
these include elevated hepatic transaminase concentrations and skin allergy 
(WHO, 2010). The drug is contraindicated for use in women of child bearing age 
due to its teratogenic properties (Dorlo et al., 2012). 
 
Paromomycin (Figure 1.13) is a broad spectrum aminoglycoside antibiotic which 
was isolated from Streptomyces krestomuceticus filtrates in 1950. Paromomycin 
has activity against many gram-positive and gram-negative bacteria, protozoa 
and cestodes. It is the only aminoglycoside with activity against leishmania 
species (Davidson et al., 2009). Paromomycin was licensed for use against 
visceral leishmaniasis in India in 2006. It is known to cause reversible ototoxicity 
in 2% of patients while renal toxicity is rare. The drug is manufactured in 
injectable and topical application forms for treatment of visceral and cutaneous 
leishmaniasis, respectively (Davidson et al., 2009).  
 
1.6.2 Amphotericin B 
Amphotericin B (Figure 1.13) as a natural product was first isolated from 
Streptomyces nodosus in 1959. It is a non-aromatic antimycotic and antiparasitic 
polyene antibiotic (Lemke et al., 2005). It has been in use for the treatment of 
leishmaniasis since the 1960s as a second line drug (Croft et al., 2006). The 
drug’s adverse side effects, nephrotoxic effects and low solubility in aqueous 
solutions limited its use. Its nephrotoxicity is due to its affinity for cholesterol in 
the renal membrane where it forms pores upon binding, leading to compromised 
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renal membrane integrity. The low solubility prevents it being administered 
orally due to lack of absorption in the gastrointestinal tract. The alternative 
route of administration is parenteral injection where it is given with a 
solubilising agent, deoxycholate. The improved solubility did not reduce the 
toxicity of the drug and therefore other formulations were made with varying 
improved properties. These formulations included colloids and emulsions, 
cochleates, nanoparticulate carrier systems and a liposomal formulation (Lemke 
et al., 2005). The liposomal formulations have increased bioavailability and 
reduced toxicity properties. This has led to the liposomal form being 
recommended by the WHO for the treatment of visceral leishmaniasis and 
AmBisome is now the drug of choice when available. Currently, AmBisome is 
available free of charge (500, 000 doses per year) to WHO for distribution to 
endemic countries (WHO/Gilead, 2011). Recently it has been proposed that 
liposomal AmBisome is given as a single injection as part of a public health 
campaign to diminish the Leishmania burden in India (Mondal et al., 2014; 
Sundar et al., 2010). This approach could be catastrophic since it implies using a 
drug dosing close to the limit of efficacy and so risks selecting resistance. 
 
  36 
 
 
Figure 1.13 Molecular structures of the drugs that are used against Leishmaniasis. 
Miltefosine is the only orally administered drug. Amphotericin B, miltefosine, paromomycin 
and antimonials show varying efficacies against different species of leishmania. 
Pentamidine is rarely used due to its unpleasant side effects. 
 
 
1.7 Shortcomings of chemotherapy in AAT and 
leishmaniasis 
The chemotherapeutic control of the trypanosomiases with the current drugs has 
been in practise for a long time. However, the usefulness of these drugs has 
been compromised by several factors including toxicity, poor efficacy and 
limited supply. There is generally a lack of interest by pharmaceutical 
companies to invest in trypanocide development for AAT due to the low value 
market of such drugs for African farmers thereby limiting the choice of drug 
treatment (Geerts et al., 2001). Moreover, chemotherapy with the available 
drugs has further been compromised by development of drug resistance and 
there are no vaccines against these diseases (Barrett et al., 2003; Brun et al., 
2011; Handman, 2001).  
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Amphotericin B, miltefosine, paromomycin and antimonials show varying 
activities against the different species of Leishmania and this has been 
attributed to differences in the parasites’ biochemical and molecular features 
(Alvar et al., 2006). This implies that no one drug can be used in the different 
geographical regions with the same success. All the recommended 
antileishmanials show varying levels of toxicity and severe side effects to the 
host. They are given intravenously or intra-muscularly and in some cases require 
to be given in hospital for patient monitoring, except miltefosine which is given 
orally (WHO, 2010). Newer drugs, namely amphotericin B and miltefosine are 
also expensive although the gratis provision of 500, 000 annual doses of 
AmBisome ameliorates this. Leishmaniasis occurs mostly in developing countries 
and affects mainly the world’s poorest people who live in remote areas with 
limited or no access to health facilities. Therefore, these people have limited or 
no access to such expensive drugs. Generally, the antileishmanial drugs are not 
easily accessible in most endemic countries resulting in an estimation of over 
50% of the affected people failing to access appropriate treatment (den Boer et 
al., 2011). Moreover, the infrequent supply of drugs leads to elevated prices on 
the black market. In such situations lack of compliance to treatment regimens is 
inevitable. Besides, the long treatment regimens can exacerbate the problem of 
compliance to treatment regimens of some of these drugs, like miltefosine, and 
may result in the development of drug resistance (Alvar et al., 2006). The 
biggest threat to limiting the use of antileishmanials seems to be emerging 
resistance, which already exists for the antimonials and is reported increasingly 
for miltefosine. However in vitro resistance has been induced to all the drugs 
and the mechanisms of action for these drugs have not been fully worked out in 
leishmaniasis (Croft et al., 2006). 
 
1.7.1 Drug resistance 
Drug resistance to therapeutic compounds in use for treatment of bovine African 
trypanosomiasis has been reported in at least 17 African countries (Figure 1.14) 
(Delespaux et al., 2008). Included in this list is Zambia, where resistance to both 
isometamidium and diminazene was reported to exist in the eastern part of the 
country (Sinyangwe et al., 2004). In most of these countries information on 
trypanocidal drug resistance is obtained from reported cases rather than 
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comprehensive study reports and baseline information on trypanosomal drug 
resistance prevalence is not available (Delespaux et al., 2008). The problem of 
drug resistance in African animal trypanosomiasis could have been exacerbated 
by several factors. For example, the relaxation in control of the importation and 
marketing of the trypanocides together with many other pharmaceutical 
products by most African countries through the privatization of veterinary 
services has led to trypanocides becoming easily accessible from various sources 
like local pharmacists, agro-veterinary suppliers and the informal sector (Geerts 
et al., 2001). All these factors coupled with the small number of prophylactic 
and therapeutic trypanocidal compounds currently in use has contributed to the 
imprudent use of these drugs, especially by poor rural farmers (Delespaux et al., 
2008; Geerts et al., 2001). Multiple drug resistance to trypanocides has been 
reported. However, trypanosomal resistance to isometamidium chloride is more 
common than that to diminazene aceturate (Delespaux et al., 2008; Geerts et 
al., 2001). 
 
 
Figure 1.14 Occurrence of trypanocidal resistance in African Animal Trypanosomiasis.  
Trypanocidal resistance is indicated by a star. (Source: Delespaux, et al., 2008) 
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1.7.1.1 Resistance to isometamidium 
Isometamidium resistance has been recognised to exist for quite some time, 
although mechanisms of resistance have not been worked out. Isometamidium 
resistant T. congolense accumulate less isometamidium chloride than 
isometamidium susceptible T. congolense (Sutherland et al., 1991). Drug 
resistant T. congolense also show reduced uptake of isometamidium (Sutherland 
et al., 1992). Samorin (isometamidium) is known to be accumulated in the 
mitochondrion and has a specific interaction with the kinetoplast of drug 
sensitive bloodstream forms of T. congolense (Wilkes et al., 1997). However, 
there are no reports of an isometamidium effect on the nuclear DNA in T. 
equiperdum and T. congolense so far (Shapiro and Englund, 1990; Wilkes et al., 
1997). 
 
The specific interaction of isometamidium with the kinetoplast probably leads to 
the loss of the kinetoplast in isometamidium resistant T. congolense (Wilkes et 
al., 1997). Loss of the kinetoplast has also been observed to be induced by 
trypanocides like hydroxystilbamidine, ethidium bromide, acriflavine, berenil 
and pentamidine, although the kinetoplast can also be lost naturally (Schnaufer 
et al., 2002; Shapiro and Englund, 1995). However, dyskinetoplastidy does not 
easily occur in both in vivo and in vitro drug induction (Timms et al., 2002). The 
complete or partial loss of the kinetoplast DNA is generally referred to as 
dyskinetoplastidy while a complete loss is called akinetoplastidy in 
trypanosomatids (Schnaufer et al., 2002). Isometamidium has been proposed to 
promote formation of kDNA – protein complexes that are easily cleaved by 
topoisomerase II leading to linearization of the minicircles and generation of 
free mincircles in T. equiperdum (Shapiro and Englund, 1990). Loss of the 
kinetoplast would entail loss of maxicircle genes whose products bloodstream 
form T. brucei are dependent upon for the generation of the mitochondrial 
membrane potential through the reverse function of ATPase or F1F0 - ATP 
synthase (Brown et al., 2006). The subunit 6 of the F0 is encoded in the 
kinetoplast DNA and therefore loss of the kinetoplast leads to loss of this 
subunit. This loss has been suggested to be compensated for by a mutation in 
the γ subunit of the F1 and this allows the dyskinetoplastic cells to generate the 
mitochondrial membrane potential for their viability (Dean et al., 2013; 
Schnaufer et al., 2005).  
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The disturbances to the structural integrity of the F0F1 ATP synthase is also 
thought to lead to reduced ATP hydrolysis in trypanosomes (Schnaufer et al., 
2005). This would suggest alteration in the generation of the mitochondrial 
membrane potential as was observed in isometamidium resistant T. congolense. 
Alteration in the maintenance of the spontaneous mitochondrial membrane 
potential resulted in altered rate of accumulation of isometamidium (Wilkes et 
al., 1997), as inhibition of the spontaneous mitochondrial membrane potential 
led to a decrease in the rate of accumulation of isometamidium. It was 
concluded that parasites expressing lower mitochondrial electrical potential 
would have decreased rates of accumulation of isometamidium and would be 
less affected by the drug due to decreased toxicity. Thus the modulation of the 
mitochondrial membrane potential was thought to possibly have a role in the 
mechanism for isometamidium resistance by T. congolense (Wilkes et al., 1997). 
 
1.7.1.2 Resistance to Antileishmanial drugs 
The use of pentavalent antimonials against leishmaniasis has continued despite 
reports of the development of resistance to these drugs by some species of 
Leishmania in some parts of the world (Croft et al., 2006). The widespread 
treatment failure rates with antimonials have been attributed largely to drug 
resistance by the parasite in north Bihar state of India. The easy accessibility of 
these drugs, lack of compliance to treatment regimen and poor quality of the 
generic forms of the drugs are some of the factors that have been identified to 
have contributed to the development of pentavalent antimonial resistance in 
this part of the world (Sundar, 2001). 
 
The mechanism of resistance to antimony is believed to involve several factors 
although definitive mechanisms are not fully understood, as what is currently 
known comes mostly from in vitro studies (Ashutosh et al., 2007).  There are 
five aquaglyceroporins (AQP) encoded by the L. major genome and one, AQP1, is 
involved in the transport of trivalent antimonials and other metalloids into the 
parasite (Mukhopadhyay, 2013). Down-regulation of AQP1 leads to less 
accumulation of SbIII in L. major and field isolates of L. donovani, thus leading 
to antimony resistance by the parasites (Mukherjee et al., 2013; Rai et al., 
2013). Down-regulation of expression of AQP1 has been found to be due to 
reduction in the copy number as a result of deletion of AQP1 gene in the 
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telomeric region of chromosome 31 (Mukherjee et al., 2013). AQP1 is thought to 
be an essential channel due to failure of generating knock-out of both of its 
alleles in Leishmania (Mukhopadhyay, 2013). Perhaps this could be one of the 
reasons why down-regulation of AQP1 is not the only cause of antimony 
resistance. Other factors are known to contribute to antimony resistance in 
Leishmania (Ashutosh et al., 2007). To further protect itself from the active 
drug that makes it into the cell, the parasites use P-glycoprotein efflux pumps, 
to pump out the drug, further reducing drug concentration inside the cell. This 
mechanism has also been reported in both laboratory and field isolates of L. 
donovani that are resistant to SbIII (Rai et al., 2013). 
 
Another method of antimony resistance involves increased trypanothione levels 
in the resistant cells. Trypanothione is a reducing cofactor that is present in 
protozaon parasites where it provides a reducing environment within the cells of 
the kinetoplastids and hence protects them against oxidative stress (Fairlamb 
and Cerami, 1992). Besides this main function, trypanothione not only reduces 
antimony drugs from the pentavalent to the more active trivalent antimony, but 
also together with other thiols like glutathione forms conjugates with trivalent 
antimony that is destined for eflux or sequestration. The Leishmania multi-drug 
resistance related protein (MRPA) pump sequesters metal-thiol conjugates as a 
way of reducing drug effect on the parasite (Haldar et al., 2011). This method of 
resistance has been found to be present in both laboratory and field isolates of 
L. donovani where higher resistance results from up-regulated expression of the 
pump (Rai et al., 2013). 
 
Elevated levels of trypanothione have been reported in antimony and arsenite 
resistant laboratory Leishmania species and field isolates of L. donovani (Haldar 
et al., 2011; Rai et al., 2013). The elevated levels of the thiols are believed to 
increase the conjugation of the drug thereby reducing the drug concentration in 
the parasites. The increased levels of thiols is said to be due to the up-
regulation of γ-glutamylcysteine synthetase and ornithine decarboxylase in 
various Leishmania species (Haldar et al., 2011). The two enzymes are involved 
in the synthesis of glutathionine and spermidine, respectively (Fairlamb and 
Cerami, 1992). However elevated levels of thiols in both laboratory and field 
isolates of L. donovani showed both up- and down- regulation of γ-
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glutamylcysteine synthetase while ornithine decarboxylase was up-regulated in 
field isolates only (Rai et al., 2013). In maintaining a reduced environment 
within the cells, trypanothione itself is kept in the reduced state by 
trypanothione reductase (Fairlamb and Cerami, 1992). The participation of 
trypanothione reductase in antimony resistance is through its overexpression. 
The over-expression of trypanothione has been detected through increased 
levels of its RNA and increased enzyme activity in both field and laboratory 
isolates of L. donovani (Rai et al., 2013). 
 
High relapse rates have been reported with miltefosine within the short time 
that the drug has been in use. This could suggest that resistance to this new drug 
could easily develop (Croft et al., 2006).  
 
Miltefosine and other analogues of glycerolphospholipids are transported into 
Leishmania cells by a plasma membrane localized P-type ATPase pump called 
the miltefosine transporter (Perez-Victoria et al., 2003b). In vitro, miltefosine 
resistant L. donovani were shown to have reduced uptake of the drug (Perez-
Victoria et al., 2003a). Point mutations in in vitro miltefosine resistant 
Leishmania parasites have been identified to be the cause of the inactivation of 
the miltefosine transporter leading to reduced translocation of the drug into the 
cells thereby reducing the parasites’ susceptibility to the drug. Point mutations 
affecting conserved amino acid residues lead to the inactivation of the protein 
and the most resistant parasites carried homozygous mutations in L. major 
(Coelho et al., 2012). In L. donovani, different point mutations were detected in 
both alleles of the miltefosine transporter that were responsible for miltefosine 
resistance (Perez-Victoria et al., 2003b). Point mutations have also been 
detected in a miltefosine resistant clinical isolate of L. infantum with one of the 
detected SNPs at L832F being common to both L. infantum and L. donovani 
miltefosine resistant parasites (Cojean et al., 2012). Miltefosine resistance in L. 
donovani promastigotes, brought about by inactivation of the miltefosine 
transporter, is maintained upon transformation into amastigotes both in in vitro 
and in vivo macrophages (Seifert et al., 2007). Miltefosine resistant L. donovani 
also show increased activity of enzymes involved in redox reactions when 
compared to the wild-type. Superoxide dismutase and ascorbate peroxidase, 
whose function is to detoxify and reduce the levels of reactive oxygen species 
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(ROS), have been indicated to have increased activity in the miltefosine resistant 
parasites. However, usually there is a marked increase in accumulation of ROS 
accompanied by reduction in the mitochondrial membrane potential in the wild-
types cells leading to their apoptotic death (Das et al., 2013). Enzymes involved 
in fatty acid metabolism have been indicated to be upregulated in miltefosine 
resitant parasites (Das et al., 2013).  
 
Paromomycin is widely used for treatment of cutaneous leishmaniasis which is 
capable of self curing and this may not influence development of resistance to 
it. However, there are indications that resistance to this drug is possible 
although no clinical resistance has been reported so far (Croft et al., 2006). In 
vitro, L. donovani paromomycin resistance seems to be a multi-factorial process 
involving processes like energy metabolism, translation, stress response, 
virulence and vesicle trafficking. An increased number of vacuolar vesicles was 
observed in paromomycin resistant cells compared with wild-type cells and there 
was a corresponding up-regulation of vacuolar ATPase pumps involved in vesicle 
trafficking, fusion and endocytosis (Chawla et al., 2011). 
   
1.7.1.3 Resistance to Amphotericin B 
The high success rate of treatment of leishmaniasis with amphotericin B may be 
short-lived due to the reported emerging resistance (Croft et al., 2006; Purkait 
et al., 2012) that may be worsened by leishmaniasis co-infection with HIV (WHO, 
2010). Amphotericin B acts by binding to ergosterol to form complexes in the 
cell membrane. At concentrations of amphotericin B that are able to kill the 
Leishmania cells, binding of amphotericin B leads to formation of trans-
membrane aqueous pores thereby disturbing the membrane integrity. This makes 
the cells leaky, leading to their death by osmotic lysis (Ramos et al., 1996). 
Amphotericin B kills Saccharomyces cerevisiae primarily by binding to ergosterol 
in the membrane and formation of pores in the membrane is reportedly only 
secondary in killing yeast, thereby enhancing the drug’s potency (Gray et al., 
2012). The binding of amphotericin B to ergosterol forms the basis of the 
selectivity of this drug against fungi, Leishmania species and Trypanosoma cruzi 
as these organisms have more ergosterol in their membranes than the vertebrate 
hosts which have cholesterol instead. The varying levels of ergosterol in the 
different species of Leishmania have been thought to be responsible for the 
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difference in the drug’s activity against different species (Croft et al., 2006; 
Lemke et al., 2005). The varying effect of amphotericin B on the sterol 
composition in both clinical isolates and laboratory adapted amphotericin B 
sensitive and resistant L. mexicana and L .donovani has been demonstrated (Al-
Mohammed et al., 2005; Mbongo et al., 1998; Purkait et al., 2012). The 
perturbation in sterol composition due to amphotericin B resistance was 
demonstrated in laboratory derived amphotericin B resistant promastigotes and 
amastigotes although amphotericin B resistant L. mexicana promastigotes and 
not amastigotes were shown to be infective to mice (Al-Mohammed et al., 2005). 
Amphotericin B resistant Leishmania have also been shown to stop synthesising 
ergosterol as it was not detected (Al-Mohammed et al., 2005; Mbongo et al., 
1998; Purkait et al., 2012) thus removing the drug target. Studies on 
amphotericin B resistant Leishmania in comparison to their wild-type progenitors 
indicate an accumulation of certain intermediates of the sterol biosynthetic 
pathway (Al-Mohammed et al., 2005; Mbongo et al., 1998; Purkait et al., 2012). 
Changes in sterol composition were shown to be a stable feature of amphotericin 
B resistance in L. mexicana even after passage of the drug resistant 
promastigotes in mice (Al-Mohammed et al., 2005). These studies have all used 
sterol targeting methods for detecting alterations in the sterol composition of 
the wild-type and amphotericin B resistant Leishmania cells. 
 
Induction of amphotericin B resistance has not been confined to its monotherapy 
use but also to drug combination therapy, although it is generally believed that 
use of drug combination therapy can delay drug resistance development (Olliaro, 
2010). It has been shown that resistance to amphotericin B in combination with 
other anti-leishmanial drugs like miltefosine, paromomycin and trivalent 
antimony, can be selected relatively easily in vitro in both promastigotes and 
amastigotes of L. donovani (Garcia-Hernandez et al., 2012). Resistance to 
combinations of amphotericin B with other antileishmanial drugs was not only 
found to be a stable phenotype but also resulted in significant cross-resistance 
to other antileishmanial drugs. For instance amphotericin B/trivalent antimony 
resistant promastigotes were found to be cross-resistant to paromomycin while 
amphotericin B/miltefosine resistant promastigotes were cross-resistant to 
paromomycin and trivalent antimony (Garcia-Hernandez et al., 2012). 
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1.8 Methods of assessing drug resistance mechanisms 
In vitro selection of drug resistance offers a clean method to study drug 
resistance risk and mechanism before it arises in the field (Berg et al., 2013a; 
Horn and Duraisingh, 2014). The derived resistant lines’ ability to tolerate the 
drug to which they are resistant, and possible cross resistance to other drugs, is 
assessed through use of toxicity or susceptibility assays. The in vitro 
susceptibility assays for Leishmania suffer from being time-consuming and their 
lack of being standardised and are performed in an environment that does not 
mimic the parasite's natural environment (Berg et al., 2013a). Animal 
trypanosomiasis field isolates can be assessed for susceptibility in vitro although 
they take longer due to their slow adaptation to in vitro culture conditions. 
Standardized in vivo susceptibility assays for animal trypanosomiasis are 
performed in mice or ruminants but they take longer and some species of 
trypanosome like T. vivax and T.congolense, do not survive readily in mice 
(Delespaux et al., 2008). 
 
Laboratory generated and field resistant isolates can be assessed for drug 
resistance using genetic methods. Genetic assessment ranges from targeted 
approaches like DNA hybridization, DNA microarrays, PCR based methods, to 
untargeted approaches like functional cloning, comparative genome 
hybridisation arrays, full genome microarrays and whole genome sequencing to 
establish single nucleotide polymorphism, copy number variations and insertion 
or deletion differences and ploidy that may have arisen due to drug exposure 
(Berg et al., 2013a; Horn and Duraisingh, 2014). Targeted genetic methods are 
useful when a sequence or gene(s) is suspected to be involved in the drug 
resistance mechanism. In the absence of prior knowledge on the possible 
mechanism of resistance the untargeted approach becomes useful. The presence 
of post-transcriptional regulation of gene expression in trypanosomatids tends to 
limit the utilisation of genomes, transcriptomes and proteomes in studying 
mechanisms of drug resistance. However, proteomics is best suited to study 
stage specific protein expression levels although it has been used successfully in 
anti-leishmanial resistance studies (Berg et al., 2013a). The end products of the 
genome's coding, the metabolites, can be studied in relation to drug resistance 
mechanism using untargeted metabolomics. The connectivity of various 
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metabolites through pathways and the global profiling capability of untargeted 
metabolomics make it a method of choice for studying mechanisms of drug 
resistance (Vincent et al., 2010). Whichever method is used to study mechanisms 
of drug resistance, the obtained results have to be confirmed experimentally 
using techniques like over-expression or transfection of the wild-type or mutated 
gene to determine whether the altered phenotype can be reversed (Berg et al., 
2013a). 
 
Genetic changes to the genome that may have arisen due to adaptation of the 
parasites to drug pressure in the environment can be assessed by sequencing the 
whole genome of a drug resistant parasite and its subsequent comparison to its 
progenitor’s and reference genome (Downing et al., 2011). The number of 
Leishmania species that can be assessed in this way has increased because of the 
availability of the reference genome sequences of L. mexicana, L. donovani and 
refined reference genome sequences of L. major, L. infantum L. braziliensis and 
the non-human pathogen L. tarentolae (Downing et al., 2011; Raymond et al., 
2012; Rogers et al., 2011). Currently, whole genome sequencing can be achieved 
by using various Next Generation DNA sequencing (NGS) platforms (Rogers et al., 
2011).  
 
1.9 Next Generation Sequencing 
NGS is a high-throughput method of determining the order or connectivity of 
bases in a DNA molecule and is relatively cheap compared to the traditional 
Sanger capillary electrophoresis method. The early next generation sequencing 
platforms were based on a common general workflow. The workflow involves the 
fragmentation of target genomic DNA (generally by physical means for example 
by nebulization or sonication to generate a DNA library), ligation of adaptor 
primers to the generated target fragments, amplification of the fragments 
mainly by emulsion PCR for signal amplification, sequencing of the fragment 
libraries and assembly of sequence reads by aligning them to a reference 
genome sequence using bioinformatics (Hui, 2014). The first three early and 
commonly used next generation sequencing platforms were the Roche/454FLX 
pyrosequencer, Applied Biosystems SOLiD sequencer and Illumina Genome 
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Analyser (Mardis, 2008). The platforms differ mainly in the method of identifying 
nucleotides during the sequencing step. 
  
In the pyrosequencer, the incorporation of an added known nucleotide leads to 
release of pyrophosphate in the presence of pyrosequencing reagents (Ansorge, 
2009; Mardis, 2008). The pyrophosphate reacts with adenosine 5’ 
phosphosulphate catalyzed by sulfurylase and produces ATP which in turn reacts 
with luciferin in the presence of oxygen and luciferase to produce oxyluciferin 
and light (Nyren and Lundin, 1985). The emission of light confirms incorporation 
of a nucleotide. The use of pyrophosphate in the sequencing step has thus led 
the platform being called a pyrosequencer (Ansorge, 2009; Mardis, 2008).  
 
The Applied Biosystems SOLiD sequencer uses octamer oligonucleotides which 
have a fluorescent group at one end and are ligated to the sequencing primer by 
a ligase in the presence of ligation reagents. Excitation of one of the four 
fluorescent groups (four DNA bases) leads to confirmation and identification of 
two bases due to the light given off. The detected fluorescent group and part of 
the oligonucleotide are cleaved off to allow ligation of the next oligonucleotide 
to the growing primer for the next identification, earning this method the name 
of synthesis by ligation (Ansorge, 2009; Mardis, 2008).  
 
The Illumina Genome Analyser (GAIIx platform) uses four nucleotides with 
different fluorescent groups and a blocked 3’-hydroxyl group in the sequencing 
step. The nucleotides with a blocked 3’-hydroxyl group allow the incorporation 
of a single nucleotide at a time. The incorporated nucleotide is detected by its 
unique fluorescent property after which the 3’-hydroxyl blocking group is 
chemically removed to allow the incorporation of the next blocked fluorescent 
nucleotide. Thus, DNA sequencing using the Illumina Genome Analyser is by 
synthesis (Ansorge, 2009; Mardis, 2008). 
 
Ion torrent’s Ion proton sequencer or Personal Genome Machines use a 
semiconductor sequencing technology based platform and is mostly designed for 
research and clinical applications (Liu et al., 2012). It uses the sequencing by 
synthesis approach and follows the same work flow as the other three 
sequencing platforms in the preparation of DNA before the sequencing steps but 
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differs in the signal detection of an incorporated nucleotide (Rothberg et al., 
2011). Detection of incorporation of a known nucleotide into the growing chain 
of DNA after providing all four nucleotides in stepwise form during sequencing is 
based on the pH change in the solutions in the flow cell caused by the released 
proton. The change in pH is proportional to the number of nucleotides 
incorporated and is detected as a voltage signal (Rothberg et al., 2011). 
Therefore, this platform does not use optics for signal detection resulting in 
reduced size of the instrument, increased speed of sequencing and is relatively 
cheap (Liu et al., 2012). 
  
The early next-generation sequencing platforms and their applications have 
continued to evolve. The most used application of the technique has been the 
whole genome sequencing with the ultimate aim of identifying insertions or 
deletions, mutations, single nucleotide polymorphism, both gene and 
chromosome copy number variation (Hui, 2014). 
 
The downstream phenotypic effects of mutations, gene and/or chromosome 
copy number variations are not easily identified. Perhaps one way of 
ascertaining these phenotypic effects would be to assess the changes in the set 
of the small molecules called metabolites. Metabolites are regarded as the best 
indicators of the biochemical status of a given cell that are closely and can 
easily be linked to the observed phenotype (Patti et al., 2012). The relevance of 
metabolites in the elucidation of phenotypic effects resulting from genetic 
alterations in drug resistance is that most drug targets have been shown to be 
metabolites and may result in alteration of their levels (Scheltema et al., 2010). 
Therefore, an assessment of these metabolites could yield a wealth of 
information regarding the cell’s biochemical and physiological status. Metabolite 
profile in a given cell or tissue sample can be obtained using metabolomics. 
 
1.10 Metabolomics 
Metabolomics is a technology that allows for the identification and 
quantification of metabolites that are required for the maintenance, growth and 
normal function of a cell (Dettmer et al., 2007; Lokhov and Archakov, 2008). 
Metabolomic analysis can be applied using both metabolic profiling (or targeted 
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metabolomics) and metabolic fingerprinting (or untargeted metabolomics). 
Targeted metabolomics specifically measures a group of related metabolites 
that may belong to a particular chemical group or one or more pathways that 
are related. It is a method that aims at providing a solution to a specific 
biochemical investigation. Untargeted metabolomics measurements aim at 
capturing as many metabolites as can possibly be achieved in a given biological 
sample at a given time. This approach is useful for establishing differences in 
patterns of metabolites in such samples as urine, plasma, and tissues or cells 
due to disease, toxin exposure including drug effect, environmental or genetic 
alterations. It can be performed without need for a specific hypothesis related 
to a question. Untargeted metabolomics is not only used to assess intracellular 
metabolites in cell culture systems but also the extracellular metabolites 
excreted into the culture medium and nutrients levels of spent medium 
(Dettmer et al., 2007; Patti et al., 2012). 
 
Several analytical separation and mass detecting platforms are used in 
metabolomics to analyse the metabolites. One such platform is liquid 
chromatography (LC) interfaced with the mass spectrometer (MS) or simply 
LC/MS. Liquid chromatography allows separation of compounds of a wide range 
of polarity with little effort in sample preparation compared to other separation 
methods that can be interfaced with the mass spectrometer. This property has 
made liquid chromatography the most versatile separation method among other 
separation methods as it brings about reduction of ion suppression caused by co-
elution of compounds. It is able to separate isomers and isobaric (isotopic) 
interferences in the case of low resolving mass analyzers (Dettmer et al., 2007; 
Moco et al., 2007). The chromatographic fractions obtained are fed into the 
mass spectrometer which is made up of three principal components, the 
ionisation source, a mass analyser and a detector (Allwood and Goodacre, 2010). 
Thus, the abundance of the generated ions from chromatographic fractions and 
their mass-to-charge (m/z) ratios are detected by the mass spectrometer. The 
retention time, relative abundance and mass-to-charge ratio forms the basis of 
small-molecule metabolite identification. 
  
There are a number of challenges in the analysis of metabolites of small 
molecular weight that are often encountered in metabolomics. The variability of 
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widely diverse and chemical complexity of the metabolites which does not 
permit their detection by a single metabolomic platform has been the biggest 
challenge to metabolomic analyses. This challenge seems to have lessened due 
to the development of the mass spectrometers of high resolution and mass 
accuracy (down to 1 ppm) detection, for example the Fourier transform ion 
cyclotron resonance mass spectrometry (FTICR-MS). Also good is the Orbitrap 
mass spectrometer family which are cheaper and easier to maintain than the 
FTICR-MS. These mass analysers have been thought to be suitable for 
metabolomics because their mass analysis accuracy increases with decreasing 
molecular weight of analytes (Breitling et al., 2006). The untargeted 
metabolomic analysis generates huge data sets that sometimes pose an equally 
huge challenge in analysing. Moreover, the widely diverse nature of the small-
molecule metabolites has led to difficulties in identifying most of the detected 
analytes in untargeted metabolomic analysis due to insufficient entries of 
standards in existing metabolite databases (Creek et al., 2012a; Patti et al., 
2012). However, despite all these challenges a lot of success has been attained 
in studying metabolism in trypanosomes and leishmania using metabolomics 
(Creek et al., 2012a). The determination of the differences in global metabolite 
levels between sodium stibogluconate sensitive and sodium stibogluconate 
resistant clinical L. donovani isolates was achieved using untargeted 
metabolomic analysis. The noted major difference was the increased abundance 
of phospholipids and sphingolipids in the resistant cell lines compared to the 
susceptible cell lines suggesting membrane lipid alterations (t'Kindt et al., 
2010). Metabolic differences during differentiation from procyclic promastigotes 
to metacyclic promastigotes and the response to sodium stibogluconate exposure 
of both sodium stibogluconate susceptible and resistant L. donovani was 
compared using LC/MS untargeted metabolomics. Higher level of resistance in 
the parasites showed a corresponding increase in the levels of indole acrylate, 
capryloylglycine, valerylglycine, butyrylglycine, and homocysteine detected. 
Moreover indole acrylate, capryloylglycine and homocysteine levels were 
observed to increase further upon exposure of the parasites to sodium 
stibogluconate leading to a proposition of these metabolites being possible 
resistance markers of sodium stibogluconate in L. donovani (Berg et al., 2013b). 
The other notable success of LC/MS untargeted metabolomics was the 
elucidation of the mode of action of eflornithine and nifurtimox in T. brucei 
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(Vincent et al., 2012). Also eflornithine resistance related to loss of a 
transporter causing loss of drug uptake, as seen by LC/MS (Vincent et al., 2010). 
 
1.11 Proteomics 
Proteomics can also be used to study drug resistance. Proteomics aims at 
characterising as many proteins as possible from a full complement of proteins 
referred to as the proteome of a given cell or tissue. It is a comparative study 
technique that determines alterations in the expression of proteins that may be 
due to changes in the environmental conditions at a given time (Prenni et al., 
2007). Mass spectrometry-based proteomics is divided into two experimental 
approaches based on the sample treatment before analysis, these are the top-
down and bottom-up proteomics. In top-down proteomics the intact protein 
samples, without any pre-analysis protein modification, are analyzed while in 
bottom-up proteomics the protein samples are first proteolytically digested 
before analysis. The bottom-up proteomics is the most commonly used approach 
(Messana et al., 2013). 
  
Proteomics experiments are broadly divided into proteomics discovery 
experiments and proteomics assay experiments depending on what is to be 
realized from the sample analysis (Mallick and Kuster, 2010). Proteomics assay 
experiments also called targeted or restrictive or directed proteomics is used to 
determine the quantity of a few predefined groups of peptides or proteins. The 
analysis of proteins which are not pre-selected for study from the onset of the 
study constitutes what is called discovery proteomics experiments (Mallick and 
Kuster, 2010).  
 
The proteomics workflow is generally the same and variations arise from the 
approach used in sample preparation. The workflow involves separation of 
proteins or peptides by either electrophoresis or chromatography or both, with 
or without fragmentation of the proteins/peptides and their subsequent 
detection in the mass spectrometer (Mallick and Kuster, 2010). 
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1.11.1 Two-Dimensional electrophoresis 
The extracted protein samples are separated by two-dimensional electrophoresis 
(2-DE) in which the proteins are first separated based on their isoelectric points 
in what is called isoelectric focusing (IEF) and then separated based on their 
mass in the second dimension. The resolved protein spots are visualised by 
either autoradiography of radio-labelled samples prior to separation or 
coomassie or silver staining (Ofarrell, 1975). 
  
1.11.2 Difference gel electrophoresis 
Difference gel electrophoresis (DIGE) is a modification of the 2-DE technique 
that uses mass and charge matched fluorescent dyes to pre-label protein 
mixtures before two-dimensional electrophoresis. There are three types of 
fluorescent dyes called CyDye DIGE fluors, namely Cy2, Cy3 and Cy5. Based on 
the protein residues that are labelled two types of CyDye fluors can be 
distinguished. The first type being the minimal Cy2, Cy3 and Cy5 dyes and allow 
for the labelling of up to three protein samples. The minimal CyDyes are 
covalently bonded to proteins through the lysine residues. The second type is 
called the saturation CyDyes comprising of the saturation Cy3 and Cy5 dyes 
which allow for labelling of up to two protein samples. The neutrally charged 
saturation CyDyes label proteins through the cysteine residues (Marouga et al., 
2005). The pre-labelled protein samples are mixed and simultaneously separated 
on a single gel compared to 2-DE in which no more than one protein sample can 
be separated on a single gel. The resolved protein spots are visualised by 
fluorescent imaging using fluorescent properties of the dyes (Marouga et al., 
2005; Unlu et al., 1997).  
 
The resolved proteins are extracted from excised gel pieces and proteolytically 
digested normally with trypsin or chemically cleaved into peptides. The peptide 
mixtures are separated by liquid chromatography. The eluates are ionised by 
either electrospray ionisation (IES) or matrix-assisted desorption/ionisation 
(MALDI) to facilitate their detection by the mass spectrometer (Prenni et al., 
2007). The electrospray ionisation and matrix-assisted desorption/ionisation are 
used in proteomics because of their soft ionisation of protein/peptide species 
which does not lead to sample degradation (Yates et al., 2009). The ion trap, 
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quadrupole, time-of-flight (TOF) and FTICR-MS are the four basic mass analyzers 
used in proteomics (Aebersold and Mann, 2003). Mass detection can also be done 
using tandem mass spectrometry (MS/MS), in which two mass spectrometers are 
coupled to each other. Tandem MS not only detects the mass with an accuracy 
of parts per million (ppm) by the first mass spectrometer but also provides a 
means of getting information on the amino acid sequence in the peptides in the 
second mass spectrometer (Prenni et al., 2007). 
 
Proteins are identified by comparing the mass spectrum for a particular peptide 
or protein generated by the mass spectrometer with the in-silico trypsin 
digestion spectrum of proteins in the database. The fragmented peptide ion 
patterns in tandem MS are compared to the theoretical fragmentation patterns 
of peptide ions in the database to get the identification of the proteins in the 
sample (Prenni et al., 2007). 
 
The proteomes have turned out to be complex and quite dynamic in nature 
resulting in huge datasets being generated in proteomics studies that possess the 
challenge of analysis (Aebersold and Mann, 2003; Mallick and Kuster, 2010). The 
achievements that can be realized from use of proteomics in studying 
phenotypic effects are thought to be limited and in drug resistance studies  
putative protein identifications are somewhat common (Scheltema et al., 2010). 
However, proteomic comparison of drug resistant and drug susceptible cell lines 
have resulted in identification of several, some unrelated, proteins leading to 
the conclusion of several factors being at play. Hence, antimony resistance was 
found to implicate several unrelated protein alterations involved in different cell 
functions (Matrangolo et al., 2013). This seems to confirm earlier observations of 
several factors being involved in antimony mode of action and resistance (Croft 
et al., 2006). MS based proteomics revealed the overexpression of pteridine 
reductase in in vitro methotrexate resistant L. major (Drummelsmith et al., 
2004). Pteridine reductase is an enzyme that performs some of the functions of 
dihydrofolate reductase-thymidylate synthetase (Bello et al., 1994) and is known 
to be the main target of methotrexate (Papadopoulou et al., 1992).  
 
 
 
  54 
 
1.12 Aims of the project 
In a quest to look for molecular markers of drug resistance, it is important to 
characterise drug resistant parasites as a way of understanding how they 
tolerate such drugs. This can then help provide possible ways of circumventing 
resistance to the drugs as well as providing diagnostic tools. 
 
Several techniques have been used to elucidate drug resistance with limited 
success. The emergence of untargeted metabolomics, with its wide coverage of 
metabolites, holds promises of elucidating more mechanisms of drug resistance 
by revealing changes in metabolite profiles. Therefore a combination of whole 
genome sequencing and metabolomics complemented with proteomics can 
provide a wealth of information due to the global metabolite and protein 
coverage which would aid understanding mechanisms of resistance. 
 
It is against this background that the aims of the project were  
 
1. To use metabolomics and Next Generation Sequencing to gain some insight or 
an understanding how isometamidium resistance occurs by comparing the wild-
type and derived isometamidium resistant laboratory adapted T. brucei.  
 
2. To use whole genome sequencing and metabolomics in complement with 
proteomics to identify the relevant changes in the genome of the amphotericin B 
resistant L. mexicana that could subsequently lead to alteration in protein or 
metabolite profiles. 
 
3. To identify possible molecular markers of resistance to isometamidium and 
amphotericin B. 
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Chapter Two 
2 Methods 
Study of drug resistance mechanisms has lately incorporated the use of the 
various "omics" in what has been termed as polyomics. Polyomics provides a 
wealth of information that can help identify the possible mechanisms of drug 
resistance. This has been made possible by the fact that detected genetic 
alterations can be correlated to changes in metabolite levels and other related 
changes in other metabolites of various pathways because of their 
connectedness in pathway networks. This can then be followed up at the protein 
and RNA levels to further confirm observed phenotypes in drug resistance. 
Therefore, polyomics allows the use of "omics" methodologies in complement to 
each other to confirm the observed phenotypic alterations.   
2.1 Culturing BSF and PCF Trypanosoma brucei and 
Leishmania mexicana promastigotes 
The procyclic form of T. brucei strain TREU927 were cultured in vitro in semi-
defined medium – 79 (SDM79) (GIBCO) (Brun and Schonenberger, 1979) 
containing 2 – 2.5 mg/ml hemin and supplemented with 10% foetal bovine serum 
- Gold (FBS) (PAA Laboratories GmbH) while the bloodstream forms of T. brucei 
strain 427 were grown in commercial HMI-9 (GIBCO) supplemented with 10% FBS 
– Gold (Hirumi and Hirumi, 1994). The procyclic forms of T. brucei 927 were 
maintained with a starting density of 1 x 105 cells/ml in 5 ml cultures in 50 ml 
Corning non-vented culture flasks incubated at 27°C and passaged every 72 
hours. Bloodstream forms of T. brucei 427 were incubated at 37°C in the 
presence of 5% CO2 in 5 ml cultures using 50 ml Corning vented culture flasks at a 
starting density of 2 x 104 cells/ml and passaged every 48 hours.  
 
L. mexicana promastigotes MNYC/BZ/62/M379 were cultured in Homem (GIBCO) 
medium (Berens et al., 1976), supplemented with 10% FBS-Gold. The cultures 
were maintained as the procyclic forms of T. brucei. 
 
The bloodstream forms of T. brucei 427 for metabolomics analysis were grown in 
50 - 60 ml cultures in 250 ml Corning vented culture flasks while cultures for L. 
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mexicana for metabolomics analysis were grown in 20 ml cultures in 250 ml 
Corning non-vented culture flasks. The bloodstream forms of T. brucei 427 and 
L. mexicana promastigotes were grown to 2 × 106 cells/ml in 200 ml and 0.5 – 1 × 
107 cells/ml in 50 ml cultures for genomic DNA extraction in vented 500 ml and 
non-vented 250 ml Corning culture flasks, respectively. 
 
2.2 Alamar Blue Assay 
The toxic effect of compounds on cells was assessed using an adaptation of the 
Alamar Blue assay (Raz et al., 1997). The cells were counted using the improved 
Neubauer hemocytometer under the light microscope and cell density adjusted 
to twice the starting cell density. Two drugs were assessed on one 96-well plate. 
The first drug was added to each of the first and third wells of the first column 
of a 96-well plate at twice the required starting concentration in 200 µl growth 
medium. Similarly, the second drug was added to each of the fifth and seventh 
wells of the first column of the same 96-well plate. One hundred micro-litres of 
culture medium was added to each of the remaining 92 wells of the plate. A 
serial dilution of the two drugs was performed across the plate into 22 wells for 
each of the four wells to which the drugs were added, leaving the last (the 24th, 
48th, 72nd, and 96th) wells drug-free as negative controls. A 100 µl inoculum of 
bloodstream forms of T. brucei was added to each well to a final cell density of 
1 × 105 cells/ml. The plates were incubated at 37°C with 5% CO2 for 48 hours. 
The plates were incubated for a further 24 hours after addition of 20 µl of 0.49 
mM resazurin (Sigma) in 1× phosphate-buffered saline (PBS) (Sigma) pH 7.4 
solution. All drugs used for sensitivity assays were bought from Sigma unless 
stated otherwise. 
 
The procyclic forms of T. brucei and L. mexicana promastigotes response to 
compound exposure was assessed as the bloodstreams forms of T. brucei but 
with an initial incubation of 72 hours and a further incubation of 48 hours after 
addition of 0.49 mM resazurin. Starting cell densities used for the assays were 5 
× 105 cells/ml and 1 × 106 cells/ml for procyclic T. brucei and L. mexicana 
promastigotes, respectively. 
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Fluorescence was measured using the FLUOstar OPTIMA (BMG LabTech, 
Germany) fluorescence spectrometer set at excitation wavelength of 530 nm and 
emission wavelength of 590 nm. The EC50 values were determined using 
GraphPad Prism 5 software. At least three replicates were done for each 
compound or set of compounds assayed. 
 
2.3 Induction of drug resistance 
Selection for drug resistance was done by stepwise increase in concentration of 
the drug exposure of the cells. The wild-type cells of T. brucei bloodstream and 
procyclic forms were exposed to a starting 0.01 nM isometamidium (Merial, 
France). The starting concentration of 0.01 nM isometamidium was chosen after  
the cells were unable to grow at the concentration equal to the EC50 value 
determined for the wild type cells or at 10 fold less than the EC50 value. At these 
drug concentrations the cells could not grow beyond the third passage. Cultures 
of wild-type cells of the two cell lines were set up in another set of flasks 
without the drug and these were passaged in parallel with the cells exposed to 
the drug. The cells were passaged for at least five times at the same 
concentration once they were assessed to survive at that drug concentration by 
checking for an increase in cell density. 
 
Amphotericin B resistance in L. mexicana promastigotes was selected by 
exposing the wild type cells to 0.0135 µM amphotericin B in the growth medium. 
A sterile-filtered 250 µg/ml Amphotericin B solution in deionised water,( product 
number A2942 from Sigma) was used. A culture of the wild type cells without the 
drug was grown in parallel to the resistance selection culture. The drug 
concentration was doubled when the cells exposed to the drug were growing to 
similar densities over a similar length of time with the wild types cells growing in 
the absence of amphotericin B. 
 
2.4 Selection of clones 
The derived cells growing in the presence of the drug during drug resistance 
selection were cloned by estimating the cell density using the improved 
Neubauer hemocytometer and diluting them to 1 cell/ml in 20 ml growth 
medium. The diluted cells were added at 200 µl per well to a transparent 96-
58 
 
well plate and incubated at growth conditions for the particular cell type. 
Clones were only obtained from plates having less than 30% of the 96 wells with 
growing cells by checking under the light microscope as calculated using the 
poisson distribution for a 96 well plate. 
 
2.4.1 Making stabilates of clones 
Stabilates of T. brucei clones growing at different concentrations of the drug 
were made in 10% glycerol at various stages of drug resistance selection. The 
stabilates were made by mixing equal volumes of cells in log phase and pre-
chilled growth medium containing sterile 20% glycerol and transferring 1 ml of 
the mixture into 1.5 or 2 ml cryovials. The cryovials were wrapped in cotton 
wool and stored at - 80°C overnight. The stabilates were kept in liquid nitrogen 
for long term storage. Stabilates of L. mexicana in log phase were similarly made 
but in 5% dimethyl sulphoxide (Sigma). 
 
2.5 In vitro transformation of AmB resistant 
promastigotes into amastigotes 
Transformation of the promastigotes to amastigotes was carried out in 
Schneider’s Drosophila Medium (SDM) supplemented with 10% heated inactivated 
calf serum, 2.5 mg/ml hemin in 50 mM NaOH with the complete medium at 
pH5.0 (Bates et al., 1992). Promastigotes in late log phase stage were washed in 
PBS. The washed promastigotes at 1 × 106 cell/ml were suspended in complete 
SDM medium in vented culture flasks and incubated at 32.5°C supplemented 
with 5% CO2. 
 
2.6 Monitoring mitochondrial membrane potential 
Bloodstream T. brucei 427 wild-type cells and derived isometamidium resistant 
cells were grown to approximately 2 × 106 cells/ml. The cells were harvested by 
centrifugation at 1, 000g for 10 min and cell densities adjusted to 1 × 106 
cells/ml in fresh medium. Four aliquots of 1 ml for each cell line were set up in 
pre-labeled 1.5 ml eppendorf tubes, for drug free, isometamidium, valinomycin 
(Sigma), and troglitazone (Sigma). Isometamidium was added to a final 
concentration of 500 nM to a set of two tubes, one from each cell line, and all 
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the tubes were incubated at 37°C supplemented with 5% CO2 for a set time. 
Valinomycin and troglitazone were added to a second set of four tubes, two for 
each cell line, to final concentrations of 1 M and 10 M, respectively. 
Troglitazone and valinomycin were used as controls for increasing and abolishing 
the mitochondrial membrane potential, respectively (Denninger et al., 2007; 
Figarella et al., 2005). The tubes were incubated as above. The samples were 
centrifuged at 2, 500g for 10 minutes at room temperature and re-suspended in 
PBS containing  25 nM Tetramethylrhodamine ethyl ester perchlorate (TMRE) 
(Sigma) dye (Perry et al., 2011) and incubated as above. The cells were 
transferred to appropriately labeled FACS tubes and kept on ice for at least 30 
minutes. The treated cells were analyzed using the CellQuest Pro software on BD 
FACSCalibur cell sorter. 
 
2.7 Genomic DNA extraction 
Genomic DNA for whole genome sequencing was extracted using the 
phenol/chloroform/isoamyl alcohol method. The cells were harvested by 
centrifuging at 2 500 rpm for 5 minutes. The pellets were washed once in 1× PBS 
and re-suspended in 500 µl NTE buffer (Appendix A) to which 25 µl of 10% SDS 
and 50 µl of 10 mg/ml RNase A (Sigma) were added. The mixture was warmed to 
37°C, mixed by inverting and incubated for 30 minutes at 37°C. The cell lysates 
were incubated at 37°C for overnight after addition of 25 µl of 20 mg/ml 
pronase (sigma). The samples were extracted twice with Phenol: chloroform: 
isoamyl alcohol (25:24:1) (Sigma) and then twice with chloroform. Before each 
extraction the samples were mixed on a rotary mixer for 5 minutes. The samples 
were centrifuged at 16, 000g for 5 minutes and the aqueous phase was 
transferred to 15 ml Falcon tubes to which absolute ethanol 2.5 times the 
volume of the aqueous phase was added. The mixture was gently mixed by 
inverting the tubes. The precipitated DNA was transferred to new 1.5 ml 
eppendorff tubes and washed with 70% ethanol. The DNA samples were 
centrifuged at 16, 000g for 10 minutes and air-dried in the fume hood before re-
suspending in 50 µl of TE buffer at 4°C overnight. The concentration of the DNA 
was measured using the NANODROP 1000 spectrophotometer (Thermo Scientific). 
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Genomic DNA for routine PCR work was extracted using the NucleoSpin Tissue kit 
following the manufacturer’s standard protocol for human or animal and 
cultured cells (Macherey-Nagel, Germany). 
 
2.7.1 Diagnostic PCR for kinetoplast DNA 
The presence of the maxicircle encoded NADH dehydrogenase (ND) subunit 
genes, ND4, ND5, ND7 and A6 subunit of ATP synthase of bloodstream forms of T. 
brucei 427 was determined by use of PCR (Domingo et al., 2003; Lai et al., 
2008). The cell nucleus encoded actin gene was used as the control. The primers 
used to amplify the genes are given in Table 2.1.  
 
Primer  Primer sequence 
PCR product 
size in bp 
Actin Forward 5’ CCGAGTCACACAACGT 3’ 
456 
Actin Reverse 5’ CCACCTGCATAACATTG 3’ 
ND5 Forward   5’ TGGGTTTATATCAGGTTCATTTATG 3’ 
395 
ND5 Reverse  5’ CCCTAATAATCTCATCCGCAGTACG 3’ 
ND4 Forward  5’ TGTGTGACTACCAGAGAT 3’ 
256 
ND4 Reverse 5’ ATCCTATACCCGTGTGTA 3’ 
ND7 Forward 5’ ATGACTACATGATAAGTA 3’ 
161 
ND7 Reverse 5’ CGGAAGACATTGTTCTACAC 3’ 
A6 Forward 5’ AAAAATAAGTATTTTGATATTATTAAAG 3’ 
381 
A6 Reverse 5’ TATTATTAACTTATTTGATC 3’ 
Table 2.1 Oligonucleotides used for amplification of kinetoplast related genes. 
 
 
The gene fragments were amplified using 2.5 U Go-Taq DNA polymerase 
(Promega) in a 25 µl reaction by polymerase chain reactions (PCR) on a G-Storm 
thermal cycler. The final concentration of the reaction mixture constituents was 
made up of 300 µM dNTPs, 300 µM primers in 1× Go-Taq DNA polymerase buffer. 
Template DNA was used at 10 ng to 60 ng. The thermal cycler program used was; 
heated lid 112°C; initial denaturation 95°C, 5 minutes; 35 cycles of denaturation 
at 95°C for 1 minute, annealing at 54°C for 1 minute, elongation 72°C for 30 
seconds and final elongation at 72°C for 8 minutes. 
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2.7.2 Next-Generation Genomic DNA sequencing 
The genomic DNA for L. mexicana M379 wild type, derived L. mexicana M379 
amphotericin B resistant (AmB-R) at 0.27 µM of amphotericin B, bloodstream 
form of T brucei 427 wild-type, isometamidium (ISMM) resistant clones growing 
in the presence of 4 nM, 40 nM and 1 µM ISMM were sequenced at Glasgow 
Polyomics, University of Glasgow. Paired-end samples of the cell lines' genomic 
DNA were sequenced using Illumina GAIIx next generation DNA sequencing 
platform. The sequencing data were analyzed by Dr. Nicholas Dickens (Wellcome 
Trust Center for Molecular Parasitology, University of Glasgow) and Dr. 
Manikhandan Mudaliar (Glasgow Polyomics, University of Glasgow). 
 
2.7.3 L. mexicana gene cloning using pNUS expression vectors  
2.7.3.1 Expression vectors and primer design  
The pNUS-HnN and pNUS-GFPcN (Figure 2.1) expression vectors for Crithidia 
fasciculata and Leishmania (Tetaud et al., 2002) were used to clone and express 
the wild-type lanosterol 14α-demethylase gene fused to the His-Tag at the N-
terminus in L. mexicana AmB-R and the GFP-Tag at the C-terminus of both wild 
type and AmB-R lanosterol 14α-demethylase genes in wild type L. mexicana, 
respectively, using neomycin for selection in both cases. Lanosterol C14-
reductase with a GFP tag at the C-terminal was similarly cloned but was 
expressed both in the wild-type and AmB resistant cell lines. CLC genomics 
workbench 6 was used to design primers for PCR amplification of gene 
fragments. Restriction sites were incorporated into the designed primers (Table 
2.2), where this was required to facilitate the ligation of the gene fragment into 
the linearized expression vector backbone. The pNUS expression vector-specific 
primers were designed using the vector sequences downloaded from 
http://www.ibgc.ubordeaux2.fr/pNUS/index.html. All the primers were bought 
from Eurofins MWG Operon, Germany. All the primer pair optimal annealing 
temperatures were determined by gradient PCR. 
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Figure 2.1 The pNUS-HnN and pNUS-GFPcN expression vector maps. 
Adapted from http://www.ibgc.u-bordeaux2.fr/pNUS/index.html and anotated using CLC 
Genomics Workbench 6 software.  
2.7.3.2 PCR amplification of gene fragments 
The gene fragments for cloning were amplified by PCR using concentrations of 
primers and dNTPs as in section 2.7.1. Phusion High-Fidelity DNA polymerase 
(New England Biolabs) was used at 1 U in 1× Phusion GC HF buffer for a 50 µl 
reaction. The Phusion High-Fidelity DNA polymerase was used because it is less 
likely to introduce PCR mutations to the fragment being amplified. The gene 
fragments were amplified from a template DNA concentration of approximately 
150 ng using the primers indicated in table 2.2. The PCR program was; heated lid 
at 112°C, initial denaturation 95°C, 5 minutes, 30 cycles of denaturation at 95°C 
for 1 minute, annealing at 69.7°C for 30 seconds, elongation 72°C for 1 minute 
30 seconds and final elongation 72°C for 5 minutes. 
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Primer 
Designation 
Primer sequence Primer specificity Restriction 
sites 
Expected 
band size 
MB769 GCATATGATGATCGGCGAGCTTCTCC lanosterol 14α-demethylase 
(CYP51) 
NdeI 
1452 bp 
MB770 CTCGAGCTAAGCCGCCGCCTTCT XhoI 
MB0243 GTAAAACGACGGCCAG 
pGEM-T easy vector 
 
*233 bp 
MB0424 CAGGAAACAGCTATGAC  
MBO781 CATCATCATCATCACAGCAGC 
pNUSHnN  
 
*103 bp 
MBO782 GTCGAAGGAGCTCTTAAAACG  
MB0037  ATGATTGAACAAGATGGATTGC 
Neomycin cassette 
 
795 bp 
MB0038  TCAGAAGAACTCGTCAAGAAG  
MBO787 CGCGAAATAGATATAAAGCACACG 43 bp from CYP51 ATG  
788 bp 
MBO788 TCGCGAGCGATGATAATCTCG CYP51 internal  
MB0755 GGTATTGAGGGTCGCATGATCGGCGAGCTTCTCCT 
pET30 Xa/LIC/CYP51 
 
1473 bp 
MB0756 AGAGGAGAGTTAGAGCCCTAAGCCGCCGCCTTCTTCT  
MB791 5’ CATATGATGATCGGCGAGCTTCTCCT 3’ 
CYP51 
NdeI 
1452 bp 
MB792  5’ AGATCTAGCCGCCGCCTTCTTC 3’ BglII 
MBO793 5’ TATCTTCCACTTGTCAAGCGAAT 3’  
pNUS-GFPcN  
 
*115 bp 
MBO794 5’ CCCATTCACATCGCCATCCAGTTC 3’   
MBO795 5’ ATGAGCAAGGGCGAGGAACTGTTC 3’  
GFP cassette 
 
717 bp 
MBO796 5’ TCACTTGTACAGCTCGTCCATGCC 3’   
Table 2.2 Oligonucleotides used in cloning experiments.  
Underlined sequences show the named restriction enzymes’ restriction sequences used. *Depending on the restriction sites used, the expected PCR 
product size would be the gene insert added to the indicated size in the table less the fragment removed by restriction digestion. 
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The PCR products were A-tailed with 300 µM dATP in the presence of 1 U Go-Tag 
DNA polymerase in 1× Go-Taq polymerase buffer at 72°C for 15 minutes and gel 
purified using the NucleoSpin Gel and PCR clean up kit (Macherey-Nagel, 
Germany). The PCR products were A-tailed to facilitate their ligation into the 
linear sub-cloning vector pGEM-T Easy vector (Promega) which has 3’–terminal 
thymidine overhang at both ends. The ligation was done by mixing 3.5 µl of 
purified A-tailed PCR product with 50 ng pGEM-T Easy vector and 1 U T4 DNA 
ligase (Promega)  in 1× Rapid ligation buffer (Promega) in 10 µl total reaction 
volume and incubation at 4°C overnight. 
 
2.7.3.3 Transformation of bacteria 
The gene insert/pGEM-T easy vector constructs were transformed into XL1 Blue 
E. coli competent cells (Promega) to obtain large quantities of the gene insert. 
The transformation was done by mixing thawed 50 µl XL1 Blue E. coli competent 
cells on ice with 5 µl of the ligation product and incubated on ice for 30 minutes. 
The cells were heat-shocked for 45 seconds in a water bath set at 42°C. The 
cells were immediately incubated on ice for 2 minutes and 100 µl SOC medium 
was added before incubating at 37°C with shaking at 250 rpm for 1 hour. A 
further 200 µl of SOC medium was added and 100 µl of the solution was plated 
out on LB agar (Sigma) plates containing 100 µg/ml ampicillin (Sigma). The 
plates were incubated at 37°C overnight. 
 
2.7.3.4 PCR colony screening 
The colonies were screened for the gene insert using PCR. The PCR reactions 
were carried out in a 20 µl total reaction volume with pGEM-T easy vector 
specific primers, MB0243 and MB0424 (Table 2.2), and dNTPs at 500 µM final 
concentrations, using Go-Taq DNA polymerase at 2.5 U in 1× Go-Taq DNA 
polymerase buffer. The following PCR program was used:- heated lid 112°C; 
initial denaturation 95°C for 3 minutes: 35 cycles of denaturation at 95°C, 40 
seconds; annealing at 55°C, 40 seconds; elongation 72°C, 1 minute 30 seconds 
and final elongation at 72°C for 5 minutes. 
 
The identified positive single colonies were picked, streaked on new LB agar 
plates containing 100 µg/ml ampicillin and incubated at 37°C overnight. The 
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positive colonies were grown in 5 ml LB broth (Sigma) containing 100 µg/ml 
ampicillin by incubating the cultures at 37°C overnight with shaking at 250 rpm. 
The cells were harvested by centrifuging at 4 500 rpm for 10 minutes.  
 
2.7.3.5 Restriction digestion 
The plasmids were extracted from the harvested cells using the NucleoSpin 
Plasmid/Plasmid (NoLid kit) (Macherey-Nagel, Germany). Three microgram of 
extracted plasmids were doubled digested with 30 U of each of the two 
restriction enzymes of interest in 1× of an appropriate buffer (Promega) 
supplemented with 1× BSA (Promega) in a 70 µl total reaction volume. The 
pNUS-HnN and pNUS-GFPcN expression vectors, a gift from Dr. E. Myburgh, 
MVLS-III University of Glasgow, were similarly digested. The restriction digests 
were resolved on a 1% agarose gel and the bands of interest were excised. The 
DNA was extracted from the gel pieces using the NucleoSpin Gel and PCR clean 
up kit (Macherey-Nagel, Germany). 
 
The gene fragments and the linear expression vectors, with complementary 
sticky ends, were ligated in 1× T4 ligase buffer with 1 U T4 DNA ligase 
(Promega). This was done by mixing 2 µl of the linear vector and 6 µl of the 
enzyme insert in a total reaction volume of 10 µl. The reaction mixture was 
incubated at 4°C overnight. 
 
The gene/expression vector constructs were transformed into XL1 Blue E. coli 
competent cells as in section 2.7.3.3. The single colonies carrying the gene 
inserts were identified by PCR colony screening using pNUS expression vector-
specific primers (Table 2.2). The PCR reaction conditions and program were 
carried out as in section 2.7.3.2 but with 2.5 U Go-Taq DNA polymerase in 1× Go-
Taq DNA polymerase buffer and 56.4°C annealing temperature. The identified 
positive single colonies were grown in 5 ml LB broth as described earlier to 
obtain large quantities of the plasmid. The plasmids or constructs were 
extracted as described earlier and were sequenced at Eurofin MWG Operon, 
Germany. The obtained sequences were aligned with the enzyme gene sequence 
downloaded from TriTryp DB website using CLC genomics workbench 6. This was 
done to check for any alterations in the sequence that could have resulted from 
various treatments that the gene was subjected to.  
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2.7.3.6 Transfection of L. mexicana promastigotes 
The pNUS-HnN plasmid with the correct sequence of the wild-type lanosterol 
14α-demethylase gene sequence with the added His-Tag was transfected into 
derived amphotericin B resistant L. mexicana promastigotes. This was done to 
determine whether the wild-type enzyme would have an influence on the 
resistance to amphotericin B status of these cells. To determine whether there 
was any difference in cell localization of the enzymes from the two cell lines, 
the plasmids with the correct sequences of the wild-type and derived 
amphotericin B resistant lanosterol 14α-demethylase gene sequences with the 
GFP tag at the C-termini were transfected into the wild type L. mexicana 
promastigotes. L. mexicana to be transfected with the expression plasmids were 
grown to log phase cell density and 1 × 107 cells/ml were harvested and washed 
once by resuspending in fresh 5 ml Homem supplemented with 10% FBS-Gold. 
The cells were centrifuged at 1000 × g for 10 minutes and resuspend in 100 µl Tb 
BSF buffer (Appendix A) and added to 10 µg of plasmid DNA in a cuvette. Using 
program U-033 the cells were zapped in an Amaxa biosystems Nucleofector®II 
(Lonza). The cells were incubated on ice for 10 minutes and then transferred 
into pre-warmed 10 ml of Homem supplemented with 10% FBS-Gold and left to 
recover for 18 hours at the usual incubation temperature for leishmania (section 
2.1). The selection drug G418 disulfate salt (Sigma) at 50 µg/ml was added to 
the growth culture medium and the Homem used for diluting cells during making 
of clones. A serial dilution of 1/24 was done, from which a 1/288 dilution was 
made and 1/576 dilution was made from the 1/288 dilution (Figure 2.2). The 
diluted cells were transferred to 3 transparent 96 well plates at 200 µl per well. 
After 14 days the clones were obtained from the third dilution plate and 
transferred to 10 ml Homem supplemented with 10% FBS-Gold containing 50 
µg/ml G418 disulfate salt. The clones were maintained in Homen containing 50 
µg/ml G418 disulfate salt and stabilates were made as in section 2.1. 
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Figure 2.2 Schematic representation of the serial dilution of the transfected L. mexicana for 
cloning. 
 
2.7.4 Protein over-expression 
The wild-type and derived AmB-R lanosterol 14α-demethylase were amplified by 
PCR using primers MB0755 and MB0756 (Table 2.2). The PCR products were 
cloned into the ligation independent vector pET-30 Xa/LIC following the 
manufacturer’s protocol (Novagen, Merk). 
 
Small scale over-expression using the pET-30 Xa/LIC- lanosterol 14α-demethylase 
constructs were carried out by growing transformed BL21 E. Coli and the 
derivative Rosetta strains (Novagen) in 50 ml LB broth containing 30 µg/ml 
kanamycin and 30 µg/ml chloramphenicol, respectively. Kanamycin and 
chloramphenicol were used for selection of BL21 and Rosetta competent cells, 
respectively. The cultures were incubated at 37°C until the OD600 was 0.6 when 
protein over-expression was induced by addition of isopropylthio-β-galactoside 
(IPTG) (Melford) to a final concentration of 1 mM. The protein over-expression 
was done at 37°C for 3 hours. The cells were harvested by centrifugation at 4, 
500 rpm for 20 minutes at room temperature. 
 
The presence of over-expressed protein was checked by performing small scale 
purification on Ni-NTA spin columns (Qiagen) using the Protein Purification under 
Native Conditions from E. coli Lysates protocol supplied together with the spin 
columns. The proteins were resolved on NuPAGE Bis-Tris Mini Gels following the 
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manufacturer’s protocol (NOVEX). The protein bands were stained with 
Coomassie blue stain (Appendix A) overnight and destained with several washes 
with destaining solution (Appendix A).  
 
2.8 Fluorescence Microscopy 
2.8.1 Immobilisation of live stained cells for imaging 
Live stained cells were immobilised using 1% agarose, low-gelling temperature 
(Sigma). This was done to limit the movements of the stained cells so that they 
could easily be viewed under the microscope (Lanteri et al., 2008). An equal 
volume of cells in PBS and 1% to 2% agarose in PBS was mixed and 50 µl of the 
mixture was added to the glass slide. Agarose at 27°C and 37°C was used for 
Leishmania and trypanosome cells, respectively. Cover-slips were applied to the 
slides and slides were left at room temperature for 10 to 15 minutes or in the 
fridge for 5 minutes before viewing on the fluorescent microscope.  
2.8.2 DNA staining with DAPI 
Fifty micro-litres of cells grown to mid-log phase were spread onto a microscope 
glass slide using a cover-slip and air dried in the fume-hood. The cells were fixed 
in absolute methanol for overnight at -20°C. The methanol was evaporated in 
the fume-hood and the fixed cells were rehydrated with 1 ml PBS for 10 
minutes. The excess PBS was removed by tilting the glass slide on a folded tissue 
paper. Fifty micro-litres of PBS containing 1 µg/ml 4, 6-diamidino-2-phenylindole 
(DAPI) (Sigma) and 1% 1, 4-Diazobicyclo-(2, 2, 2) octane (DABCO) (Sigma) was 
applied to the glass slides and observed under UV light using the DAPI filter with 
excitation wavelength of 365 nm and emission wavelength of 445 nm on a ZEISS 
Axioplan 2 Imaging fluorescent microscope under oil immersion after applying 
the cover slips. 
 
2.8.3 Mitochondria staining with Mito-Tracker 
The mitochondria were stained with the mitochondrion selective probe CMXRos 
Mito-Tracker (Invitrogen) in PBS to a final concentration of 1 nM using 2 × 107 
cells/ml in 1 ml growth medium. The cells were washed once in PBS and re-
suspended in PBS. The cells were further stained with DAPI as in section 2.7.2. 
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The cells were immobilized with agarose as in section 2.7.1 and observed using 
the Cy3 or DSRed filter set with an excitation wavelength of 550 nm and 
emission wavelength of 605 nm.  
 
2.8.4 Filipin III staining of parasite sterols 
The presence of sterols in live cells was visualized by staining with filipin III 
(F4767, Sigma). Cells at 1 × 107 per ml were washed with fresh growth medium 
and re-suspend in pre-warmed fresh medium containing 1 µM filipin III. Stock 
solution of filipin III was initially dissolved in DMSO at 5 mM and then diluted to 
200 µM in PBS before further dilution or addition to the growth medium. The 
cells were incubated at 26°C protected from light for 3 hours and every 15 
minutes an aliquot of 25 µl cells was immobilized as in section 2.7.1 and viewed 
under the fluorescent microscope using DAPI filters. 
2.8.5 Endoplasmic reticulum (ER) staining with ER-Tracker Red 
dye 
The endoplasmic reticulum (ER) was labeled with the ER-Tracker Red dye for live 
cells (Invitrogen). The cells in log phase were harvested and adjusted to 1 × 107 
cells/ml and washed in PBS by centrifuging at 1, 000g for 10 minutes. The cells 
were re-suspended in 100 µl complete Homem medium containing 100 nM ER-
Tracker Red dye and incubated at 27°C for 30 minutes. The cells were 
centrifuged at 1, 000g for 10 minutes and re-suspended in fresh complete 
Homem without the staining dye. The cells were fixed with paraformaldehyde to 
a final concentration of 2% at 27°C for 2 minutes and subjected to 5 minutes 
wash in PBS twice. The cells were mounted onto glass slides and covered with 
cover slips. The treated cells were observed under oil immersion using the DSRed 
filters as in section 2.7.2 on a ZEISS Axioplan 2 Imaging fluorescent microscope. 
 
2.8.6 Imaging cells expressing GFP-tagged proteins 
The cells expressing GFP-tagged proteins were fixed in methanol (section 2.8.2). 
They were observed on a ZEISS Axioplan 2 Imaging fluorescent microscope under 
oil immersion using the GFP filter set with excitation wavelength of 470 nm and 
emission wavelength of 525 nm.  
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2.8.7 Cell length measurement 
The cell length of L. mexicana promastigotes was estimated using the SoftWoRx 
5.5 software on the DeltaVision microscope. The cells in the late log phase were 
fixed in methanol and stained with DAPI (section 2.8.2). The cell length was 
measured from the anterior end to the posterior end of the cell body. 
 
2.9 [
3
H]Pentamidine Uptake Assay 
The uptake of 0.1 µM tritriated pentamidine was done using approximately 1 × 
108 cells/ml in assay buffer (Appendix A) (DeKoning and Jarvis, 1997) at room 
temperature. The cells were harvested, washed once and re-suspended in assay 
buffer. The cells were mixed with pentamidine on 300 µl oil [7/1; v/v; 
dibutylphalate/light mineral oil; Density 1.018 g/ml] (sigma) in 1.5 ml Eppendorf 
tubes. At the set end time of incubation the reactions were stopped by 
centrifuging the tubes at 16, 100g for 1 minute. The tubes were frozen in liquid 
nitrogen and the bottoms of the tubes containing the cells were cut off into 
scintillation tubes. Three replicates were set up for each time point. To each of 
the tubes for the various time points and three tubes with no tritriated 
pentamidine for negative radiation controls were set up and 300 µl of 2% SDS 
was added to the tubes. A further three tubes containing 10 µl of 0.4 µM 
tritriated pentamidine were set up for radiation level controls. All the samples 
were mixed on the rocker for at least 30 minutes. To each of the tubes, 3 ml 
Optiphase ‘Hisafe’ 2 scintillation liquid (PerkinElmer) was added for the 
determination of radiolabel count per minute. The samples were incubated at 
room temperature for overnight. Three replicates of the experiment were done. 
The radioactivity was read on 1450 Microbeta Wallac trilux Liquid scintillation 
and luminescence counter (PerkinElmer). The counts were converted to pmole 
uptake of pentamidine per 1 × 107 cells over time in minutes and plotted using 
the GraphPad Prism 5 software. 
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2.10 Metabolomics analysis 
2.10.1 Sample extraction 
The samples were extracted using the chloroform:methanol:water (1:3:1) 
solvent mixture containing 1 µM each of Theophylline, 5-Fluorouridine, Cl-
phenyl-cAMP, N-methyl glucamine, Canavanine and Piperazine as internal 
standards. The internal standards used are not expected to be present in 
biological systems and are used to monitor the instrument response during 
separation and detection of masses. Cell culture volumes containing 1 × 108 cells 
for each sample were calculated using the culture cell density. Calculated 
volumes of cells cultures of less than 10 ml were transferred to 15 ml Corning 
tubes while calculated volumes of cells of more than 20 ml were transferred to 
50 ml Corning tubes. Cells were quenched rapidly by cooling them to 4°C by 
submerging Falcon tubes in a dry ice/ethanol bath while mixing vigorously during 
cooling to avoid freezing and possible cell lysis. The cells were centrifuged at 1, 
250g for 10 minutes at 4°C in a refrigerated bench top centrifuge and 5 µl of 
supernatant was removed for spent medium analysis while the rest of the 
supernatant was discarded leaving about 1 ml in which the pellet was re-
suspended. The re-suspended cells were centrifuged at 2, 500g for 5 minutes at 
4°C and the supernatant was removed completely. The pellet was re-suspend in 
200 µl of chloroform:methanol:water (1:3:1) at 4°C. The same amount of 
extraction solvent was added to the 5 µl supernatant and 5 µl of growth medium. 
The samples were broken up and re-suspended in extraction solvent by pipetting 
up and down vigorously. The samples were incubated at 4°C for 1 hour with 
vigorous shaking. The mixtures were centrifuged at 13, 000g for 5 minutes at 
4°C. An equal amount of extraction solvent as the samples was set aside and 
treated as the other samples for use as a blank. The supernatant (180 µl) was 
removed and stored under argon gas at -80°C until analysis using LC/MS. 
 
2.10.2 Liquid Chromatography/Mass spectrometry 
The Dionex UltiMate 2000 Liquid chromatography system coupled to the Orbitrap 
Exactive mass spectrometer was used for the separation and mass detection of 
the metabolites at the Scottish Metabolomics Facility (ScotMet), University of 
Glasgow (by either Dr. Karl Burgess or Dr Darren Creek or Miss Suzanne Eadie or 
72 
 
Dr. Stefan Weidt or Dr Hyun Dong Kim) all of whom use the same procedure. The 
samples were run on the LC/MS alongside 179 authentic standards at 10 µM each 
because they provide a means of recalculating the retention times that may 
result from varying performances of the column. Moreover, the authentic 
standards are useful in ruling out false identification by comparing their 
retentions times and mass-to-charge ratios with those of the putative 
identifications during data analysis (Creek et al., 2011). The auto sampler was 
set at 4°C with an injection volume of 10 µl. The ZIC-HILIC (Hydrophilic 
Interaction chromatography) column with the diameter of 4.6 mm, column 
length of 150 mm and pore size of 5 µm were used. A ZIC pHILIC column was 
used which provides a better resolution of both sugar phosphates and carboxylic 
acids, two classes of molecules integral to energy metabolism and is best suited 
for metabolites such as nucleotides. The column temperature was 24°C and the 
flow rate was set at 300 µl/min. A 0.1% solution of formic acid in water and 
0.08% formic acid in acetonitrile as solvents A and B and 20 mM ammonium 
carbonate in water and acetonitrile as solvents A and B for the ZIC-HILIC and 
ZIC-pHILIC columns respectively, were used. The gradient for liquid 
chromatography was 0 min 80% B; 30 min 20% B; 32 min 5% B; 40 min 5% B; 42 
min 80% B; 47 min 8% B. The mass detection of the eluates was performed with 
the mass spectrometer set at a resolution of 50, 000 and switching mode 
between positive and negative mode.  The mass spectrometer was operated with 
spray voltages of +4.5 and -3.5 kV; Capillary voltage +40 V and -30 V; Tube 
voltage +70 V and -70 V; Skimmer voltage +20 V and -18 V; HEIS and Capillary 
temperatures 150°C and 250°C respectively; Sheath, Auxiliary, and Sweeping 
gases 40 units, 20 units and 1 unit, respectively. 
 
2.10.3 Data processing 
The raw data was processed and analyzed using Identification and evaluation of 
metabolomics data from LC/MS (IDEOM). IDEOM is an excel spreadsheet 
automated to process untargeted metabolomics data. It utilizes the features of 
XCMS and mzmatch.R tools to process raw data from LC/MS for identification of 
metabolites and automatically generates scripts that are executed in R software 
to provide a statistical presentation of results (Creek et al., 2012b). Data was 
obtained from Glasgow Polyomics as an IDEOM file. 
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2.11 Proteomics analysis 
2.11.1 Protein extraction 
All protocols from section 2.11.1 to 2.11.6 were performed by Mr. Alan Scott. 
The protein samples were extracted from 1 × 108 cells of each of wild type and 
AmB resistant L. mexicana promastigotes. The cells were harvested and washed 
twice in 1× PBS by centrifugation at 1, 000g for 10 minutes. The cell pellets were 
re-suspended in lysis buffer (Appendix A) by vigorous pipetting up and down in 
1.5 ml eppendorf tubes. The cells were immediately lysed by ten 1 - 2 second's 
probe sonication cycles with 1 minute of cooling on ice between sonications. The 
lysates were incubated at room temperature for 10 minutes with gentle mixing. 
The insoluble materials were removed by centrifuging at 13 000 × g for 10 
minutes and the supernatants were transferred to new 1.5 ml eppendorf tubes. 
The soluble proteins were precipitated using 4 times the volume of the 
supernatant of cold acetone at -20°C. The samples were mixed and incubated at 
-20°C for least 1 hour. The samples were centrifuged at 13, 000 × g for 10 
minutes and the pellets were washed twice with cold 80% acetone. The protein 
samples were re-suspended in small volumes of the lysis buffer to get protein 
concentration of more than 5 mg/ml. The re-suspended protein samples were 
centrifuged at 13, 000 × g for 10 minutes to remove the insoluble material. The 
supernatants were transferred to new eppendorf tubes. 
 
2.11.2 Protein concentration determination 
The protein concentrations of the samples were determined by the Bradford 
assay using bovine serum albumin (BSA) (Promega) as the standard. A series of 
BSA standards from 0 to 0.5 mg/ml were prepared for a standard curve of 
absorbance against protein standard concentration. Water was used as a blank. 
A 1 in 10 dilution of protein samples was done using distilled water. Ten 
microlitres of the standards and the protein samples were transferred to a 96 
well plate in duplicates. Two hundred microlitres of the Bradford reagent 
diluted five times with distilled water was added to the samples. The solutions 
were mixed for 5 minutes to fully develop the color of the reacted Bradford 
reagent. The absorbances of all samples were read at 595 nm. The protein 
sample concentrations were determined by interpolating their absorbance values 
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on the standard curve. The concentration of the samples was adjusted to 5 
mg/ml using the lysis buffer. 
 
2.11.3 Protein labeling 
The wild-type line protein samples were labeled with Cy3 while the 
amphotericin B resistant line protein samples were labeled with Cy5. The 
protein samples at 5 µg in lysis buffer were labeled with the two cyanine dyes. 
The protein samples were mixed with the cyanine dyes at 400 pmol and 
incubated at 4°C for 30 minutes in the dark. The reactions were stopped by 
addition of 10 mM lysine and incubated for 10 minutes on ice and in the dark. 
The labeled samples were otherwise stored at -80°C until use. Otherwise, the 
labeled samples were mixed together and the volume made up to a total of 450 
µl with DiGE rehydration buffer (Appendix A). 
 
A 100 µl of unlabeled protein samples at 5 mg/ml were mixed with 350 µl DiGE 
rehydration buffer for running preparative gels for the two protein samples. 
 
2.11.4 Iso-Electric Focusing 
The protein sample solutions were added to the IEF ceramic IPG strip holders 
and covered with the IPG (pH 3 – 10) strips with the gel surface facing 
downwards. The protein sample solutions and IPG strips were then overlaid with 
mineral oil without trapping any air bubbles. The IEF was run on the Ettan IPG 
phor Iso-Electric Focusing  System (Pharmacia Biotech) with the following 
parameters; 50 µA per strip, step 1 was done at 30 volts (V) for 10 hours (hr), 
step 2 at 300 V for 1 hr, the gradient steps 3, 4, and 5 at 600 V for 1 hr, 1000 V 
for 1 hr, 8000V for 3 hrs respectively, and step 6 (step and hold) at 8000 V for 8 
hrs and 30 minutes. 
 
2.11.5 Second dimension electrophoresis 
The run IPG strips were equilibrated in DiGE Equilibration buffer I (Appendix A) 
and DiGE Equilibration buffer II (Appendix A) for 15 minutes in each buffer. The 
equilibrated strips were washed by dipping in 1× SDS running buffer (Appendix A) 
and were then applied to the top of the SDS gels. The IPG strips were sealed in 
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place with 0.5% agarose sealing solution, containing 0.5% bromophenol blue. The 
gels were run at 120 V overnight on Ettan DALT II System (Pharmacia Biotech) 
with a 1× SDS running buffer in the bottom chamber and the 2× SDS running 
buffer in the top chamber. Electrophoresis was stopped immediately after 
bromophenol blue had run through the bottom of the gel. 
 
The gels were scanned on the Typhoon 9400 variable mode imager. Cy3 labeled 
proteins were scanned at an excitation wavelength of 532 nm (green) and 
emission wavelength of 580 nm with a band pass (BP) filter 30. While the Cy5 
labelled protein were scanned at 633 nm (red) excitation wavelength and 
emission wavelength 670 nm (BP 30). 
 
2.11.6 Total protein staining 
Preparative gels were stained with Coomassie blue (Appendix A) for total protein 
visualization. The run gels were stained with Coomassie blue stain solution and 
destained with the destaining solution as in section 2.6.4. The destained gels 
were scanned at 633 nm (red laser) on the Typhoon 9400 variable mode imager.  
 
2.11.7 Protein spot picking 
The scanned DiGE gel images were analyzed by Dr. Richard J. S. Burchmore and 
were processed using the DeCyder 2-D Differential In-gel Analysis (DIA) Software 
(GE Healthcare) to compare the protein (spots sizes) expression levels and 
generate the picking list. Using the picking list from the DiGE gel analysis, 
corresponding protein spots of interest on the preparative Coomassie blue 
stained gels were manually cut out. 
  
2.11.8 In-gel trypsin digestion 
The protein spots were subjected to in-gel trypsin digestion to obtain peptides 
fragments. The excised gel pieces were washed for one hour with 100 mM 
ammonium bicarbonate with shaking at room temperature. The gel pieces were 
then washed twice with 50% acetonitrile in 100 mM ammonium bicarbonate for 
one hour and the second wash was done with shaking. The gel pieces were 
dehydrated with acetonitrile for 10 minutes and dried in the speed vac 
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(Eppendorf concentrator 5301) after removal of the solvent. Trypsin at 0.2 µg/µl 
in 25 mM ammonium bicarbonate was added to rehydrate the gel pieces for 15 
minutes thereafter excess trypsin solution was added to completely cover the 
fully rehydrated gel pieces. The digestion was done at 37°C incubation for 
overnight. The digestion reactions were stopped with 1% Trifluoroacetic acid. 
The digested protein samples were desalted using the ZipTips (Merck Millipore) 
using the manufacturer’s protocol. 
 
2.11.9 Protein separation, detection and identification 
The proteins were separated and protein spectra generated using the Nanoflow 
HPLC Electrospray Tandem Mass Spectrometry (nLC-ESI-MS/MS) by Dr. Stefan 
Weidt. Peptides were solubilized in 0.5% formic acid and separated on a 
nanoflow uHPLC system (Thermo RSLCnano) prior to online analysis involving 
ionisation by electrospray ionisation (ESI) and mass detection on an Amazon ion 
trap MS/MS mass spectrometer (Bruker Daltonics). The peptides were separated 
on a Pepmap C18 reversed phase column (LC Packings), using a 5 - 85% v/v 
acetonitrile, in 0.5% v/v formic acid gradient, run over 45 minutes with a flow 
rate of 0.2 l/min. The continuous duty cycle of survey MS scan followed by up 
to ten MS/MS analyses of the most abundant peptides was used to perform mass 
spectrometric analysis, opting for the most intense multiply charged ions with 
dynamic exclusion for 120s. 
 
Bruker Data Analysis Software and the automated Matrix Science Mascot Daemon 
server (v2.1.06) were used to process MS data. The Mascot search engine was 
used for protein identification assignment following interrogation of protein 
sequences in the NCBI Genbank database with an allowance mass tolerance of 
0.4 Da for both MS and MS/MS analyses. Data was obtained from Glasgow 
polyomics as a Microsoft spread sheet with web links for the identified proteins. 
 
2.12 Statistical Analysis 
Statistical analysis was done using GraphPad Prism 5, Microsoft Excel and IDEOM. 
Comparison of means was done using Unpaired Student’s t-test and ANOVA. A P-
value cut-off of 0.05 was used, with P < 0.05 being considered significant.  
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Chapter Three 
3 Amphotericin B resistance in Leishmania 
mexicana promastigotes 
3.1 Introduction 
Chemotherapy has remained the main control method for infections with 
Leishmania species, although there are many known challenges to this method. 
Amphotericn B has emerged as the drug of choice for visceral leishmaniasis, 
when used in its liposomal form. There have been concerns expressed over the 
preservation of the efficacy of Amphotericin B due to the ease with which 
resistance to the drug can be induced in vitro. Although resistance to 
amphotericin B in the field is rare in fungi, for which the drug was initially used 
and it is not known to exist in leishmaniasis (Olliaro, 2010) there is a clear risk 
that resistance is possible. The introduction of a liposomal formulation has 
reduced toxic effects (Lemke et al., 2005) making it the drug of choice in many 
regions. It is also convenient and effective to use as a single dose therapy 
(Mondal et al., 2014). The single dose use of liposomal amphotericin B has been 
associated with reduced cost of treatment, ease of administration, increased 
safety due to the reduced side effects and an ability to be administered in rural 
remote areas (Mondal et al., 2014; Sundar et al., 2010). Further, even when 
compared to miltefosine which has a more convenient oral route of 
administration, liposomal amphotericin B single dose infusion (10 mg/kg of body 
weight) therapy can be used in children and women of child bearing age (Mondal 
et al., 2014). The drug has also undergone tests to be used in combination 
therapy to combat the lethal form of leishmaniasis, visceral leishmaniasis, in 
India with promising results (Olliaro, 2010). The drug may enter into mass use 
due to these favourable attributes. However, use of a drug singly and its mass 
use tends to predispose the drug to development of resistance by the parasites 
(Sinha and Bhattacharya, 2014). The situation may be exacerbated for 
Amphotericin B because the single dose use pushes the drug towards its 
maximum usable concentration. Amphotericin B no doubt holds an important 
place in the control of leishmaniasis. Therefore to safeguard its continued use, 
Leishmania parasites resistant to amphotericin B need to be characterised to 
learn about the mechanisms of resistance. This in turn can lead to development 
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of ways to assess resistance and also to inform on ways to use the drug that 
might minimise the risk of resistance. 
 
We undertook to characterise in vitro amphotericin B resistance in L. mexicana 
promastigotes with the aim of highlighting the characteristics of the resistant 
parasites that can help to mitigate the effects of amphotericin B resistance 
should it arise in future. To achieve our aims we have utilised a complementary 
use of metabolomics and genomic DNA sequencing to identify characteristics 
that differentiate generated Amphotericin B resistant cells from wild-type cells. 
  
3.2 Results 
3.2.1 Selection for Amphotericin B resistant L. mexicana 
Resistance to amphotericin B (AmB) was induced by stepwise increases in drug 
concentration over 18 passages stretching over six months. During this period, a 
13-fold increase in the EC50 value was recorded, indicating a significant 
difference (P = 0.0007) in EC50 value between the wild-type and a clone of 
highest level AmB resistance. While there was a gradual increase in AmB EC50, 
for the two intervening resistant clones closer to the wild-type, there was a 
jump in the EC50 value to reach the highest level (Figure 3.1 and Figure 3.6). 
There was no significant difference (P = 0.9647) in the EC50 value for the clones 
growing in the presence of 0.027 µM of AmB and the wild-type. However, there 
was a significant difference in AmB EC50 values for the clones growing in the 
presence of 0.054 µM (P = 0.0001), 0.081 µM (P < 0.0001) and 0.27 µM (P < 
0.0001) AmB as compared to that of the wild-type L. mexicana. There was a 
significant difference (ANOVA, P < 0.0001) in the AmB EC50 mean values between 
all of the clones.  We did not observe appreciable differences in the growth 
phenotype between the resistant clones and the wild-type cells, although during 
the process of drug resistance induction, there were prolonged periods during 
which the cells needed to adapt to a given drug concentration before they could 
grow at similar rates as the wild-type cells before raising the drug concentration 
in growth medium.  
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Figure 3.1 Comparison of AmB EC50 values for various L. mexicana AmB resistant clones. 
The EC50 values were determined using the modified alamar blue assay of 72 hours drug 
exposure of cells with the starting cell density of 1 × 10
6
 cells/ml and colour development 
over 48 hours of incubation following addition of 0.49 mM resazurin in PBS. Absorbance 
results were analysed in GraphPad Prism 5.0. (** P = 0.0001, *** p < 0.0001). Results are 
presented as Mean ± SEM for at least three independent experimental replicates. 
 
  
3.2.2 Characterisation of the derived amphotericin B resistant L. 
mexicana promastigotes 
3.2.2.1 Comparison of cell body length of wild-type and AmB resistant 
clones 
Differences in cell size were noticed between the wild-type and the derived AmB 
resistant cells when viewed under the light microscope. We investigated this by 
fixing the late log-phase cells with methanol at -20°C and measured the cell 
body length of 126 individual cells for each of the two cell lines using the 
software SoftWoRX 5.5 on the delta-vision microscope. There was a significant 
difference (t-test; P < 0.0001) in cell body length between the wild-type and the 
AmB resistant clones exhibiting the highest resistance trait i.e., growing in the 
presence of 0.27 µM AmB (Figure 3.2). The wild-type cells had an average cell 
body length of 11.16 ± 0.19 µm while that of the resistant clone was 9.86 ± 0.16 
µm. 
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Figure 3.2 Comparison of the cell body length of the wild-type and the AmB resistant cells. 
(A) Scatter dot plot of the comparison of the cell body length of L. mexicana wild-type and 
AmB resistant clone growing in the presence of 0.27 µM. (B) Cells were fixed in methanol at 
-20°C overnight and stained with 1 µg/ml DAPI/1%DABCO in PBS before applying to slides 
and viewing under the fluorescent microscope. The slides were observed under oil 
immersion. N = nucleus; K = kinetoplast; Bar = 15 µm. 
 
3.2.2.2 Stability of AmB resistance  
To check the stability of the induced AmB resistance, the clones of highest 
resistance were grown in the absence of AmB for 15 passages. The resistant 
clone growing in the presence of 0.27 µM AmB exhibited no change in the AmB 
EC50 value as determined by the modified alamar blue assay. A significant 
difference (P < 0.0001) in AmB EC50 between the wild-type and the resistant 
clone was maintained. 
 
3.2.2.3 Amphotericin B cross-resistance to other drugs 
The stability of the induced AmB resistance led us to investigate any possible 
AmB cross-resistance to other anti-leishmanial drugs. AmB cross-resistance to 
other drugs was assessed using the modified alamar blue assay and then 
comparing the EC50 values between those of the wild-type and the resistant 
clone growing in the presence of 0.27 µM AmB. There was a significant 
difference in the determined EC50 values between the wild-type and the AmB 
resistant clone for (R)-N-(1-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-yl) ethyl)-4-
(5-phenyl-1, 3, 4-oxadi-azol-2-yl) benzamide (VNI), a compound that is specific 
for Sterol 14α-demethylase and shows potency against T.cruzi (Villalta et al., 
2013), (P = 0.0005) and ketoconazole (P = 0.0007) with fold-increase in the EC50 
values of 1.5 and 1.7, respectively (Figure 3.3). These compounds were tested 
subsequently to finding a role for Sterol 14α-demethylase mutation in resistance 
(see section 4.3.4) Cross-resistance to potassium antimony tartrate (PAT), 
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representing the trivalent active form of antimony drugs, and miltefosine 
involved fold change in EC50 values of 2.9 and 3.9 representing significant 
differences (P = 0.0005 and P < 0.0001) in EC50 values as compared to the wild-
type, respectively. 
 
 
Figure 3.3 Amphotericin B cross-resistance to other anti-leishmanial drugs. 
AmB cross-resistance to other anti-leishmanial drugs in a derived AmB resistant clone 
growing in the presence of 0.27 µM AmB. Cross-resistance and susceptibility to other anti-
leishmanial drugs was determined using the modified alamar blue assay and the EC50 
values were computed using the Graph Pad Prism software. VNI = (R)-N-(1-(2, 4-
dichlorophenyl)-2-(1H-imidazol-1-yl) ethyl)-4-(5-phenyl-1, 3, 4-oxadi-azol-2-yl) benzamide; 
PAT = Potassium Antimony Tartrate. Results are for at least three independent experiments 
and plotted as Mean ± SEM. 
 
 
Interestingly, the AmB resistant cells were found to be very significantly more 
susceptible to paromomycin (P = 0.0002) and pentamidine (P = 0.0001) with fold-
decreases in determined EC50 values of 96.5 and 13.3, respectively. 
 
3.2.2.4 [3H]Pentamidine up-take by AmB resistant cells 
The susceptibility of the resistant cells to pentamidine was further investigated 
by comparing the uptake of radiolabel pentamidine by the AmB resistant cells 
and the parental wild-type L. mexicana promastigotes. The AmB resistant clone 
showed significant (P < 0.0001) increase in the uptake of pentamidine at a rate 
of 0.258 ± 0.031 pmol/107 cells/min than the wild-type cells which took up the 
drug at a rate of 0.062 ± 0.009 pmol/107 cells/min (Figure 3.4). 
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Figure 3.4 [
3
H]Pentamidine up-take in AmB resistant cells compared to the wild-type cells. 
The uptake was performed with 1 × 10
8
 cells/ml in triplicates for each time-point at 0 sec, 30 
sec, 1 min, 5 min and 10 min for each experiment. The data was analysed using GraphPad 
Prism. The data is for four independent replicates. Results are presented as Mean ± SEM. 
 
 
3.3 Genomic DNA sequencing and comparison of Wt and 
AmB resistant L. mexicana 
The gDNA of derived AmB resistant clone of highest resistance and the wild-type 
that were passaged in parallel during the induction of resistance was sequenced 
at University of Glasgow – Glasgow Polyomics. Data was analysed by Dr. Nicholas 
Dickens and Dr. Manikhandan Mudaliar. A total of 32,238,036 and 27,514,220 
reads were obtained and of these 17,138,430 and 15,392,124 reads were aligned 
for the wild-type and the AmB resistant clone, respectively. 
 
An alignment of the derived AmB resistant to the wild-type and both to 
reference L. mexicana MHOM/GT/2001/U1103 genome, revealed differences in 
chromosome numbers between the resistant clone and the wild-type cells 
(Figure 3.5). The AmB resistant cells had gained an extra chromosome for 
chromosome 05, 19, 22, and 27 and lost a chromosome for chromosome 12 and 
17 as compared to the parental wild type cells.There were 22, 692 single 
nucleotide polymorphisms (SNPs) detected in the wild-type and 23, 641 SNPs in 
the AmB resistant cells’ gDNA as compared to the reference L. mexicana 
MHOM/GT/2001/U1103 genome. Of these SNPs differences, 2, 049 and 2, 998 
were found to be unique to the wild-type and the resistant cell line, respectively 
(Table 3.1). Because of the large numbers of SNPs, we used metabolomics 
analysis (as presented in section 3.5) to gain more insight into the two cell lines. 
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Figure 3.5 Comparison of CNV of parental wild-type and the derived AmB resistant clone. 
Data was analysed and provided by Dr. Nicholas Dickens and Dr. Manikhandan Mudaliar. 
 
 
 Wild-type AmB resistant 
Total SNPs 22, 692 23, 641 
Exonic SNPS 9, 530 9, 722 
Coding changes 5, 313 5, 458 
Unique SNPs 2, 049 2, 998 
Table 3.1 SNPs distribution in wild-type and AmB resistant with reference to U1103 genome. 
The NGS gDNA sequences of AmB resistant parasites and their parental wild-type passaged 
in parallel during AmB resistance selection were aligned to MHOM/GT/2001/U1103 reference 
genome. Data was analysed and provided by Dr. Nicholas Dickens and Dr. Manikhandan 
Mudaliar. 
 
3.3.1 Identification of genetic alterations in sterol biosynthetic 
pathway enzymes 
Metabolomics revealed perturbations in the ergosterol biosynthetic pathway. S. 
cerevisiae’s 24 enzymes of the sterol biosynthetic pathway were used to identify 
21 ortholog enzymes of L. mexicana (Table 3.2 and Appendix D) which were used 
for gDNA sequence analysis. As a result a total of 13 and 10 SNPs were detected 
in the coding sequences of AmB resistant cells and the wild-type, respectively, 
with regard to the ergosterol biosynthetic pathway enzymes (Table 3.2). Most of 
these SNPs were concluded to be SNP calling inconsistencies and only one of 
them represented a non-synonymous mutation in the AmB resistant cells 
(Appendix E). The SNP was located on gene ID LmxM.11.1100 positioned at 
11.443299, involving a change from A to T within the coding sequence of 
lanosterol 14α-demethylase replacing an asparagine residue with isoleucine at 
position 176 (N176I) of the primary structure of the enzyme. The mutation was 
found on both alleles of the gene and hence a homozygous mutation. 
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S cerevisiae 
Enzyme name 
Enzyme gene ID 
Ortholog L. mex 
Chromosome 
number 
Ploidy 
Wt AmB-R 
Thiolase protein-like (most 
likely trifunctional protein 
Beta subunit) 
LmxM.30.1640 30 4 4 
Hydroxy-3-methylglutaryl 
coenzyme a reductase 
LmxM.29.3190 29 2 2 
Mevalonate kinase LmxM.30.0560 30 4 4 
Phosphomevalonate kinase LmxM.15.1460 15 2 2 
Diphosphomevalonate 
decarboxylase 
LmxM.18.0020 18 2 2 
Isopentenyl-diphosphate delta-
isomerase 
LmxM.34.5330 34 2 2 
Farnesyl pyrophosphate 
synthase FPPS 
LmxM.22.1360 22 2 3 
prenyltransferase, putative LmxM.28.1320 28 2 2 
Farnesyl diphosphate 
synthetase/solanesyl 
diphosphate synthase 
LmxM.15.1020 15 2 2 
Geranylgeranyl transferase 
type II beta subunit, putative 
LmxM.33.4030 33 2 2 
Squalene synthase/farnesyl 
transferase 
LmxM.30.2940 30 4 4 
Squalene monooxygenase LmxM.13.1620 13 3 3 
Lanosterol synthase LmxM.06.0650 06 2 2 
Sterol 14-alpha (lanosterol) 
demethylase (CYP51) 
LmxM.11.1100 11 2 2 
C-14 sterol reductase, putative LmxM.31.2320 31 2 2 
NAD(p)-dependent steroid 
dehydrogenase-like protein 
LmxM.06.0350 06 2 2 
Sterol 24-c-methyltransferase 
LmxM.36.2380 / 
LmxM.36.2390 
36 2 2 
C8-sterol isomerase LmxM.08_29.2140 29 2 2 
Lathosterol oxidase-like 
protein |C5 sterol desaturase 
LmxM.23.1300 23 2 2 
C-22 sterol 
desaturase/cytochrome p450-
like protein 
LmxM.29.3550 29 2 2 
C-24 sterol desaturase LmxM.32.0680 32 2 2 
Table 3.2 Ploidy of chromosomes harbouring enzymes of the sterol biosynthetic pathway. 
S. cerevisiae sterol biosynthetic enzyme sequences were used to search for their 
Leishmania mexicana orthologs in TriTryp DB and used in gDNA sequence analysis. 
Comparison of the ploidy for involved chromosomes is made in the last two columns of the 
table labelled wild-type (Wt) and amphotericin B resistant (AmB-R) promastigotes of L. 
mexicana. Farnesyl pyrophosphate synthase (bold) is the only enzyme of the sterol 
biosynthetic pathway which was potentially affected by chromosome number change. 
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3.3.2 Status of N176I mutation in AmB resistant clones of lower 
resistance 
To ascertain the point at which the N176I mutation arose during the resistance 
induction, we sequenced lanosterol 14α-demethylase for three intervening 
resistant clones between the wild-type and the resistant clone growing in the 
presence of 0.27 µM AmB. Sequencing of the PCR products of at least 10 samples 
of clones growing in the presence of 0.027 µM and 0.054 µM inserted into the 
pGEMT easy vector revealed the absence of the N176I mutation. However, the 
resistant clone growing in the presence of 0.081 µM showed the presence of the 
mutation (Figure 3.6) as in the clone of higher resistance which was sequenced 
by NGS. 
 
 
Figure 3.6 Point of N176I occurrence in AmB resistant clones at different selection points. 
The occurrence of N176I mutation in various AmB resistant clones was determined by 
sequencing PCR amplified Sterol 14α-demethylase of the clones growing in the presence of 
the shown AmB concentration in the graph. The point at which the mutation was detected is 
shown by the vertical dashed line starting from the clone growing in the presence of 0.081 
µM AmB. The EC50 values plotted are an average of three replicates. 
 
The other enzyme of the sterol biosynthetic pathway which might have been 
affected by AmB resistance induction was farnesyl diphosphate synthase. The 
enzyme is located on chromosome 22 with the gene ID LmxM.22.1360. The AmB 
resistant clone was found to have gained an extra chromosome 22 (Figure 3.5) 
when compared to the parental wild-type cells as a result an extra gene copy of 
farnesyl diphosphate synthase was thought to have arisen (Table 3.2).  
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Having noticed alterations in putrescine and trypanothione levels (section 4.5), 
we looked at the possibility of the enzymes linked to these metabolites being 
affected by CNV. A copy number for trypanothione reductase (Gene ID 
LmxM.05.0350) was found to increase from 2 to 3 due to the extra chromosome 
05 gained by the resistant cells. However, ornithine decarboxylase (Gene ID 
LmxM.12.0280) was thought to have lost a gene copy due to loss of chromosome 
12 (Figure 3.5) when compared to the wild-type at the end of resistance 
induction. 
 
3.4 Proteomics analysis of the wild-type and AmB 
resistant cells 
Following the differences in chromosome number and metabolome (presented in 
section 3.5) between the wild type and the AmB resistant cells, we investigated 
possible differences in protein expression between the two cell lines. Proteomics 
analysis was hoped to provide explanations of the differences in metabolomic 
analysis and also confirm whether differences in protein expression could be 
attributed to genetic changes observed in gDNA NGS analysis. We used DiGE by 
labelling the wild-type and the resistant line with Cy3 and Cy5, respectively, to 
facilitate comparison of the protein spots from the two cell lines run on one gel 
using the DeCyder 2-D Differential In-gel Analysis (DIA) Software and generate a 
protein picking list. The selected protein spots for identification were manually 
cut from two preparative gels, one for each cell line, and subjected to nLC-ESI-
MS/MS.
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Protein ID Gene 
Accession 
number 
Mascot 
score 
Nominal 
mass 
(Da) 
Spot Fold 
increase 
pI Enzyme 
EC 
number 
Chromosome 
number 
Farnesyl diphosphate synthase    LmxM.22.1360 32 41, 460 2.36 5.42 2.5.1.10 22 
Cis-prenyltransferase-like protein  LmxM.13.0020  25 44, 180 2.32 8.47 2.5.1.1 13 
S-adenosylmethionine synthetase LmxM.29.3500 38 34, 286 4.08 5.42 2.5.1.6 29 
Table 3.3 Proteins identified in proteomics as expressed differently by the wild-type and AmB resistant cells. 
Protein samples were extracted from the wild-type and AmB resistant cells and subjected to two-dimensional gel electrophoresis and Nanoflow HPLC 
Electrospray Tandem Mass Spectrometry (nLC-ESI-MS/MS). MS data was analysed using Data Analysis Software (Bruker) and the automated Matrix 
Science Mascot Daemon server (v2.1.06). Protein identification was done by interrogation of protein sequences in the NCBI Genebank database
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Out of a total of 37 spots picked from the wild-type and the AmB resistant 
sample preparative electrophoretic plates that were processed for 
identification, three proteins (Table 3.3) with links to the sterol biosynthetic 
pathway were noted, although with low mascot scores. Most of the other 
identifications were hypothetical proteins (Appendices H and I), a Blast search of 
which in other organisms like yeast (S. cerevisiae) in NCBI yielded no orthologous 
proteins of known function. It is worth noting that among the identified proteins 
was farnesyl diphosphate synthase which was noted to be potentially affected by 
CNV of chromosome 22 in gDNA NGS data analysis. The proteomics data 
indicated an up-regulation of the protein in the derived AmB resistant cell line 
with a spot increase of 2.36 which is consistent with the additional copy of 
chromosome 22. Up-regulation of the enzyme has been indicated to be 
responsible for resistance to risendronate in L. major (Ortiz-Gomez et al., 2006). 
 
3.5 Metabolomic comparison of Wt and AmB resistant L. 
mexicana 
The comparison of the derived AmB resistant cells to the parental wild-type L. 
mexicana promastigotes was extended to untargeted metabolomics to capture as 
many differences as possible in terms of metabolites. PCA analysis indicated a 
clear separation of the wild-type from AmB resistant cell samples (Figure 3.7). 
All medium related samples clustered together while the quality control (QCs) 
samples were grouped separately. 
 
The clear separation of the two cell lines derived samples in PCA analysis 
indicated that there were differences between the two cell lines. To explore 
these differences, we looked for differences in the sterol biosynthetic pathway 
metabolites that have been reported (Al-Mohammed et al., 2005; Mbongo et al., 
1998; Purkait et al., 2012) in Leishmania AmB resistance studies with regard to 
alterations in the sterol biosynthetic pathway (Table 3.4). These studies used a 
targeted approach of GC/MS to identify altered sterols.
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Figure 3.7 PCA of the metabolomic comparison of Wild-type and AmB resistant cells. 
The first principal depicts the differentiation of samples using the main variable feature 
while the second component shows other variations among the samples. PCA analysis was 
done using IDEOM. The analysis was done using three independent experimental replicates.  
 
The sterols detected in our study (Table 3.5 and Appendix J) were not those that 
have been reported by other studies (Table 3.4), except ergosterol. The 
difference could be due to the differences in the platforms used for the analysis 
of the sterols. We used untargeted metabolomics utilising LC/MS while all earlier 
studies used GC/MS targeted at sterol metabolite analysis. Our use of untargeted 
metabolomics was to capture other metabolite changes that could also result 
from AmB resistance(attached CD). Further, the metabolites were extracted 
from leishmania samples using different solvent systems to suit the separation 
and detection methods. Earlier studies reported detection of ergosterol in the 
wild-type cells and not in the amphotericin B resistant cells but we were able to 
detect ergosterol in the wild-type cells and diminished levels in amphotericin B 
resistant cells. This may have been due to difference in sample extraction and 
platforms of analysis as well as the level of resistance of the cells used in the 
studies.
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Sterol 
Monoisotopic 
mass 
Formula % of total sterol/Reference 
Species/Reference 
 Wt AmB-R 
Ergosta-5, 7, 24 (28)-trien-3β-ol 396.34 C28H44O 85.1A; 32M; 34P - L. mex/A; L. don/M; P 
Ergosta-7,24,(28)-dienol 398.35 C28H46O 4.2A - L. mex/A 
Stigmasta-5,7,24(28)-trienol 410.36 C29H46O 10.6A - L. mex/A 
4,14,Dimethyl-cholesta-8,24-dienol 414.40 C29H44O - 62.4A; 5M L. mex/A 
4,14,Dimethyl-cholesta-7,24-dienol 414.40 C29H44O - 6.5A L. mex/A 
Lanosta-8,24-dienol 426.72 C30H50O - 31.1A L. mex/A 
Cholesta-5,7,24-trien-3β-ol 382.32 C27H42O - 62P; 58M L. don/M; P 
14α-Methylergosta-5,7,24(28)-trien- 3β-ol 393.31 C28H41O 8M - L. don/M 
Ergosterol (Ergosta-5,7,22E-trien-3β-ol) 396.34 C28H44O 28P; 30M - L. don/M; P 
Cholesterol 386.36 C27H46O 11P; 13M 24P; 27M L. don/M; P 
Table 3.4 Reported altered sterol composition in amphotericin B resistant Leishmania species. 
The shown sterol composition and alterations in wild-type and amphotericin B resistant (AMB-R) L. mexicana (L.mex) and L. donovani (L. don) 
promastigotes were determined by targeted GC/MS method. Monoisotopic masses and formulae were obtained from chemspider.com.The letters after the 
percentage values under % of total sterol/reference column and leishmania species/reference column represent the source of the data, thus A= Al 
Mohammed et al., 2005; M = Mbongo et al., 1998; P = Purkait et al., 2012.
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Mass 
(m/z) 
RT 
(min) 
Formula Identified metabolite Fold 
change 
410.35 5.013 C29H46O 4,4-dimethylcholesta-8, 11,24-trien-3β-ol 111.53 
426.35 4.939 C29H46O2 
4α-formyl-4β-methyl-5α-cholesta-8-24-
dien-3β-ol 
20.93 
396.34 5.026 C28H44O Ergosta-5, 7, 22E-trien-3β-ol 0.84 
394.32 4.983 C28H420 Ergosta-5, 7, 22, 24(28)-tetraen-3β-ol 0.07 
Table 3.5 Sterol metabolites detected in L. mexicana AmB resistant and wild-type cells. 
The wild-type and AmB resistant samples were extracted using the methnol: chloroform: 
water mixture at 4°C. The sterol biosynthetic pathway metabolites were identified following 
LC/MS and IDEOM analysis. The fold change is the ratio of the detected sterol metabolite 
between the wild-type as the control and the derived amphotericin B resistant cells. Rt = 
Retention time; m/z = mass to charge ratio. 
 
The accumulation of 4, 4-dimethyl-cholesta 8, 11, 24-trienol in AmB resistant 
cells was accompanied by depleted relative abundance levels of ergosta-5, 7, 
22, 24(28)-tetraen-3β-ol (Table 3.5). Ergosta-5, 7, 22, 24(28)-tetraen-3β-ol a 
sterol biosynthetic pathway intermediate which occurs in traces in Leishmania 
and is derived from ergosta-5, 7, 24 (28)-trienol the reportedly major sterol of L. 
mexicana, L. tropica, and L. donovani (Goad et al., 1984). The minor sterol of 
Leishmania, ergosta-5, 7, 22E-trien-3β-ol or ergosterol (Roberts et al., 2003) 
showed reduced levels in the resistant cells (Table 3.5). Use of the volcano plot 
(Figure 3.8) revealed 4, 4-dimethyl-cholesta 8, 11, 24-trienol an isomer of 4, 4-
dimethyl-cholesta 8, 14, 24-trienol as the metabolite that significantly changed 
with high intensity ratio. 4, 4-dimethyl-cholesta 8, 14, 24-trienol is a product of 
lanosterol 14α-demethylase (Figure 1.8), an enzyme that was found to have a 
non-synonymous mutation in NGS analysis. 4, 4-dimethyl-cholesta 8, 14, 24-
trienol was identified based on IDEOM identification of the metabolite through 
use of the retention time and the m/z ratio (Attached CD). It is interesting to 
note that 4, 4-dimethyl-cholesta 8, 14, 24-trienol has been reported in yeast 
treated with ketoconazole (Baloch et al., 1984) and it is listed in the predicted 
Leishmania sterol biosynthetic pathway in the Biocyc.org website (Figure 1.8).
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Figure 3.8 Volcano plot of the identified metabolites in metabolomics analysis. 
Identification of the significantly changing metabolites identified from the comparison of the 
AmB resistant cells and the parental cells. 4, 4-dimethyl-cholesta 8, 14, 24-trienol a product 
of lanosterol 14α-demethylase highlighted in yellow, was identified to be significantly 
changing. The volcano plot was generated in IDEOM. The analysis was done using three 
independent experimental replicates. Graphs were plotted using Mean ± SD. 
 
3.5.1 Alterations in the polyamine and thiol metabolic pathways 
We also noted alterations in the precursors and metabolites of the polyamine 
pathway (Figure 3.9 and Table 3.6) that were detected during the metabolomic 
comparison of the parental wild-type and the derived AmB resistant cell lines. 
The polyamine pathway provides the parasites with molecules that protect them 
against oxidative stress because spermidine links with two molecules of 
glutathione creating trypanothione (Fairlamb et al., 1985). The polyamines also 
play key roles in cell proliferation and are involved in binding to various cellular 
anions including DNA, RNA and membrane phospholipids (Bacchi, 1981). 
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Figure 3.9 Comparison of polyamine and thiol metabolites in Wt and AmB resistant cells. 
The wild-type (Wt) and amphotericin B (AmB) resistant samples were extracted using 
chloroform; methanol; water at 4°C. The extracted samples were analysed using LC/MS and 
IDEOM. The analysis was done using three independent experimental replicates. Wtcells = 
samples derived from cells; Wtsup = medium in which wild-type cells were grown; 
AmBRcell = metabolites extracted from AmB resistant cell samples; AmBRsup = medium in 
which the cells were grown; Medium = fresh growth medium. Graphs were plotted using 
Mean ± SD. 
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Metabolite  Fold-difference P value 
S-Adenosyl-L-methionine  0.65 0.09007 
L-ornithine  0.14 0.11771 
Putrescine  0.68 0.015073 
Glutathione  1.44 0.584761 
Trypanothione  1.87 0.271301 
Table 3.6 Polyamine precursor/substrates and thiols abundance in Wt and AmB-R cells. 
Relative abundance of polyamines substrates and thiols were compared using IDEOM 
following analysis of samples extracted using the chloroform:methanol:water protocol by 
LC/MS. 
 
The relative abundances of trypanothione and glutathione were elevated with 
fold differences of 1.87 and 1.44 in the resistant cells although this was not 
statistically significant (P = 0.271301 and P = 0.584761, respectively) (Figure 3.9 
and Table 3.6). Ornithine, putrescine and S-adenosyl-L-methionine showed 
depleted levels. Although there were differences in the levels of the polyamine 
precursors and metaboltes detected between the two cell lines only the change 
in putrescine levels was statistically significant (Table 3.6). The difference in the 
polyamine precursors, polyamine and thiols could be part of the attainment of 
AmB resistance by the cells as AmB has been shown to induce accumulation of 
ROS that cause oxidative stress in L. infantum (Moreira et al., 2011). 
  
3.5.1.1 Comparison of response to oxidative stress 
Because of the possible difference in oxidative stress response, we exposed the 
wild-type and AmB resistant cells (2 × 106 cells/ml) to varying concentrations (20 
µM, 200 µM, 500 µM and 1 mM) (Das et al., 2001) of H2O2 in growth medium in 6-
well plates to compare the response by the two cell lines through observation 
under a light microscope at different time points for 72 hours. Generally, both 
cell lines were unaffected by 20 µM H2O2. The resistant cells were more affected 
by H2O2 than the wild-type cells at concentrations of H2O2 starting from 200 µM. 
The resistant cells looked swelled and rounded in shape and were settling to the 
bottom of the plate within 90 minutes, while the wild-type maintained their 
shape and looked like the wild-type control cells grown in H2O2 free medium. 
After 4 hours of incubation a few wild-type cells seemed affected by settling to 
the bottom of the plate with reduced movement while resistant cells continued 
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to swell and settle at the bottom of the plate. However, both cell lines did 
recover after 24 hours of incubation. 
 
Exposure of the two cell line to 500 µM and 1 mM H2O2, had no apparent 
immediate effect on the cells. However swelled and round-shaped cells at both 
concentrations of H2O2 were observed after 5 minutes of incubation. The cells 
exhibited sluggish to no movement with the effect being pronounced in the AmB 
resistant cells in the presence of 500 µM H2O2 in growth medium after 30 
minutes. While the cells in 1 mM H2O2 showed no movement after 30 minutes, 
leading to cell clumping after 90 minutes, although the cells were of normal 
shape. These effects were observed up to 24 hours of exposure after which cells 
were noticed to have started to recover in growth medium containing 500 µM 
H2O2. The cells in growth medium containing 1 mM H2O2 died within 24 hours. 
After 72 hrs, more of the wild type cells than the AmB resistant cells had 
recovered in growth medium containing 500 µM H2O2 to about 9 × 10
6 cells/ml 
and 4 × 106 cell/ml, respectively. 
  
We also used methylene blue to further explore the susceptibility of the AmB 
resistant cells to oxidative stress. Methylene blue is known to induce oxidative 
stress by depleting the levels of NADPH + H+ resulting in the activation of the 
pentose phosphate pathway to provide fresh NADPH + H+ for anti-oxidant use and 
hence has been used to observe or test both phenomena (Maugeri et al., 2003). 
The AmB resistant cells were found to be significantly (P < 0.0001) more 
susceptible to methylene blue than the wild-type cells (EC50 values: 0.117 ± 
0.001 µM and 4.20 ± 0.22 µM, respectively). 
  
3.5.1.2 Use of NAC to alleviate oxidative stress 
The observation that the AmB resistant cells seemed to be affected more by 
oxidative stress than the wild-type led us to carrying out susceptibility assays 
through the modified alamar blue assay in the presence of an antioxidant N-
Acetyl-L-cysteine (NAC). Twenty millimolar NAC has been used to scavenge for 
reactive oxygen species that cause oxidative stress in Leishmania, as well as 
serving as a precursor to glutathione synthesis (Verma et al., 2011). We first 
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Drug 
Wt  AmB-R 
- NAC + NAC 
Fold 
Change 
 
- NAC + NAC 
Fold 
Change 
AmB  0.071 ± 0.0007 0.033 ± 0.0011 0.47  1.311 ± 0.17 0.43 ± 0.0149 0.33 
PAT 197.6 ± 11.79 448.6 ± 8.59 2.27  564.6 ± 32.65 282.8 ± 3.45 0.50 
Miltefosine  5.824 ± 0.11 5.362 ± 0.41 0.92  22.58 ± 0.20 12.88 ± 0.49 0.57 
Pentamidine  4.19 ± 0.27 2.99 ± 0.05 0.71  0.316 ± 0.0077  0.307 ± 0.0017 0.97 
Paromomycin  3019 ± 773.40 1255 ± 180.4 0.42  36.68 ± 1.05 79.60 ± 1.89 2.17 
M. blue 4.20 ± 0.22 0.658 ± 0.040 0.16  0.1173 ± 0.001 0.0557 ± 0.006 0.47 
Table 3.7 Comparison of EC50 values of anti-leishmanial drugs in the presence and absence of N-acetyl-cysteine. 
The EC50 values were determined both in the presence and absence of 200 µM NAC by the modified alamar blue assay and analysed using Prism 
GraphPad. The analysis was done using three independent replicates. The wild-type were less sensitive to PAT while the AmB resistant cells were less 
sensitive to Paromomycin in the presence of NAC. EC50 values expressed as Mean ± SEM, NAC = N- acetyl-L-cysteine; PAT = Potassium Antiomny Tartrate; 
M. Blue = Methylene blue; Wt = wild-type cells; AmB-R = Amphotericin B resistant cells; Fold change = AmB-R EC50/ Wt EC50. All values are in µM.
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determined the toxicity of NAC on both the wild-type and the AmB resistant cell 
lines. There was a significant difference (P = 0.03) in NAC EC50 values of 44.5 ± 
10.1 mM and 12.1 ± 1.1 mM for the wild-type and the resistant cells, 
respectively. We therefore used 200 µM as the concentration that would not kill 
both cell lines. The AmB resistant cells were less sensitive to paromomycin in 
the presence of 200 µM NAC with a fold-change in EC50 value of 2.17. There was 
no change in the EC50 value for pentamidine but the AmB resistant cells showed 
increased susceptibility to the rest of the drugs tested (Table 3.7). The wild-type 
cells were protected from PAT with a fold-increase in EC50 value of 2.27. NAC 
had no effect on the EC50 value for miltefosine in the wild-type cells. Interesting 
NAC was found to sensitive both the wild-type and the AmB resistant cells to 
methylene blue with fold-changes in EC50 values of 0.16 and 0.47, respectively. 
 
3.5.2 Ergosterol supplementation in growth medium 
Bloodstream forms of T brucei are known to take up host cholesterol for their 
use (Green et al., 2003). In vitro ergosterol supplementation of L. donovani with 
a single knock-out of lanosterol 14α-demethylase gene were reported to have 
had their growth enhanced than those without ergosterol supplementation 
(Verma et al., 2011). The reduced abundance of ergosterol in the AmB resistant 
cells as compared to the wild-type therefore led us to assess whether exogenous 
supply of ergosterol to the resistant cells would restore their susceptibility to 
AmB. This was investigated by supplementation of growth medium with 7.6 µM 
ergosterol (Verma et al., 2011) for more than five passages of AmB resistant 
cells and the wild-type. The susceptibility assays were performed both in the 
presence and absence of ergosterol in growth medium. We also assessed the 
susceptibility of both cell lines to pentamidine, to which the AmB resistant cell 
lines, as stated earlier, were found to be significantly sensitive.  
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Figure 3.10 Susceptibility to AmB and pentamidine in the presence of exogenous ergosterol  
The wild-type and the AmB resistant were grown in the presence of 7.6 µM ergosterol in the 
growth medium for five passages before the modified alamar blue assay was done both in 
the presence and absence of 7.6 µM  ergosterol. The data was analysed in Graph Pad Prism 
software. A significant (P = 0.0004) increase in AmB EC50 value for the AmB resistant cells 
was observed while there was no change in AmB and pentamidine EC50 values for the wild-
type cells and pentamidine for AmB resistant cells. The results are for three independent 
experimental replicates. Ergo = ergosterol. 
 
The EC50 values for AmB for the wild-type cells changed from 0.072 ± 0.0008 µM 
in the absence of ergosterol supplementation to 0.079 ± 0.0009 µM in the 
presence of ergosterol supplementation representing a fold-change of 1.11 
(Figure 3.10). This modest change in EC50 value for AmB was found to be 
statistically significant (P = 0.0023). However, there was a significant (P = 
0.0004) increase in EC50 values for AmB with a fold-change of 2.84 for the AmB 
resistant cells (Figure 3.10). This result suggested a possible binding of the AmB 
to the ergosterol supplemented in the medium. This being the case, the 
resistant cell line having less ergosterol compared to the wild-type had a 
pronounced increase (nearly threefold) in AmB EC50 value. Since the wild-type 
cells express more ergosterol (which would render them more susceptible to 
AmB), than the resistant cells, exogenous ergosterol would be expected to have 
little effect on their AmB EC50 value at the concentration of exogenous 
ergosterol concentration used in the experiment. The sensitivity of the resistant 
cells to pentamidine after supplementation of growth medium with exogenous 
ergosterol remained unchanged. 
 
The lack of reduction in AmB EC50 value for the resistant cells suggests a lack of 
taking up exogenous ergosterol by these cells. This is further confirmed by lack 
of change in AmB EC50 value for pentamidine for the resistant cell line.  
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3.5.3 In vitro transformation and infectivity of AmB resistant L. 
mexicana promastigotes 
AmB resistant L. mexicana promastigotes have been shown to transform into 
amastigotes and were able to infect mice and the cells were found to maintain 
their resistance trait (Al-Mohammed et al., 2005). Therefore we determined 
whether AmB resistance in the presence of an N176I mutated lanosterol 14α-
demethylase had the capacity to transform into axenic amastigotes, the 
clinically relevant life cycle form in leishmaniasis. Our AmB resistant cells were 
able to transform axenically into amastigotes. However, the transformed 
resistant cells were not able to grow beyond a second passage while the wild-
type could not grow beyond a third passage. It was also noticed that the 
transformed AmB resistant amastigotes grew slower than the wild-type with the 
wild-type cells growing to a three-, four-fold higher density than the AmB 
resistant cells over a period of one week (Figure 3.11A). The failure to 
continuously cultivate these cells in culture was attributed to the fact that the 
ability of Leishmania to transform from promastigotes to amastigotes diminishes 
with the number of previous passages (Pimenta and Desouza, 1987). We used 
cells that have been continuously passaged and were not passaged in vivo, prior 
to start of resistance selection. We observed an increase in the number of 
passages for the transformed wild-type cells with different batches of serum in 
growth medium. Infection of macrophages, a natural environment for 
amastigotes, with AmB resistant promastigotes for three hours and incubation 
for three days was achieved. Andrew Pountain (M.Res. Student I supervised for 
his M.Res. project) showed that AmB resistant promastigotes were able to infect 
the murine RAW 246.7 macrophages in 72 hours incubation. Both cell lines 
showed low infectivity rates with that by wild-type promastigotes being the 
lowest (Figure 3.11B and C). However, the AmB resistant cells with an N176I 
mutated lanosterol 14α-demethylase were able to infect and survive within 
macrophages, their habitat in natural infections. 
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Figure 3.11 Comparison of transformation into amastigotes and infectivity between Wt and 
AmB resistant L. mexicana promastigotes. 
 (A) Transformation of promastigotes into amastigote was done in complete Schneider’s 
Drosophila medium for one week prior to counting transformed cells. (B) Percentage of 
macrophages infected. The percentage of macrophages infected was counted 72 hours post 
infection, by counting 100 macrophages in three separate wells for each cell line. (C) DAPI 
staining of macrophages infected with AmB resistant parasites. DAPI staining was done 
with 0.5 µg/ml DAPI/1% DABCO in PBS. Large stained nuclei are those of the macrophage 
and smaller stained nuclei are those of infecting AmB resistant parasites. Graphs were 
constructed using Mean ± SD between wells within a single experiment. Results are for 
three independent replicates. Bar = 10 µm. (Data generated by Andrew Pountain)  
 
3.5.4 Filipin III staining 
Having established that there were differences in the ergosterol levels between 
the wild-type and the AmB resistant cell lines in metabolomics analysis, we 
aimed at finding a simple test that could be used to distinguish the two cell 
lines. It was hoped the test could be adopted for field use as a marker for AmB 
resistance. For this purpose filipin III was used to determine staining differences 
between the wild-type and the AmB resistant cells. Filipin is known to 
specifically bind to sterols in the plasma membrane of yeast cells (Van Leeuwen 
et al., 2008). An increasing fluorescent signal (Figure 3.12) with increasing time 
of exposure of the cells to 1 uM filipin was observed in the wild type cells and 
not the AmB resistant cells of L. mexicana promastigotes. The observed 
fluorescent signal with the wild-type cells started at about 30 minutes and 
became more intense after 3 hours of cell exposure to filipin. Wild-type cells 
were observed to assume a round shape after about 90 minutes of exposure to 
filipin III and the number of deformed cells increased with time of incubation. 
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Unfortunately, Photo-bleaching of the stain was observed within five seconds of 
exposure to UV light. The photo-bleaching was observed for all samples that 
were taken out at various time points to be viewed under UV illumination during 
the four hours of incubation of cells in the stain.  
 
 
Figure 3.12 Differential filipin III staining of the wild-type and AmB resistances cells. 
Live cells were stained with 1 µM filipin III in growth medium and immobilised in 1% low 
gelling temperature agarose before observation under UV on a ZEISS Axioplan 2 Imaging 
fluorescent microscope under oil immersion. A, B and C represent images for the wild-type 
cells observed after 30 min, 1 hr and 3 hrs, respectively, of incubation in filipin, while D and 
E are for the AmB resistant cells with no fluorescent signal. B and C show the deformation 
of the cell shape observed after the stated time of exposure to filipin III. Bar = 10 µm. 
 
3.5.4.1 Filipin staining of transformed infecting amastigotes 
Having managed to successfully differentiate the wild-type cells from the AmB 
resistant cells using filipin III due to differences in sterol contents and following 
transformation of the AmB resistant promastigotes into amastigotes and 
subsequent infection of macrophages, we set out to determine whether filipin 
staining could be used to distinguish wild-type and AmB resistant amastigotes 
within macrophages. This assay was carried out as use of amastigotes within 
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macrophages was more clinically relevant because this would then indicate 
whether fluorescent microscopy could be adopted for field use in identifying 
AmB resistant parasites. Andrew Pountain infected murine RAW 246.7 
macrophages with the two cell lines and stained them with filipin. No stained 
amastigotes were observed in the macrophages (Figure 3.13). 
 
This could have been due to background staining by the macrophages. Even 
individual amastigotes within the vicinity of macrophages could not be seen to 
be stained when exposed to UV light (Figure 3.13 B and D). The macrophages 
have been shown to stain with filipin due to presence of cholesterol (Leventhal 
et al., 2001). The background staining of macrophages coupled with low 
infectivity alluded to in section 3.5.3 and photo-bleaching of filipin upon 
exposure to UV light may have led to lack of observation of amastigotes in the 
macrophages.  
 
 
Figure 3.13 Fillin staining of macrophages infected with Wt and AmB resistant L. mexicana. 
Live infected cells were stained with 1 µM filipin III and observation under UV on a ZEISS 
Axioplan 2 Imaging fluorescent microscope under oil immersion. Individual amastigotes are 
seen in A and C while B and D show amastigote within the vicinity of the macrophages. B 
and D illustrate the overshadowing of filipin staining of amastigotes by the macrophages. 
Bar ≈ 10 µM. (Data generated by Andrew Pountain). 
 
 
We conclude, therefore, that in spite of selective binding of filipin to wild-type 
over AMB resistant cells, a test based on this reagent would be too difficult to 
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adapt to field use. However, other tests e.g. spectroscopic methods that detect 
ergosterol (Naewbanij et al., 1984; Sokol-Anderson et al., 1988) might be used. 
 
3.6 Discussion 
The reduction in the cost of the liposomal amphotericin B for monotherapy and 
possibly combination therapy use (Olliaro et al 2009) could go a long way in 
alleviating the problems associated with leishmaniasis treatment.  However, the 
drug should be used judiciously, to avoid development of resistance. We have 
studied the characteristics of in vitro AmB resistant L. mexicana promastigotes 
to bring to light characteristics that may assist in monitoring for and countering 
resistance development. 
 
3.6.1  Stability of AmB resistance 
The 23 fold-increase in AmB EC50 for the derived AmB resistant cell line is 
comparable to the 16 fold increase reported by Al Mohammed et al (2005) 
although our resistant lines were able to grow at a much lower concentration of 
AmB in the growth medium. It is worth noting that the EC50 values for AmB of 
0.103 ± 0.004 µM for our wild-type and 2.407 ± 0.11 µM for the AmB resistant 
lines are also comparable to 0.10 ± 0.01 µM and 1.89 ± 0.12 µM reported for the 
wild-type and AmB resistant L. donovani promastigotes, respectively (Mbongo et 
al., 1998). In vitro resistance to AmB, as a single drug and in combination with 
other anti-leishmanial drugs, is stable once acquired (Al-Mohammed et al., 2005; 
Garcia-Hernandez et al., 2012; Mbongo et al., 1998). Our resistant cell lines had 
also acquired a stable resistance trait to AmB as they were able to grow in drug 
free medium for 15 passages without any change in the drug’s EC50 value. Our 
AmB resistant clones had not only acquired a stable resistance trait but were 
also able to infect macrophages in line with the result by Al Mohammed and co-
workers (Al-Mohammed et al., 2005). However, our inability to continuously 
propagate both the wild-type and AmB resistant amastigotes axenically and low 
infectivity rates achieved could be due to the increased number of passages they 
have been through as this has been reported to compromise the transformation 
and infectivity ability of these parasites (Pimenta and Desouza, 1987). It may, 
therefore, not be the altered sterol composition or the genetic changes in the 
AmB resistant cells that were responsible for lack of continuous cultivation of 
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transformed amastigotes of the resistant lines, as AmB resistant promastigotes 
were reported to be infective to mice and were transformed back into 
promastigotes again though with altered morphologies (Al-Mohammed et al., 
2005). 
 
3.6.2 AmB resistant L. mexicana cross-resistance to other 
antileishmanial drugs  
The stability of AmB resistance may pose a serious threat to management of 
leishmaniasis especially where the disease is anthroponotic as the resistant 
parasites can spread into the population. The spread of such parasites could be 
catastrophic as there is a possibility of cross-resistance to other anti-leishmanial 
drugs. Our AmB resistant cell lines show cross-resistance to trivalent antimony 
(PAT), the active form of antimony drugs, and miltefosine with fold-increases in 
EC50 values of 2.9 and 3.9, respectively (Table 3.8). Further, in vitro resistance 
to combinations of AmB and miltefosine, AmB and paromomycin, and AmB and 
antimony have been reported. These drug combination resistant parasites were 
also found to be cross-resistant to paromomycin and antimony (Garcia-
Hernandez et al., 2012). Therefore, single-dose liposomal AmB and miltefosine 
combination use (Sinha and Bhattacharya, 2014) should be carefully considered 
as our study shows a significant AmB cross-resistance to miltefosine. Moreover, 
use of amphotericin B as a single dose seems to be pushing the drug towards the 
highest concentration that can be tolerated by the host and thus exposing the 
parasites to higher drug concentrations. In a study on the safety and use of 
single dose of amphotericin B, the few participants that failed the single dose 
therapy were rescued by treatment with 3 mg/kg body weight over 5 days 
(Sundar et al., 2010). This practise needs to be revisited as the same parasites 
that were exposed to a higher drug concentration were later exposed to reduced 
concentrations of the drug over a period of 5 days. A full understanding of the 
drug's pharmacokinetics and pharmacodynamics, with different Leishmania 
strains is needed to fully assess this risk. Although a high cure rate was 
recorded, even with the few that failed treatment should parasites infecting 
them become resistant the possibility of their spreading into the general 
population are quite high because of the anthroponotic nature of the disease in 
this part of the world. We are concerned that the WHO policy of single dose 
liposomal AmB maybe ill-advised and linking it to subsequent higher dose 
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treatment a potential disaster. A case in point was the continued use of 
increasing doses of antimonials for treatment of leishmaniasis which never 
prevented the emergent of antimony resistant parasites in India (Sundar et al., 
2000). In fact the strategy might well contribute to the problem. 
 
Our resistant cells showed significantly increased sensitivity to paromomycin and 
pentamidine. A similar situation was shown in L. donovani promastigotes 
(Mbongo et al., 1998) though with less sensitivity compared to our AmB resistant 
cells (Table 3.8). We found that the AmB resistant cells were able to accumulate 
more pentamidine than the wild-type cells, rendering them more susceptible to 
the drug. This is in contrast to pentamidine resistant L. mexicana that 
accumulate less pentamidine in the mitochondrion (Basselin et al., 2002).  
 
Pentamidine accumulates in the mitochondrion where it is able to induce ROS 
production in Leishmania (Basselin et al., 2002; Moreira et al., 2011). Indeed, 
pentamidine’s action against L. donovani promastigotes was suggested to be 
potentiated by the ROS generated by the inhibition of complex II of the electron 
transport chain (Mehta and Shaha, 2004). Further, pentamidine was reported to 
interact with the kinetoplast by binding to the A-T rich regions of the minicircles 
whose sequences were altered in petamidine resistant L. donovani and L. 
amazonensis although the significance of this kDNA alteration is not known. 
Amphotericin B and paromomycin resistant Leishmania do not have alterations 
to their kDNA sequences (Basselin et al., 1998) hence are like wild-type cells in 
this respect. Therefore, the kDNA in this case can be viewed as contributing to 
the retention of pentamidine in the mitochondrion of our AmB resistant cells and 
their enhanced accumulation of pentamidine makes them more vulnerable to 
the toxic effects of the drug. Therefore, our results suggest the use of 
pentamidine and paromomycin as possible options for use as rescue drugs in the 
event of AmB treatment failure due to resistance. However, since other studies 
did not reveal the same degree of hypersensitivity this approach might be highly 
strain specific. 
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Drug 
 Wt AmB-R Fold 
change 
 Wt AmB-R Fold 
change 
 Wt AmB-R Fold 
change  EC50 (µM)  EC50 (µM)  EC50 (µM) 
AmB  0.10 ± 0.01 1.89 ± 0.12 18.9  0.70 ± 0.01 0.14 ± 0.04 2  0.10 ± 0.004 2.41 ± 0.11 23 
Pentamidine  2.7 ± 0.8 1.4 ± 0.2 0.52  - - -  4.19 ± 0.27 0.3164 ± 0.008 0.08 
Paromomycin  47.5 ± 3.5 41.0 ± 11.7 0.86  12.09 ± 1.76 19.67 ± 1.30 1.63  3515 ± 278.0 36.42 ± 1.219 0.01 
Ketoconazole  >1.9 0.13 ± 0.01 < 0.07  - - -  15.06 ± 0.66 26.05 ± 0.942 1.73 
Miltefosine  - - -  5.84 ± 0.43 5.28 ± 0.58 0.90  5.82 ± 0.11 22.58 ± 0.20 3.88 
SbIII (PAT)  - - -  87.33 ± 5.72 74.38 ± 4.98 0.85  197.6 ± 11.79 564.6 ± 32.65 2.86 
Reference  Mbongo et al., 1998  Garcia-Hernandez et al., 2012  This study 
Table 3.8 Comparison of cross-resistance to other antileishmanial drugs between reported AmB L donovani and AmB L. mexicana resistant parasites. 
The reported AmB resistance quoted in the table are for L. donovani promastigotes while we used L. mexicana. Wt – Wild-type; AmB-R – Amphotericin B 
resistant parasites; Fold change is the ratio of the EC50 value for a given drug of the resistant parasite to that of the wild-type parasites. The columns 
relating to particular study are shown by the reference label in the bottom row of the table. (Data adapted from Mbongo et al., 1998; Garcia-Hernandez et al., 
2012).
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Ketoconazole is an antifugal drug belonging to a group of compounds called 
azoles which target lanosterol 14α-demethylase (de Souza and Rodrigues, 2009). 
VNI, a gift from Prof. G. I. Lepesheva of Vanderbilt University, Nashville TN., is a 
compound that has been found to be potent against experimental acute and 
chronic forms of Chagas' disease in mice and has also been shown to be highly 
selective for protozoan lanosterol 14α-demethylase (Villalta et al., 2013). There 
was slight cross-resistance to both ketoconazole and VNI exhibited by our AmB 
resistant L. mexicana with EC50 fold-changes of 1.73 and 1.52, respectively, that 
significantly (p = 0.0005 and P = 0.0007, respectively) differed from that of the 
wild-type. This suggested a possible difference in the target, lanosterol 14α-
demethylase or sterol metabolism more generally, between the wild-type and 
the AmB resistant cells, although the very marginal difference might relate to 
other things too.  
 
3.6.3 Genetic alterations in sterol biosynthetic pathway enzymes 
Chromosome number variation leading to aneuploidy is a frequent event in 
Leishmania species and does not seem to have an effect on the viability of these 
cells (Rogers et al., 2011). Aneuploidy is part of the plasticity of the Leishmania 
genome that allows them to survive in various environments. For example, 
aneuploidy contributed to the genetic changes that were observed in antimony 
resistant L. infantum (Leprohon et al., 2009). Our AmB resistant cells were 
found to have altered chromosome number, but only one enzyme found in the 
sterol biosynthetic pathway was likely to be affected by the chromosome 
number change. The enzyme was farnesyl diphosphate synthase which was 
observed to be possibly affected by CNV of chromosome 22 (Table 3.2). Our 
proteomics results also showed over-expression of this enzyme in the AmB 
resistant cells abeit with low mascot score. Moreover, no associated metabolite 
change was detected in the metabolomics analysis. However, we tested the 
sensitivity of our AmB resistant cells to alendronate. Alendrionate (Sigma – 
A4978) is a biphosphonate drug that targets farnesyl diphosphate synthase 
thereby inhibiting the isoprenoid portion of the sterol biosynthetic pathway (de 
Souza and Rodrigues, 2009). The drug had no effect on either wild-type or the 
resistant cells even when assayed at the possible maximum concentration of 30 
mM. Moreover, neither the substrate nor the product of the enzyme was 
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detected during metabolomic analysis. However, over-expression of this enzyme 
in L. major promastigotes was shown to result in 10-fold increase in resistance 
to another bisphosphonate, risedronate (Ortiz-Gomez et al., 2006). 
  
Cis-prenyltransferase belongs to a group of ubiquitous enzymes called 
prenyltransferases that catalyze the attachment of an isopentenyl diphosphate 
to a growing allyl diphosphate chain in the isoprenoid pathway. There are two 
types of prenyltransferases depending on the proton that is eliminated from 
isopentenyl diphosphate. The cis-prenyltransferase action result in a cis 
configuration at the end of the growing allyl diphosphate chain while trans-
prenyltransferase result in a trans-configuration at the growing end of the allyl 
diphosphophate (Takahashi and Koyama, 2006). These reactions occur before the 
cyclization reactions of the sterol biosynthetic pathway. Although we found a 
2.32 spot fold-increase for cis-prenyltransferase-like protein (LmxM.13.0020) in 
our proteomics analysis, the number of copies for the responsible chromosome, 
chromosome 13, was the same in both cell lines and we were unable to detect 
metabolites that could be attributed to this enzyme in our metabolomics 
analysis. 
  
3.6.4 Response of L. mexicana to different concentrations of AmB 
The formation of the aqueous pores by amphotericin B that are responsible for 
cell death have been reported to occur at concentrations equal to or greater 
than 0.1 µM AmB in the growth medium for L. mexicana promastigotes (Ramos et 
al., 1996). The N176I mutation detected in our clone of highest AmB resistance 
was also detected in the resistant clones growing in the presence of 0.081 µM 
AmB in the growth medium. This value agrees with the required concentration of 
0.1 µM of AmB for the formation of aqueous pores reported by Ramos et al 
(1996). This would suggest that the parasites respond to exposure to such a 
concentration of AmB by effecting changes at the genetic level involving 
lanosterol 14α-demethylase that leads to perturbation of the sterol biosynthetic 
pathway. Our AmB resistant clones show homozygousity for the mutation starting 
from 0.081 uM AmB in growth medium while the resistant clones surviving at 
concentrations of AmB less than 0.081 uM do not have this mutation. A 
heterozygous mutation in the gene for lanosterol 14α-demethylase would still 
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render the parasites susceptible to AmB which is likely to allow the formation of 
amphotericin B aqueous pores making them susceptible to the drug. Therefore, 
to avoid formation of pores and hence the lytic effects of AmB, the mutation has 
to be homozygous. Indeed this line of thought is supported by an earlier report 
in which a single knock-out of the gene for CYP5122A1, a L. donovani lanosterol 
14α-demethylase sharing 98% amino acid sequence with L. mexicana’s lanosterol 
14α-demethylase, resulted in reduced ergosterol in such cells and that they 
showed about 84% viability in the presence of 1 µM AmB compared to 62% for the 
wild-type cells. Moreover, a double knock-out for the gene was not achieved 
suggesting a possible essentiality of the gene (Verma et al., 2011). 
 
Amphoptericin B at concentrations lower than 0.1 µM was reported to arrest the 
growth of the parasites (Ramos et al., 1996). Further, AmB was shown to kill 
yeast by merely binding to ergosterol in the membranes before formation of the 
membrane pores (Gray et al., 2012). The AmB resistant clones growing in the 
presence of AmB concentrations of less than 0.081 µM AmB did not show the 
presence of the N176I mutation. The absence of N176I mutation in the resistant 
clones of lower resistance does not rule out a role played by other genetic 
changes that were observed and these could relate to resistance at lower levels. 
This would suggest, therefore, that the resistant clones surviving in the presence 
of lower (< 0.081 µM) AmB concentrations may do so by withdrawal of ergosterol 
from their membrane to some extent as a way of tolerating lower AmB 
concentrations resulting in a similar mechanism that underlies differences in 
toxicity of the drug to different species of leishmania due to differences in 
ergosterol concentration in their membranes (Croft et al., 2006). Moreover, 
membrane fluidity of the AmB resistant Leishmania has been reported to be 
increased compared to wild-type cells resulting in a disordered membrane. The 
disordered membrane has been suggested to reduce the binding specificity of 
AmB for ergosterol (Purkait et al., 2012). This suggests that our resistant clones 
of lower AmB resistance could have been surviving at the stated drug 
concentration based on the disordered membrane due to different levels of 
ergosterol withdrawal from their membranes. Indeed a gradual decrease in 
ergosterol level was observed as resistance to the drug increased. 
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3.6.5 Effect of exogenous ergosterol supplementation 
In vitro AmB resistant L donovani were shown to stop synthesis of ergosterol as it 
was not detected in cell extracts (Al-Mohammed et al., 2005; Mbongo et al., 
1998; Purkait et al., 2012). However, we detected ergosterol in AmB resistant 
cells of L. mexicana, albeit at much reduced levels when compared to the 
parental wild-type cells. Supplementation of ergosterol in the growth medium 
was shown to improve the diminished growth phenotype of half knock-out of 
lanosterol 14α-demethylase in L. donovani (Verma et al., 2011). Therefore, we 
investigated whether supplementation of ergosterol in growth medium would 
restore the sensitivity of resistant cells to AmB and pentamidine following taking 
up of exogenous ergosterol. The wild-type cells showed a modest but 
statistically significant (P = 0.0023) 1.11 fold-change of AmB EC50 value while 
pentamidine EC50 values remained unchanged following supplementation with 
ergosterol in the growth medium. Our AmB resistant clones exhibited a 
significant (P = 0.0004) increase in the EC50 for AmB with a fold-change of 2.84. 
This indicates that the cells probably do not accumulate and target to the 
membrane exogenous ergosterol contrary to what was reported in L. donovani 
(Verma et al., 2011). The related trypanosomatid, bloodstream forms of T. 
brucei, is capable of accumulating exogenous cholesterol for their viability 
(Coppens et al., 1988; Green et al., 2003). 
 
3.6.6 Dependence of filipin staining on presence of ergosterol 
The difference in the expression of ergosterol between the wild type and the in 
vitro generated AmB resistant parasites can be appreciated by staining both 
cells lines with the sterol-specific stain, filipin III. Filipin III is an antifungal 
antibiotic that belongs to the same family as amphotericin B called polyene 
antibiotics. It is a neutral yellow compound and easily decomposes when 
exposed to oxygen (air) and light. It is almost insoluble in water and chloroform 
but soluble in most organic solvents (Whitfield et al., 1955). It has been used to 
stain sterols in fungi, plants (Boutte et al., 2011; Van Leeuwen et al., 2008) and 
leishmania (Ignacio et al., 2011; Pimenta and Desouza, 1987) at varying 
concentrations. In fungi it has been shown to specifically bind to ergosterol in 
situ and the florescence intensity increases with increasing concentration of 
ergosterol (Van Leeuwen et al., 2008). Our AmB resistant cells showed no 
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fluorescence with filipin at 1 µM but the wild-type cells did. This clearly showed 
and confirmed the difference in sterol content as was observed in metabolomics 
analysis between the two cell lines. While there was a fluorescent signal after 
filipin staining of the wild-type cells, longer times of staining resulted in the 
cells assuming rounded shapes of the wild type cells. However, the shape of the 
resistant cells remained the same for the same duration of staining. It seems 
swelling of the cells is a common effect at a given concentration of filipin and 
AmB. Amphotericin B has been reported to cause swelling of the cells giving 
them a round shape (Ramos et al., 1996). We observed the same effect on the 
wild-type and not the AmB resistant cells upon incubation in 1 uM AmB resulting 
in cells dying within 15 minutes of incubation while the AmB resistant cells 
remained an affected. The ability to stain the wild-type and not the AmB 
resistant cells suggests a possible use of filipin to distinguish AmB resistant cells 
from wild-type cells, at least in L. mexicana promastigotes. 
 
To adopt the filipin assay as a field test to distinguish AmB resistant parasites 
from drug sensitive ones, the assay has to be as simple as possible. Therefore, 
we attempted to stain cells fixed in methanol. We could not achieve staining of 
fixed cells at various concentrations of filipin, both higher and lower than that 
used for staining live cells, a result that is consistent with the requirement for 
live cells to stain with filipin as reported for L. m. amazonensis (Pimenta and 
Desouza, 1987). While it is not possible to stain fixed Leishmania cells with 
filipin, it is possible to do so with fixed macrophages and fibroblasts based on 
their cholesterol content (Rabhi et al., 2012; Takamura et al., 2013). Indeed, 
accumulation of cholesterol in amastigotes has been shown to increase following 
infection with Leishmania parasites (Rabhi et al., 2012). The accumulation of 
cholesterol by infected amastigotes would therefore cause such high background 
staining with filipin that it would be difficult to differentiate cholesterol staining 
from that with infecting Leishmania parasites as was observed in our attempt to 
stain infected amastigotes. Therefore use of filipin to distinguish AmB resistant 
and AmB susceptible would require use of live parasites that have been 
transformed from isolated amastigotes into promastigotes, since AmB resistance 
is a stable trait as shown in this study and other studies (Al-Mohammed et al., 
2005). The promastigotes transformed from AmB resistant amastigotes would not 
be expected to show fluorescence with the stain.  
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Photo-bleaching of filipin was observed within five seconds of exposure of 
stained cells. Filipin photo-bleaching has been attributed to use of low 
concentration of stain in plant root tissues and quick acquisition of images and 
use of low laser power is suggested to reduce photo-bleaching (Boutte et al., 
2011). It is also possible to raise the concentration of filipin with reduced time 
of incubation although the exposure time is still restricted to less than ten 
seconds to avoid photo-bleaching (Van Leeuwen et al., 2008). We could not raise 
the concentrations of filipin to specifically stain ergosterol, because of possible 
competition for specificity of the stain between ergosterol and phospholipids 
(Milhaud et al., 1996). Moreover, we noted cell lysis, as observed by others 
(Pimenta and Desouza, 1987), at higher concentrations of the stain and this may 
not be ideal for differentiating cells expressing different levels of ergosterol. 
However, the rounding up phenotype of the AmB sensitive cells could be used as 
an assay to differentiate the AmB sensitive from the AmB resistant cells 
following exposure of the cells to the drug for 15 minutes. Filipin’s ability to 
cause rounding up of the AmB sensitive cells can also be used to differentiate 
the wild type cells from the resistant cells based on the round up phenotype 
rather than its fluorescence property which is disadvantaged by photo-bleaching. 
 
3.6.7 Sensitivity of AmB resistant L. mexicana to oxidative stress 
Amphotericin B is accumulated more by wild-type than AmB resistant L. 
donovani and this has been shown to be accompanied by an accumulation of ROS 
in wild-type cells only in response to exposure to AmB (Mbongo et al., 1998; 
Purkait et al., 2012). It was also shown that AmB resistant cells had an up-
regulation of mRNA for the enzymes involved in the thiol metabolic pathway 
which is involved in generation and maintenance of trypanothione in the reduced 
state. This was suggested to be part of AmB resistance mechanism that results in 
protection of AmB resistance cells from ROS that result from the auto-oxidation 
of amphotericin B (Purkait et al., 2012). We observed depleted levels of S-
adenosyl-L-methionine, ornithine and putrescine with fold-differences of 0.65, 
0.14 and 0.68, respectively, in AmB resistant cells as compared to the parental 
wild-type cells in metabolomics analysis. However, a comparison of these 
changes with the chromosome number variation from the genomic DNA 
sequencing data, only ornithine decarboxylase (Gene ID LmxM.12.0280) found on 
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chromosome 12 was found to have one chromosome 12 less in AmB resistant 
cells as compared to the wild-type cells. This would imply reduction in copy 
number of the enzyme and may explain the 0.68 fold-difference of putrescine 
detected in AmB resistant cell lines as compared to the wild-type. There was no 
change in chromosome number for the other enzymes namely, Spermidine 
synthase (LmxM.04.0580), Trypanothione synthetase (LmxM.36.4300), S-
adenosylmethionine synthetase (LmxM.29.3500) whose product, S-
adenosylmethionine, which is a substrate for S-adenosylmethionine 
decarboxylase’s (LmxM.29.3110 ) was found to be depleted in the AmB resistant 
cell lines. This is in contrast to the mRNA up-regulation for all enzymes except S-
adenosylmethionine synthetase, found in AmB resistant L. donovani (Purkait et 
al., 2012). Our proteomics data indicated an up-regulation of S-
adenosylmethionine synthetase in the resistant cells although its reaction 
product, S-adenosylmethionine, was found to be statistically not significantly (P 
= 0.09007) depleted in resistant cells by a 0.65 fold-difference as compared to 
the wild-type cells. An up-regulation would suggest an effort to keep up with the 
demand for its product. 
 
Methylene blue’s use as an oxidant is due to its ability to deplete cells of their 
reducing power, NADPH, resulting in accumulation of NADP+. The depletion of 
NADPH mimics that observed with detoxification of H2O2 (Atamna et al., 1994; 
Baquer et al., 1977). We therefore used methylene blue to investigate the 
susceptibility of the generated AmB resistant cells growing in the presence of 
0.27 µM AmB and the parental wild-type L. mexicana promastigotes to oxidative 
stress. The generated AmB resistant cells were much more susceptible than the 
wild-type cells to methylene blue and hence oxidative stress. This was further 
confirmed by the response of the two cell lines to exposure to H2O2 in growth 
medium with the resistant cells being more affected than the wild-type cells. 
We observed a dose dependent effect of H2O2 on both wild-type as reported 
elsewhere (Das et al., 2001) and our AmB resistant cells, with the resistant cells 
being more affected than the wild type cells indicating hypersensitivity to 
oxidative stress. Oxidative stress brought about by exposure to H2O2 
concentrations lower than 4 mM was shown to kill L. donovani through an 
apoptotic-like death (Das et al., 2001). 
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Ergosterol plays the role of an antioxidant among other functions in S. cerevisiae 
(Dupont et al., 2012; Landolfo et al., 2010). Yeast is able to take up exogenous 
ergosterol for their cellular use under anaerobic conditions (Lorenz and Parks, 
1991). Ergosterol supplementation in growth medium has been shown to protect 
yeast from both internal and external oxidative stress challenge (Landolfo et al., 
2010). Susceptibility of yeast to oxidative stress is enhanced with inhibition of 
either Sterol C24-methyltransferase (erg6) or sterol C7, 8-isomerase (erg3)  or 
both but less so with the enzymes downstream sterol C7, 8-isomerase (Dupont et 
al., 2012). The susceptibility to oxidative stress by ROS has been attributed to 
the absence of the conjugated double bonds in fecosterol and episterol. The 
conjugated double bonds (in ring B) which are close to the hydroxyl group (on 
ring A) in ergosterol (Figure 3.14) are said to provide delocalisation of a lone pair 
of electrons during an attack on ergosterol by ROS (Dupont et al., 2012). This 
property of ergosterol is said to protect the phospholipids in membranes against 
oxidative stress (Dupont et al., 2012). Therefore, our AmB resistant clones were 
made more susceptible to oxidative stress challenge than the wild-type cells due 
to the reduced levels of ergosterol in their membranes which could not protect 
them against oxidative stress. 
 
 
Figure 3.14 Molecular structure of ergosterol showing the numbering of atoms 
 
Amphotericin B, miltefosine and trivalent antimony have all been shown to 
induce production of ROS in the mitochondrion, reduction in mitochondrial 
membrane potential and degradation of gDNA leading to an apoptotic-like death 
of L. infantum (Moreira et al., 2011). The ROS are known to cause oxidative 
stress in cells. We therefore investigated whether the use of N-acetyl cysteine 
(NAC), an antioxidant, would protect the resistant cells from miltefosine, 
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potassium antimony tartrate (PAT) and other antileishmanial drugs. We observed 
a sensitisation of the resistant cells with fold-changes in EC50 values of 0.57 for 
miltefosine, 0.33 for AmB and 0.50 for PAT. Our AmB resistant lines could have 
reacted to exposure to AmB, miltefosine and PAT in the same way as in vitro L. 
infantum cell lines resistant to these drugs, i.e. L. infantum resistant to either 
AmB or miltefosine or PAT could not be induced to produce ROS by the drug to 
which they were resistant (Moreira et al., 2011). Therefore, the reduction in 
EC50 values for the three drugs suggests that NAC may have exerted toxic effect 
on the cells. Our results show a different role of NAC other than that of an 
antioxidant in cells and this is indicative of something complex happening when 
cells are exposed to drugs in the presence of NAC.  
 
Pentamidine was shown to induce ROS production in wild-type cells while 
paromomycin was unable in both the wild-type and paromomycin resistant L. 
infantum and the two drugs were suggested to kill Leishmania through a 
different unknown mechanism (Moreira et al., 2011). However, our L. mexicana 
promastigotes resistant to AmB got some protection from paromomycin in the 
presence of NAC with a 2 fold-increase in EC50 value from 36.68 ± 1.05 µM in the 
absence of NAC to 79.60 ± 1.89 µM in the presence of NAC and this is in stark 
contrast with the fact that paromomycin was reportedly unable to induce ROS 
production (Moreira et al., 2011) which would be scavenged by NAC. The EC50 
value for Pentamidine in AmB resistant cells remained the same despite an 
indication that it was able to induce ROS production in L. infantum (Moreira et 
al., 2011). The wild-type used in this set of experiments only showed an increase 
in EC50 value for PAT with a fold-change of 2.27, a result that agrees with the 
expected role of NAC, that of scavenging ROS (Verma et al., 2011) whose 
generation may have been induced by PAT (Moreira et al., 2011). However, our 
results indicate that NAC, at the concentration used, seems to potentiate, to 
some extent, the action of paromomycin, pentamidine, AmB and methylene blue 
on wild-type controls while the action of miltefosine essentially remained 
unaltered in these cells. 
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3.6.8 Reduction in cell length of AmB resistant L. mexicana 
Cell size reduction was noticed in AmB resistant cells when compared to the 
wild-type cells under the light microscope. Shorter and more rounded cells, 
following exposure of L. donovani promastigote wild-type cells to pentamidne 
and in pentamidine resistant L. mexicana promastigotes, have been reported 
(Basselin et al., 2002; Mehta and Shaha, 2004). However, our AmB resistant cells 
were predominantly of comparable shape to the wild type, except they were 
smaller and shorter. To investigate this further we measured the cell body 
length of individual cells from the two cell lines. We used cell body length to 
compare the cell sizes of the two cell lines because it does not change 
significantly at different cell densities although it is represented by a relatively 
broad range of cell sizes. While cell width as opposed to cell body length is 
inversely proportional to cell density (Wheeler et al., 2011) and therefore may 
not be a good comparison parameter. Cultures of the two cell lines were grown 
to similar cell densities and used the same cell density for both cell lines to fix 
the cells for measurement. The cell body length range for the wild-type was 
7.19 – 16.24 µm, a range that is comparable to that by Wheeler et al., (2011). 
Compared to the wild-type, the AmB resistant cells had a reduced cell body 
length (section 3.2.2.1). Sterols are known to perform among other functions 
that of structural integrity of membranes (Lepesheva and Waterman, 2007; 
Roberts et al., 2003). It is therefore possible that the reduction in cell body 
length may have been due to the reduced ergosterol level and the general 
perturbation of sterol level that was observed in the AmB resistance cells. In 
fact, reduction in body size is in agreement with what was observed in L. 
donovani with a single knock-out of lanosterol 14α-demethylase that showed 
reduced levels of ergosterol as compared to the wild-type cells (Verma et al., 
2011).  
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Chapter Four 
4 Participation of Leishmania mexicana lanosterol 
14α-demethylase in amphotericin B resistance 
4.1 Introduction 
One of the biggest threats to use of chemotherapy for control of leishmaniasis is 
development of drug resistance. Antimonial drugs have thus been stopped from 
use in Bihar state of India due to development of resistance (Sundar et al., 
2000).  Moreover, no single drug has had its mechanism of resistance fully 
worked out although in vitro drug resistance has been demonstrated to almost 
all anti-leishmanial drugs (Croft et al., 2006). Furthermore, only a handful of 
drugs for use against leishmaniasis are available with limited knowledge of their 
cellular targets. 
 
The membrane sterols of mammals are different from those of Leishmania 
species and this includes differences in their sterol biosynthetic pathways.  
Mammals have cholesterol, the end product of their sterol biosynthetic pathway, 
as the major sterol of their cell membranes. Leishmania have ergosterol, the 
end product of their sterol biosynthetic pathway in these organisms, in their 
membranes instead of cholesterol when compared to mammals (de Souza and 
Rodrigues, 2009). Leishmania species together with other trypanosomatids are 
also known to synthesise 24-alkyl sterols which are not found in mammals 
(Chawla and Madhubala, 2010). These differences in the sterol biosynthetic 
pathway between mammals and Leishmania provide opportunities for drug 
selectivity and hence unique drug targets (Chawla and Madhubala, 2010; de 
Souza and Rodrigues, 2009). 
 
The sterol biosynthetic pathway and sterol composition of fungi and Leishmania 
species are similar (Berman, 1988). As a result many antifungals that target 
sterol biosynthetic pathway enzymes have subsequently been indicated to be 
active against Leishmania species (de Souza and Rodrigues, 2009; Roberts et al., 
2003). Thus, the antifungal azole compounds, exemplified by ketoconazole, 
posaconazole, itraconazole, fluconazole and voriconazol, which target the 
lanosterol 14α-demethylase, have been indicated to be active against 
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Leishmania species (Beach et al., 1988; de Macedo-Silva et al., 2013). AmB is an 
antifungal drug which has increasingly been used for treatment of leishmaniasis 
and its use against leishmaniasis stems from the similarities in sterol metabolism 
of fungi and Leishmania species. Various studies have established the effect of 
AmB on the sterol biosynthetic pathway in Leishmania. It has been shown that 
AmB resistance selection perturbs the sterol biosynthetic pathway leading to 
accumulation of various intermediates of the pathway and inhibition of 
ergosterol synthesis (Al-Mohammed et al., 2005; Mbongo et al., 1998; Purkait et 
al., 2012). The perturbation of the sterol biosynthetic pathway in response to 
selecting resistance to AmB has been attributed to the need by the parasites to 
reduce the drug’s target, ergosterol, thereby reducing its toxicity on the 
parasites. 
  
It has not been demonstrated how this perturbation of the pathway comes 
about. However, our study has identified a non-synonymous mutation in the 
lanosterol 14α-demethylase gene of AmB resistant L. mexicana promastigotes. 
We also observed an accumulation of 4, 4-dimethyl-cholesta 8, 14, 24-trienol, 
which is a reaction product of lanosterol 14α-demethylase. We therefore aimed 
to determine the role of the mutated lanosterol 14α-demethylase gene in the 
induced in vitro AmB resistance. 
 
4.2 Results 
4.2.1 Position of N176I in L. mexicana’s lanosterol 14α-
demethylase 
Use of gDNA sequencing and metabolomics in tandem to compare the wild-type 
and the AmB resistant cells revealed a non-synonymous point mutation in the 
lanosterol 14α-demethylase gene (Chapter 3). The discovery of a definite non-
synonymous point mutation in this gene led us to establish, by secondary 
structure prediction, whether the mutation was in the catalytic site of the 
enzyme. The non-synonymous mutation (Appendix F) found in the lanosterol 
14α-demethylase (Gene ID LmxM.11.1100) was found to be outside the catalytic 
site of the enzyme (courtesy of Prof. G. I. Lepesheva (Figure 4.1)). However, the 
mutation involved a substitution of an amino acid which has a hydrophilic side 
chain with an aliphatic amino acid whose side chain is hydrophobic at pH7.0 
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(Monera et al., 1995). The mutated residue was found to be in one of the 
peripheral helices of the predicted secondary structure of the enzyme as 
deduced from the amino acid secondary structure prediction in CLC workbench 
6. 
 
 
Figure 4.1 L. mexicana wild-type promastigote lanosterol 14α-demethylase structure. 
The enzyme structure shows the position of the mutated amino acid residue from the active 
site. (Enzyme structure was provided by Prof. G. I. Lepesheva, Vanderbilt University. 
Nashville TN; Hargrove et al., 2011)  
 
4.2.2 Alignment of various trypanosomatid lanosterol 14α-
demethylase 
Certain amino acid residues of lanosterol 14α-demethylase are known to be 
conserved across the CYP51 family, and the conserved residues which fulfil the 
structural role have been thought to be involved in the folding and overall shape 
of the proteins (Lepesheva and Waterman, 2011b). Mutations of residues that 
are conserved have been shown to affect the enzyme function (Lepesheva et al., 
2006). We investigated whether the mutated residue was conserved in various 
trypanosomatids. An alignment of the primary structures of lanosterol 14α-
demethylase from different trypanosomatids, yeast and humans as downloaded 
from tritrypDB, GeneDB and nextprot.org websites revealed that the mutated 
asparagine residue affected by the mutation was conserved among 
trypanosomatid species analysed but not in yeast (S. cerevisiae) or humans (H. 
sapiens) (Figure 4.2 and Appendix G). The conservation could be important as we 
consider its conservation in other trypanosomatids, for instance it could be 
important for protein-protein interaction. 
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Figure 4.2 Primary structure alignment of lanosterol 14α-demethylase of trypanosomatids. 
The conserved residue in leishmania species and trypanosomes is indicated, but it is not 
conserved in S. cerevisiae and H. sapiens. The sequences were downloaded from the 
TritrypDB, GeneDB and nextprot.org, and aligned using CLC Genomics Workbench 6 
 
 
4.3 Expression of L. mexicana Wt lanosterol 14α-
demethylase into AmB resistant L. mexicana 
To confirm a role of the identified mutation in drug resistance, confirmatory 
experimental assays were carried out (Berg et al., 2013a). We cloned the wild-
type enzyme for expression in the AmB resistant cells, using an expression vector 
for Crithidia fasciculata and Leishmania, pNUS-HnN plasmid (Tetaud et al., 
2002). 
  
4.3.1 Checking for presence of both Wt and AmBR lanosterol 14α-
demethylases in re-expresser clones 
The presence of both the chromosomal and extra-chromosomal copies of 
lanosterol 14α-demethylase in the L. mexicana re-expresser cells was 
determined using the pNUS-HnN plasmid specific primers (MB0781 and MB0782) 
(Table 2.2) and the gene specific primers (MB0769 and MB0770) (Table 2.2) 
whose PCR products sizes were 1, 650 bp and 1, 452 bp, respectively. We used 
the parental wild-type and the derived AmB resistant cells’ DNA as controls. The 
re-expresser cells yielded two bands for both sets of primers indicating the 
presence of both the chromosomal and extra-chromosomal copies of lanosterol 
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14α-demethylase, while the wild-type and the AmB resistant cells yielded a 
single PCR product with the gene-specific primers (Figure 4.3). 
 
 
Figure 4.3 PCR amplification of chromosomal and extra-chromosomal AmB-R CYP51. 
The PCR products were amplified from DNA extracted from parental wild-type, AmB 
resistant cells (AmB-R) and AmB resistant cells expressing the wild-type CYP51 (lanosterol 
14α-demethylase) (Re-expresser). The PCR products were separated on a 1% agarose gel 
with SYBR safe staining. The PCR products were separated along a 1kb DNA ladder. G.S = 
Gene specific primer and V.S = Vector specific primer. G.S bands = 1452 bp; V.S band = 
1650 bp. 
 
The presence of both the chromosomal (mutated) and extra-chromosomal (wild-
type) copies of lanosterol 14α-demethylase were determined/confirmed by 
sequencing the PCR products. We used a 24 bp forward primer (MBO787) (Table 
2.2) starting from 43 bp from the start codon of the gene and a 21 bp reverse 
primer (MBO788) (Table 2.2) starting from 231 bp from the point mutation within 
the gene to amplify the chromosomal copy of lanosterol 14α-demethylase 
portion of AmB resistant cells to give a 788 bp PCR product. To amplify the 
extra-chromosomal copy we used a pNUS-HnN plasmid specific 21 bp forward 
primer (MBO781) and MBO788 resulting in a 790 bp PCR product. Sequenced PCR 
products revealed presence of the wild-type copy of lanosterol 14α-demethylase 
as an extra-chromosomal copy and the mutated lanosterol 14α-demethylase as a 
chromosomal copy (Figure 4.4). 
 
 
G.S V.S V.S   G.S V.S G.S
Wild-type AmB - R Re-expresser
1500bp
122 
 
 
Figure 4.4 Sequence alignment of the chromosomal and extra-chromosomal CYP51. 
The PCR amplified products were sequenced after insertion into the pGEMT easy vector. 
The sequences were aligned to the CYP51 (lanosterol 14α-demethylase) sequence using 
CLC genomics Workbench 6. The conflict indicated shows the mutated base in the AmB 
resistant cells. The sequencing was done at Eurofins MWG Operon, Germany. 
 
 
4.3.2 Restoration of Ergosterol levels in re-expresser cells 
AmB resistance has been reported to be accompanied by inhibition of ergosterol 
synthesis in resistant cells as a way of protecting themselves against AmB. This 
follows lack of detection of ergosterol in samples derived from in vitro 
generated AmB resistant cells (Al-Mohammed et al., 2005; Mbongo et al., 1998; 
Purkait et al., 2012). Therefore, following the observation that ergosterol was 
depleted in the AmB resistant cells as compared to the parental wild-type cells 
(chapter 3), we investigated whether AmB resistant cells expressing an extra-
chromosomal copy of wild-type lanosterol 14α-demethylase had started 
synthesising ergosterol using metabolomics. We observed restoration of the 
ergosterol levels in AmB resistant cells expressing an extra-chromosomal copy of 
wild-type lanosterol 14α-demethylase as compared to the wild-type cells and the 
AmB resistant cells (Figure 4.5 Table 4.1 and Appendix J). Ergosterol was 
restored in AmB resistant cells with wild-type lanosterol 14α-demethylase 
complementation to similar levels as in the parental wild-type cells. 
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Figure 4.5 Restoration of ergosterol levels in AmB resistant cells expressing Wt CYP51 
The samples were extracted from the parental wild-type (Wt), derived AmB resistant and Wt- 
lanosterol 14α-demethylase (CYP51) expressing AmB resistant L. mexicana using cold (-4C°) 
chloroform: methanol: water (1:3:1;v/v). The samples were analysed using LC/MS and IDEOM. 
The data are for three independent experimental replicates. Wtcell = samples derived from 
wild-type cells; Wtsup = samples from supernatant from the growth medium in which the 
cells were grown; ARcell = AmB resistant cell samples; ARsup = AmB resistant supernatant; 
pWtcell = re-expresser cells; ARsup = re-expresser supernatant. 
 
The characteristics described in table 4.1 whose chromatogram is given in 
Appendix J are consistent with those of ergosterol (ergosta-5, 7, 22E-trien-3β-
ol). 
 
Attribute Determined 
Mass (m/z) 396.34 
Retention Time (min) 5.261 
Formula C28H44O 
Identified metabolite Ergosta-5,7,22E-trien-3β-ol 
Fold change    
AmBR 0.05 
Re-expressor 0.88 
Table 4.1 Characteristics of detected ergosterol in Wt, AmB-R and re-expressor cell lines. 
The identification of ergosterol was done by analysis of wild-type (Wt), amphotericin B 
resistant (AmB-R) and amphotericin B resistant cells expressing Wt copy of lanosterol 14α-
demethylase (re-expressor) by LC/MS and analysis using IDEOM. The fold change is the 
comparison of the relative abundance of ergosterol in AmB-R and Re-expressor cells to that 
in the Wt as the control.  
 
 
4.3.3 Reversal of resistance to AmB 
The presence of both copies of the wild-type and the mutated AmB resistant 
lanosterol 14α-demethylase in the re-expressers cells and following restoration 
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of ergosterol led us to check the effect of AmB on these cells. Single knock-out 
of lanosterol 14α-demethylase resulted in having reduced ergosterol levels and 
reduced susceptibility to AmB (Verma et al., 2011). Resistance to AmB was 
reversed in the re-expresser cells with a significant difference (t-test; P < 
0.0001) in EC50 value for AmB between the AmB resistant cells and the re-
expresser cells (Figure 4.6) with a fold-change in EC50 value of 0.03. The re-
expresser cells were found to be significantly (P = 0.0009) more sensitive to AmB 
than the parental wild-type cells with a fold-change in EC50 value of 0.77. This 
confirmed the requirement of the presence of ergosterol for the drug to exert its 
toxic effect on the cells. 
 
Expression of wild-type lanosterol 14α-demethylase in AmB resistant leishamania 
caused a reversion to wild-type levels of susceptibility to AmB in transformants. 
Ergosterol expression was also restored to levels of those of the wild-type 
indicating that ergosterol levels are directly responsible for resistance to AmB. 
 
 
Figure 4.6 Reversal of AmB resistance by complementation of AmB-R with Wt CYP51. 
The effect of AmB on the wild-type (Wt), AmB resistant (AmB-R) and AmB resistant cells 
expressing wild-type lanosterol 14α-demethylase (Wt CYP51) (Re-expresser) was done 
using the modified alamar blue assay of 72 hrs cell incubation with the inhibitor. The cells 
were further incubated for another 48 hrs following addition of 12.5 mM resazurin in PBS. 
The absorbance data was analysed using GraphPad Prism software. EC50 values; Wt = 
There was a significant difference (ANOVA; P < 0.0001) in the EC50 values. The data 
analysed was for three independent experiments.  
    
4.3.4 AmB resistant cells expressing Wt- lanosterol 14α-
demethylase’s sensitivity to other anti-leishmanial drugs  
AmB resistant Leishmania showed cross-resistance to ketoconazole, PAT and 
miltefosine, and increased susceptibility to pentamidine and paromomycin 
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(Chapter 3). These derived cells were characterised by depleted levels of 
ergosterol as compared to the parental wild-type cells. 
 
The restoration of the wild-type character in terms of susceptibility to AmB and 
ergosterol levels by AmB resistant cells expressing the wild-type lanosterol 14α-
demethylase led us, therefore, to also check whether the response of these cells 
to other anti-leishmanial drugs would be comparable to that of the wild-type 
cells. We determined the sensitivity of the AmB resistant L. mexicana expressing 
the wild-type copy of lanosterol 14α-demethylase to other antileishmanial 
compounds using the modified alamar blue assay. The cells were found to be 
more resistant to ketoconazole with a fold change in EC50 value of 2.60 
representing a significant difference (P = 0.0072) in EC50 value as compared to 
wild type cells (Table 4.2). The AmB resistant cells expressing the wild-type 
gene for lanosterol 14α-demethylase were found to have lost sensitivity to 
pentamidine by reverting back to the wild-type EC50 value for pentamidine with 
a fold-change of 0.997. The re-expresser cells were also found to be more 
sensitive to miltefosine than the parental wild-type cells with a significant 
difference (P < 0.0001) in EC50 value. There was a 0.62 fold-change in EC50 value 
for miltefosine in comparison to the parental wild-type cells while a fold change 
in EC50 value for miltefosine between the wild-type and the AmB resistant cells 
was 3.88 (Table 4.2). 
 
Drug 
EC50 (µM) Fold 
change1 
EC50 (µM) Fold 
change2 Wt AmB-R Re-expresser 
Pentamidine 4.19 ± 0.27 0.32 ± 0.01 0.08 4.18 ± 0.10 0.997 
Miltefosine 5.82 ± 0.11 22.58 ± 0.20 3.88 3.591 ± 0.06 0.62 
Ketoconazole  15.46 ± 0.84 24.73 ± 0.57 1.60 40.23 ± 4.82 2.60 
Table 4.2 Effect of anti-leishmanial drugs on AmB resistant cells expressing the Wt CYP51. 
The effect of pentamidine on the wild-type (Wt), AmB resistant (AmB-R) and re-expresser 
(AmB resistant cells expressing wild-type lanosterol 14α-demethylase (Wt CYP51) was 
determined using the modified alamar blue assay. A density of 1 × 10
6
 cells/ml incubated for 
72 hrs in the presence of the drug and a further 48 hrs following addition of 12.5 mM 
resazurin in PBS. The absorbance data was analysed using GraphPad Prism software. The 
data are for three independent experimental replicates. All values are expressed as Mean ± 
SEM. Fold-change
1
 = Ratio of AmB-REC50 to Wt EC50; Fold-change
2
 = Ratio of WtEC50 to Re-
expresser EC50. 
 
However, the AmB resistant cells complemented with the wild-type lanosterol 
14α-demethylase showed no sensitivity to either paromomycin or potassium 
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antimony tartrate, although the wild-type showed EC50 values of 2, 959 ± 883.4 
µM and 198.4 ± 14.80 µM for paromomycin and PAT, respectively. 
 
4.4 Effect of sterol C14-reductase inhibitors on AmB 
resistant cells 
Experiments where Wt lanosterol 14α-demethylase (EC#: 1.14.13.70) expression 
in AmB resistant cells caused a reversion to sensitivity to the drug demonstrate 
that the mutation to lanosterol 14α-demethylase is indeed responsible for the 
resistance phenotype. However, the mutation to lanosterol 14α-demethylase in 
the resistant line is not within the enzyme's catalytic site. Moreover, the product 
of lanosterol 14α-demethylase (4, 4-dimethyl-cholesta 8, 14, 24-trienol) 
continues to be produced, which indicates that this enzyme is still active. 
However, accumulation of the product could indicate that it is a failure of this 
metabolite to be further metabolised that causes its accumulation. The next 
enzyme in the ergosterol biosynthetic pathway is sterol 14α-reductase (EC#: 
1.3.1.71). We therefore investigated whether a defect in the ability of lanosterol 
14α-demethylase enzyme product to reach sterol C14-reductase might underlie 
resistance. We tested the sensitivity of the AmB resistant cells to reported sterol 
C14-reductase specific inhibitors: amorolfine, spiroxamine and fenipropidin 
(Debieu et al., 2000; Katz, 2000; Marcireau et al., 1992; Polak-Wyss, 1995). 
  
We found a mixed response by the AmB resistant cells to the three sterol C14-
reductase specific inhibitors. The AmB resistant cells were found to tolerate 
spiroxamine in a similar way to the parental wild-type cells (Table 4.3). There 
was no significant difference (P = 0.07) in spiroxamine EC50 for the two cell 
lines. 
 
The AmB resistant cells were found to be more sensitive to amorolfine, with a 
fold-change in EC50 value for the drug of 0.65, than the wild-type with a 
significant difference (P = 0.03) in EC50 value. However, there was no significant 
(P = 0.08) difference in EC50 value for fenipropidin with a fold-change of 1.42 
between the wild-type and the resistant cell lines (Table 4.3). Generally, the 
EC50 value for amorolfine of the wild-type and the AmB resistant cells was found 
to be minimal albeit statistically different. 
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Drug 
EC50 (µM) Fold-
change 
P 
Wild-type AmB-R 
Amorolfine 46.15 ± 2.41 29.76 ± 4.35 0.65 0.03 
Spiroxamine 36.43 ± 2.51 30.16 ± 0.35 0.83 0.07 
Fenipropidin 90.14 ± 4.80 128.50 ± 15.39 1.42 0.08 
Table 4.3 Comparison of sterol C14-reductase specific inhibitors on AmB resistant cells. 
The effect of sterol C14-reductase specific inhibitors was determined using the modified 
alamar blue assay of 72 hrs incubation of cells in the presence of the drug followed by 
another 48 hrs for reaction of 12.5 mM resazurin. The absorbance data for three 
independent experiments were used for the analysis. The data was analysed using the 
GraphPad Prism software. Results are presented as Mean ± SEM. Fold-change is the ratio of 
AmB-REC50 to that of WtEC50. 
 
 
4.4.1 Effect of exposure of L. mexicana Wt to Sterol C14-
reductase inhibitors and fenhexamid on AmB sensitivity 
The observed minimal difference in the response to sterol C14-reductase 
inhibitors between the wild-type and the resistant cell lines was in line with the 
absence of alteration to the enzyme gene sequence in both cells (chapter 3). We 
determined whether exposure of the wild-type cells to the sterol C14-reductase 
inhibitors, spiroxamine and fenpropidin, and fenhexamid would result in 
increased tolerance to AmB. Fenhexamid is an antifungal inhibitor of sterol C3-
keto reductase of the sterol biosynthetic pathway (Debieu et al., 2001) and it 
was included in the assay to find out whether inhibition of the sterol 
biosynthetic pathway at various points would cause an increase in tolerance to 
AmB by the wild-type L. mexicana. Andrew Pountain (a placement student under 
my supervision) showed that exposure of wild-type cells to concentrations of 
spiroxamine and fenpropidin equivalent to EC50 value and 10-fold less the EC50 
value and fenhexamid at 100 µM for 24 hrs (as exposure for longer resulted in 
cell death) a 5.5-fold significant (P = 0.008) reduction in sensitivity to AmB for 
cells treated with fenpropidin at a concentration equivalent to EC50 value and a 
significant (P = 0.014) 1.8-fold decrease for cells exposed to a concentration of 
the drug equivalent to 10-fold less the EC50 value (Figure 4.7). Spiroxamine 
resulted in a marginal decrease in sensitivity to AmB while fenhexamid showed 
no effect on AmB sensitivity (Figure 4.7). 
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Figure 4.7 L. mexicana Wt sensitivity to AmB after exposure to sterol biosynthesis inhibitors 
L. mexicana parasites were exposed to fenpropidin and spiroxamine for 24 hours at 
concentrations shown and to 100 μM fenhexamid before withdrawal of the drug and 
performing AmB sensitivity assays. Fold change equal to EC50 obtained after drug treatment 
to EC50obtained of untreated wild type parasites, both of the same replicate. AmB resistant 
cells sensitivity to AmB was used as a control. Error bars represent standard deviation. 
Asterisk represents significant differences (P < 0.05) between untreated and drug treated. n 
= 4 for fenpropidin and spiroxamine treatment, n = 5 for AmBR cells and n = 1 for 
fenhexamid treatment. (Data generated by Andrew Pountain) 
 
 
4.4.2 Ergosterol expression after exposure to Sterol C14-
reductase inhibitors and fenhexamid 
AmB resistance is accompanied by depleted levels of ergosterol. We have used 
depletion of ergosterol to differentiate wild-type and the AmB resistant cells 
using filipin staining (chapter 3). This made us believe that ergosterol could be 
used as a marker of AmB resistance. The observed reduction in sensitivity to 
AmB by sterol C14-reductase inhibitors of the wild-type cells led us to test out 
whether exposure to Sterol C14-reductase inhibitors and fenhexamid would lead 
to depletion of ergosterol as observed in AmB resistance. We used LC/MS while 
other studies used GC/MS (Al-Mohammed et al., 2005; Mbongo et al., 1998; 
Purkait et al., 2012) to assess levels of sterols in AmB resistant cells. Because of 
the requirement for a simple assay for field use, we adopted the use of UV 
spectroscopy utilising the presence of conjugated doubles bonds in ergosterol. 
Ergosterol is known to absorb UV light at about 282 nm (Naewbanij et al., 1984; 
Sokol-Anderson et al., 1988). The work was carried out with Andrew Pountain, a 
student under my supervision. 
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Following exposure of the wild type cells to the sterol C14-reductase inhibitors 
and fenhexamid as in section 4.4.1, we showed a clear difference in detected 
ergosterol between the wild type and AmB resistant parasite samples that were 
used as controls (Figure 4.8), as monitored at λ = 281 nm, consistent with the 
observation using metabolomics analysis of the two cell lines. Treatment of AmB 
resistant cells with fenhexamid showed no effect on ergosterol synthesis as 
compared to the resistant cells not exposed to the drug. Interestingly, 
spiroxamine- and 100 µM fenhexamid-treated wild-type cells showed marked 
reductions in the absorbance compared to the wild-type cells, indicating a quick 
adjustment to ergosterol expression by the cells following a 24 hr exposure to 
the drugs. A surprising result was obtained for fenpropidin which showed more 
potency in reducing AmB sensitivity (section 4.4.1) by the wild-type cells and yet 
had a minimal effect on ergosterol expression compared to the wild-type cells 
which were not exposed to the drug prior to measurement of absorbance.  
 
At this stage we have not validated the spectrophotometric test for ergosterol 
detection. It would be of interest to use the metabolomics platform to assess 
the role of fenpropidin and spiroxamine on cells. 
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Figure 4.8 Sterol biosynthetic pathway inhibitors’ effect on ergosterol expression. 
The UV spectra for ergosterol of wild type and AmB resistant cells exposed to sterol C14-
reductase and sterol C3-keto reductase inhibitors was compared to the UV spectra of the 
two cell line not exposed to the drugs. 2 x 10
6
 cells/ml cells were treated with the drugs for 
24 hrs prior to sterol extraction with hexane. (A) Measurement of absorbance at 281 nm 
following exposure to the inhibitors shown. n = 2 for all drug-exposed samples and n = 3 for 
AmB resistant cells. (B) The UV spectra was recorded from 190 nm to 320 nm on a 
Shimadzu UV-2550 UV-vis spectrophotometer and analysed using UVProbe software 
(Shimadzu), ergosterol peak is around 281 nm. Hexane was used as a blank. Data is for two 
independent experimental replicates. Error bars represent standard deviation. (Data 
generated by Andrew Pountain) 
 
4.5 Sub-cellular localisation of lanosterol 14α-
demethylase 
We investigated whether the identified non-synonymous mutation affected the 
localisation of the lanosterol 14α-demethylase in the cells by tagging both the 
wild-type enzyme and the AmB resistant enzyme with green fluorescent protein 
(GFP) at the C-terminus. The tagged enzymes were expressed in wild-type and 
AmB resistant cells. The C-terminus was chosen because it is known that 
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Leishmania lanosterol 14α-demethylase possesses a trans-membrane domain at 
the N-terminus that might be important to localisation (Hargrove et al., 2011; 
Verma et al., 2011). A staining of the GFP-tagged lanosterol 14α-demethylase 
expressing cells with Mito-Tracker and ER-Tracker for co-localisation of the 
enzymes revealed co-localisation mainly in the mitochondria with indications of 
some, albeit minimal, co-localisation in the ER (Figure 4.9). L. donovani 
lanosterol 14α-demethylase has been shown to localise to the ER, mitochondria 
and glycosomes (Verma et al., 2011).There were no apparent indications that 
the mutated enzyme localises differently from the wild-type enzyme in the two 
cell compartments between the two cell lines. Therefore, the mutation did not 
seem to affect the localisation of the enzyme in the cell compartments.  
 
 
Figure 4.9 Mito- and ER-Tracker staining of GFP-tagged wild-type and AmB resistant CYP51. 
Live GFP-tagged CYP51 (lanosterol 14α-demethylase) expressing wild-type and AmB 
resistant cells were stained by incubation for 20 – 30 minutes with 1 nM Mito-Tracker or 100 
nM ER-Tracker. ER-Tracker stained cells were fixed in 4% formaldehyde for 2 minutes and 
washed twice in 1× PBS. Stained cells were immobilised in 1% low gelling temperature 
agarose before viewing under oil immersion on a ZEISS Axioplan 2 Imaging fluorescent 
microscope. GIMP free software was used to merge the images; Bar = 10 µm. 
 
 
4.6 Sub-cellular localisation of sterol C14-reductase 
Following up on the possibility of lanosterol 14α-demethylase functioning as a 
complex with sterol C14-reductase, we investigated whether sterol C14-
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reductase would localise in the same compartment of the cell as lanosterol 14α-
demethylase. Staining with Mito-Tracker and ER-Tracker of wild-type and the 
AmB resistant cells expressing C-terminus GFP-tagged sterol C14-reductase did 
show minimal co-localisation in the mitochondria but showed strong indications 
of co-localisation to the endoplasmic reticulum (Figure 4.10). However, there 
were no apparent indications of alteration in localisation of the sterol C14-
reductase in either the endoplasmic reticulum or the mitochondria of the wild-
type and AmB resistant cells. 
 
 
Figure 4.10 Mito- and ER-Tracker staining of GFP-tagged Wt and AmB-R sterol C14-
reductase. 
Live GFP-tagged lanosterol 14α-demethylase expressing wild-type and AmB resistant cells 
were stained by incubation between 20 to 30 minutes with 1 nM Mito-Tracker or 100 nM ER-
Tracker. ER-Tracker stained cells were washed twice in 1× PBS following fixing in by 
incubating in the presence of 4% formaldehyde in growth medium for 2 minutes. Stained 
cells were immobilised in 1% low gelling temperature agarose before viewing under oil 
immersion on a ZEISS Axioplan 2 Imaging fluorescent microscope. Images were merged 
using GIMP; Bar = 10 µm. 
 
 
GFP tagged lanosterol 14α-demethylase and sterol C14-reductase localises 
differently and therefore the lanosterol 14α-demethylase mutation is not likely 
to cause a lanosterol 14α-demethylase and sterol C14-reducatse decoupling. 
Moreover, Julie Kovarova and Andrew Pountain showed no pull-down partners 
(lanosterol 14α-demethylase and sterol C14-reductase) by immunoprecipitation 
using anti-GFP antibodies. However, yeast has been shown to have sterol 
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biosynthetic enzymes function as a complex called an "ergosome" that allows for 
protein-protein interaction among them. Lanosterol 14α-demethylase is found at 
the core of the ergosome with Sterol C4-methyloxidase and sterol C3-keto 
reductase and share more interactions with the other enzymes of the pathway. 
Apparently, sterol C14-reductase has been shown to have a moderate interaction 
with lanosterol 14α-demethylase in yeast (Mo and Bard, 2005). It must be 
mentioned that these enzymes are both localised to ER while lanosterol 14α-
demethylase also localises in the cytoplasm in yeast (Natter et al., 2005).  
 
4.7 Cloning and over-expression of lanosterol 14α-
demethylase in E. coli 
The restoration of susceptibility to AmB of AmB resistant cells expressing an 
extra-chromosomal copy of lanosterol14α-demethylase gene, led us to clone 
whole genes of both the wild-type and mutated enzymes in E. coli for over-
expression and eventual comparison of their activity. The enzymes cloned into 
BL21 E. coli did not show over-expression of the enzymes. However, the two 
enzymes were over-expressed in the Rosetta and Rosetta pLysS competent cells 
(Figure 4.11 A). Rosetta E. coli is suitable for over-expression of the proteins 
whose genes contain codons that are rare in E. coli. However, we were unable to 
purify the enzyme using the Ni-NTA spin columns (Qiagen). The inability to purify 
the protein was attributed to the protein being expressed as inclusion bodies. 
Inclusion bodies in E. coli are known to be a major impediment to isolation of 
overexpressed proteins that are not E. coli endogenous proteins (Ventura and 
Villaverde, 2006).  
 
We initially used the whole gene sequence to clone lanosterol 14α-demethylase, 
other studies have used truncated gene sequences to clone the enzyme 
(Hargrove et al., 2011). With the removal of the trans-membrane domain 
comprising of 23 residues at the N-terminus, Dr. Jean-Christophe Le Bayon got 
the soluble protein (Figure 5.11 B) from inclusion bodies using Rosetta E. coli. 
Therefore determination and comparison of activity of the wild-type and 
mutated enzymes will form part of future work. 
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Figure 4.11 Over-expression of Wild-type and AmB resistant lanosterol 14α-demethylase. 
Wild-type and AmB resistant lanosterol 14α-demethylase (CYP51s) were inserted into pET30 
over-expression vector and cloned into Rosetta E. coli competent cells. E. coli were grown 
at 37°C and induced with 1 mM IPTG when O.D reached 0.6 for three hours. Bacteria was 
boiled in loading dye at 95°C to obtain a crude extract of the proteins which were resolved 
on NuPAGE Bis-Tris Mini Gels 200 volts. W1 = un-induced wild-type E.coli with the wild-type 
CYP51; W2 = Induced wild-type E.coli with the wild-type CYP51; A1 = un-induced wild-type 
E.coli with the AmB resistant CYP51; A2 = Induced wild-type E.coli with the wild-type 
CYP51. In (A) Over-expression of full length gene sequence of lanosterol 14α-demethylase 
and (B) over-expression of a truncated sequence of lanosterol 14α-demethylase. Bacteria 
was lysed in 10mM Imidazole containing 300mM NaCl, 50mM sodium phosphate (pH8.0) in 
the presence of Lysozyme and Benzonase nuclease. The pellet was re-suspended in 5M 
Urea/ 5mM EDTA in PBS  and incubated for 30 min at  4°C prior to  Freezing at  -20°C for 20 
min and defrosting. The supernatant was run on a gel as above following centrifugation at 
13.000 × g for 30 min at 4°C 
 
4.8 Discussion 
Lanosterol 14α-demethylase is an enzyme found in most eukaryotic organisms 
including plants, fungi, animals and protozoa. It belongs to the cytochrome P450 
group of enzymes. Lanosterol 14α-demethylase is an important enzyme involved 
in synthesis of ergosterol in fungi and leishmania species and cholesterol in 
mammals. These molecules are important for the formation and function of cell 
membranes (Lepesheva and Waterman, 2011b). L. mexicana shares 97% of its 
amino acid sequence with L. infantum. Both L. mexicana and L. infantum have 
480 amino acid in their structure with a mass of approximately 54 kD (Hargrove 
et al., 2011). 
 
4.8.1 N176I mutation affected a conserved amino acid residue 
 Mutations of conserved residues of lanosterol 14α-demethylase can elicit 
dramatic changes to the functionality of the enzyme. For instance mutation of 
phyla specific I105F in T. cruzi shifts its substrate to that of plants (Lepesheva et 
al., 2006). Point mutations, including those of conserved amino acid residues, 
have also been implicated in resistance to miltefosine (Coelho et al., 2012; 
Perez-Victoria et al., 2003a; Perez-Victoria et al., 2003b). T420N in L. donovani 
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and, P782T, G852D, and G565R in L. infantum are some of the point mutations 
that have been shown to inactivate the miltefosine transporter and are located 
in conserved sequences of the miltefosine transporter protein (Coelho et al., 
2012; Perez-Victoria et al., 2003b). The point mutation in lanosterol 14α-
demethylase in our study was found to affect a conserved residue among 
trypanosomatids whose sequences were assessed. The conservation of the 
mutated residue suggests some importance of the residue to these species. The 
mutation involved a substitution of asparagine with isoleucine in one of the α-
helices of the predicted secondary structure of the enzyme. The occurrence of 
the helix in this part of the enzyme corresponds to an αE-helix in the secondary 
structure of L. infantum (Hargrove et al., 2011). Asparagine has a polar 
uncharged side chain while isoleucine has a bulky and more hydrophobic side 
chain. Isoleucine has the capability to form more stabilised α-helices than 
asparagine (Monera et al., 1995). The introduction of a bulky side chain that has 
the capability to destabilize the protein may have been compensated for by the 
isoleucine’s ability to form stabilised α-helices. Therefore, replacement of a 
small polar side chain with a more hydrophobic bulky side chain suggests a 
change in the overall conformation of the protein. Moreover, asparagine is able 
to form hydrogen bonds and therefore its replacement with isoleucine, which is 
able to form hydrophobic bonds and not hydrogen bonds, is likely to alter the 
native protein structure. Despite the mutation being outside the active site this 
may possibly have had an effect on the enzyme function. The alteration in the 
enzyme function may have led to perturbation of the sterol biosynthetic 
pathway that aims at protecting the parasites against the effects of AmB. 
 
4.8.2 Restoration of ergosterol synthesis following 
complementation of AmB-R cells with wild-type lanosterol 
14α-demethylase 
The role of the non-synonymous mutation in the lanosterol 14α-demethylase 
gene in Amphotericin B resistance was assessed by use of complementation of 
the AmB resistant cells with an episomal vector carrying the wild-type copy of 
the enzyme. This strategy has been used successfully in other studies to restore 
an altered phenotype in leishmania (Roberts, 2011; Verma et al., 2011). The 
complementation of the AmB resistant cells with wild-type gene of lanosterol 
14α-demethylase restored ergosterol levels in these cells. The restoration of 
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ergosterol levels in AmB resistant cells expressing episomal wild-type lanosterol 
14α-demethylase is in agreement with the restoration of ergosterol levels in 
lanosterol 14α-demethylase single knock-out L. donavani. Ergosterol level 
restoration in the L donovani lanosterol 14α-demethylase single knock-out 
complemented with wild-type lanosterol 14α-demethylase was twice that in the 
single knock-out lanosterol 14α-demethylase cells but half that in the wild-type 
cells (Verma et al., 2011). However, in our study we witnessed a full restoration 
of ergosterol in AmB resistant cells complemented with wild-type lanosterol 14α-
demethylase. 
  
4.8.2.1 Restoration of wild-type-like tolerancy of antileishmanial drugs by 
AmB-R 
Associated with complementation of AmB resistant cells with wild-type 
lanosterol 14α-demethylase resulting in restoration of ergosterol levels was 
restoration of susceptibility to AmB. This implies that the restored levels of 
ergosterol resulted in restoration of the drug’s target in these cells resulting in 
their losing the tolerance level of AmB they had acquired when they became 
resistant to the drug. This result further confirms earlier reports of the 
dependence of AmB’s action on the presence of ergosterol in cells in leishmania. 
Thus, in vitro AmB resistance in leishmania has been associated with inhibition 
of synthesis of ergosterol (Al-Mohammed et al., 2005; Mbongo et al., 1998; 
Purkait et al., 2012). We also observed the restoration of tolerance of 
pentamidine by the re-expressers cells to the same level as the wild-type cells. 
In view of the increased uptake of pentamidine by AmB resistant cells with 
depleted ergosterol levels than the wild-type, the restoration of ergosterol in 
the re-expressor would suggest reduced uptake of pentamidine. This reduces 
accumulation of the drug in the cells leading to reduced toxicity. The restoration 
of tolerance to pentamidine amid restoration of ergosterol would also suggest 
the restored ergosterol was able to protect the cells through its antioxidant 
properties as has been reported in yeast (Dupont et al., 2012; Landolfo et al., 
2010) against ROS since pentamidine has been shown to induce accumulation of 
ROS in wild-type L. infantum (Moreira et al., 2011). 
 
Restoration of sensitivity to miltefosine was observed after complementation of 
AmB resistance cells with the wild-type lanosterol 14α-demethylase. In fact, the 
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re-expressor cells were more sensitive to miltefosine than the wild-type cells 
with a fold-change in EC50 of 0.62. Resistance to miltefosine has been attributed 
to point mutation in the gene for the membrane bound miltefosine transporter 
which result in reduced translocation of the dug into the cells (Coelho et al., 
2012; Cojean et al., 2012; Perez-Victoria et al., 2003a; Perez-Victoria et al., 
2003b). Indeed chemical depletion of sterols from the membranes of wild-type 
and miltefosine resistant L. donovani resulted in increased tolerance of 
miltefosine by both wild-type and miltefosine resistant cells (Saint-Pierre-
Chazalet et al., 2009). Therefore, reversing of tolerance to miltefosine following 
restoration of ergosterol in the re-expressor cells in this case would suggest the 
removal of ergosterol from the membrane may have affected the function of the 
miltefosine transporter possibly due to changes to the conformation structure of 
the transporter. Indeed it has been shown in nematodes (Haemonchus cortortus) 
that the number of active, albeit with the correct conformation, membrane 
pumps (the P-glycoproteins) increased, to an optimum, as the concentration of 
free cholesterol (a sterol) increased. It was suggested that the correct 
conformation of these proteins required a given concentration and distribution 
of cholesterol in the membranes (Riou et al., 2007). Treatment of S. cerevisiae 
with AmB prior to DNA microarray analysis revealed up-regulation and down-
regulation of various membrane proteins involved in nutrient and ion transport 
across the membrane to counter the loss of these through AmB pore formation 
(Zhang et al., 2002). A related polyene antibiotic, natamycin, was shown to 
inhibit membrane transport proteins, including amino acid transporters and the 
glucose transporter proteins in fungi (Aspergillus niger) and yeast (S. cerevisiae) 
(te Welscher et al., 2012). Although natamycin does not form membrane pores 
like AmB, it is believed to bind ergosterol like AmB. Because different types of 
proteins were inhibited it was thought that natamycin was able to inhibit the 
membrane transport proteins by altering ergosterol-protein interaction (te 
Welscher et al., 2012) and probably resulting in altered conformations of these 
proteins and hence their inhibition. 
 
Interestingly the complementation of AmB resistance with wild-type lanosterol 
14α-demethylase resulting in restoration of ergosterol levels was accompanied 
by increased resistance to ketoconazole with a fold-change in EC50 values from 
1.60 for the AmB resistant cells compared to the wild-type cells to 2.60 for the 
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AmB resistant cells complemented with the wild-type lanosterol 14α-
demethylase as compared to the wild-type cells. Ketoconazole belongs to azole 
compounds that are known to target lanosterol 14α-demethylase and have been 
shown to be potent against leishmaniasis (Beach et al., 1988; de Macedo-Silva et 
al., 2013). Therefore this result suggests an increased drug target resulted in the 
mildly increased resistance to the drug in line with one of the known strategies 
of increased drug target employed by parasites to become resistant to a drug. 
Indeed our result is in agreement with in vitro ketoconazole resistance by L. 
amazonensis, where up-regulation of lanosterol 14α-demethylase resulted in 
resistance to the drug with a five-fold increase in IC50 value (Andrade-Neto et 
al., 2012). 
 
4.8.3 Lanosterol 14α-demethylase interaction with other sterol 
biosynthetic pathway enzymes 
Our lack of detection of lanosterol, the substrate of lanosterol 14α-demethylase, 
but its product 4,4-dimethylcholesta-8, 14, 24-trien-3β-ol, despite a lack of 
indication of any changes to the gene sequence of the enzyme that comes after 
lanosterol 14α-demethylase, sterol C14-reductase, in the sterol biosynthetic 
pathway (Figure 1.8), led us to believe that lanosterol 14α-demethylase may 
have specific interactions with sterol C14-reductase. Unique protein-protein 
interactions to form functional enzyme complexes called “ergosomes” in sterol 
biosynthetic pathway have been reported in yeast. The complexes have been 
reported to function in association with other enzymes of the pathway (Mo and 
Bard, 2005). These interactions can be assumed to provide an efficient way of 
channelling metabolites from one enzyme to the next in the pathway. The 
centre of the ergosome is occupied by lanosterol 14α-demethylase, sterol C4-
methyloxidase, sterol C3-keto reductase and a protein designated as erg28p (Mo 
and Bard, 2005). Erg28p provides a means of bringing sterol C4-methyloxidase, 
sterol C3-keto reductase and sterol C3 dehydrogenase together to enhance their 
interactions (Gachotte et al., 2001). If an “ergosome” exists in Leishmania, it 
may be different from that in yeast based on the localisation to different 
cellular compartments of the sterol biosynthetic enzymes. This would mean that 
lanosterol 14α-demethylase cannot bind sterol C14-reductase and therefore may 
need to bind a membrane protein, like the role of a tether played by erg28p in 
yeast (Gachotte et al., 2001), to efficiently pass on or carry its product to 
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another cell compartment. Lanosterol 14α-demethylase has been shown to show 
specificity to more than one substrate in L. infantum (Hargrove et al., 2011). 
Therefore, existence of an ergosome may also serve the purpose of making sure 
that the correct substrates are channelled to the next enzyme in the pathway. 
The fact that the N176I mutation in lanosterol 14α-demethylase does not seem 
to affect the activity of the enzyme leading to the accumulation of its product, 
4,4 dimethylcholesta-8, 14, 24-trien-3β-ol, it suggests instead an altered 
transfer of the metabolite to the next enzyme in the pathway. This could 
happen by a disrupted protein-protein interaction of the enzymes. Indeed, 
lanosterol 14α-demethylase has been shown to have a weak interaction with 
sterol C14-reductase in yeast (Mo and Bard, 2005). In leishmania, however, the 
demethylase and reductase seem to have different localisations. Therefore, 
failure to bind to a different element involved in the pathway appears to be 
responsible. 
  
It is interesting to note that inhibition of yeast’s sterol C14-reductase with 
fenipropidin results in accumulation of 4, 4-dimethylcholesta-8, 14, 24-trienol 
(Baloch et al., 1984). It would be interesting to investigate if a similar increase 
occurs in fenipropidin treated leishmania. However, ketoconazole’s specific 
inhibition of lanosterol 14α-demethylase in leishmania does not appear to lead 
to accumulation of lanosterol in such cells (Beach et al., 1988). It was suggested 
lanosterol is metabolised by non P450 lanosterol 4α-demethylase and isomerised 
to 4α, 14α-dimethylzymosterol, the major sterol detected in the ketoconazole 
inhibited leishmania cells (Beach et al., 1988). As lanosterol 14α-demethylase 
appears to remain active, producing 4,4 dimethylcholesta-8, 14, 24-trien-3β-ol, 
it is not surprising sensitivity close to wild-type, presumably as ketoconazole 
prevents production of 4,4 dimethylcholesta-8, 14, 24-trien-3β-ol and thus 
cannot produce what we presume to be a replacement sterol for ergosterol. The 
fact that other studies show a rise in 4,4 dimethylcholesta-8, 14, 24-trien-3β-ol 
indicate that this sterol and not the subsequent intermediates in the pathway 
might be able to replace ergosterol, thus it might be that lanosterol 14α-
demethylase mutations, similar to our N176I, underlie AmB resistance in other 
studies. 
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Apparently sterol C4-demethylase, (ERG25 or EC 1.14.13.72; C4-Sterol methyl 
oxidase), of S. cerevisiae catalyses the conversion of 4, 4-dimethylzymosterol to 
4α-methylzymosterol through four intermediates (Figure 4.12), 4α-
Hydroxymethyl-4β-methyl-5α-cholesta-8-24-dien-3β-ol, 4α-formyl-4β-methyl-5α-
cholesta-8-24-dien-3β-ol, 4-methylzymosterol-4-carboxylic acid, 3-keto, 4-
methylzymosterol (Bard et al., 1996). 
  
We were able to detect elevated levels of, 4α-formyl-4β-methyl-5α-cholesta-8-
24-dien-3β-ol (Table 3.5) an intermediate product of sterol C4-methyl oxidase 
and a substrate of sterol C3-dehydrogense (sterol C4-decarboxylase) (Figure 
4.12), both of these enzymes have been shown to have moderate interactions 
with lanosterol 14α-demethylase in yeast (Mo and Bard, 2005). Sterol C4-
methyloxidase is not listed in the sterol biosynthetic pathway of leishmania. 
However, a blast search using S. cerevisiae’s C4-Sterol methyloxidase protein 
sequence gave a hypothetical protein with unknown function (LmxM.36.2540.1) 
in GeneDB for L. mexicana. Therefore a disturbance to the sterol biosynthesis 
enzyme complex, as maybe the case in this study due to the mutated lanosterol 
14α-demethylase, assuming sterol C4-methyl oxidase exist in leishmania, may 
help explain the elevated levels of 4α-formyl-4β-methyl-5α-cholesta-8-24-dien-
3β-ol that we observed. It seems likely that leishmania lanosterol C14α-
demethyalse functions in complex with other enzymes. 
  
4.8.4 Effect of sterol C14-reductors inhibitors on wild-type and 
AmB resistant L. mexicana  
An assessment of the effect of sterol C14-reductase specific inhibitors showed 
varying potency to both the wild-type and AmB resistant cells. The 
interpretation of the opposing effect of amorolfine and fenpropidin towards the 
AmB resistant cells was quite challenging although the results did not seem to 
indicate whether the altered sequence of lanosterol 14α-demethylase had 
affected sterol C14-reductase in any way. However, the sterol C14-reductase 
inhibitors did show varying potency towards the wild-type and AmB resistant 
cells. It is unknown how well these compounds enter these cells, nor if they are 
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Figure 4.12 4, 4-dimethylcholesta-8, 14, 24-trien-3β-ol to 4α-zymosterol part of the sterol biosynthetic pathway of yeast. 
The reactions shown with dashed arrows represent reactions as they occur in yeast and yet to be reported in Leishmania. The metabolites that were 
elevated in the metabolomic analysis of our AmB resistant Leishmania mexicana promastigote are indicated by an upward pointed arrow. 1 – lanosterol 
14α-demethylase; 2 – sterol C14-reductase; 3 – sterol C4-methyl oxidase; 4 – sterol C3-decarboxylase (-dehydrogenase). (Reaction scheme adapted from 
Mo and Bard, 2005).
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metabolised or necessary potent inhibitors of the enzyme. Indeed, it is possible 
they affect different enzymes in leishmania and we did not assess these here. 
Sterol C14-reductase inhibitors have indicated the possibility of inducing 
resistance to AmB to varying degrees. Despite Fenpropidin inducing a marked 
increase of tolerance, 5.5-fold increase in EC50 value, by wild-type to AmB it 
showed the least reduction in ergosterol synthesis at least judged by the 
adaption of a spectroscopic method. This result may suggest a mechanism of 
action that is not directly connected to ergosterol synthesis while fenhexamid 
and spiroxamine show a link to ergosterol synthesis. Based on these results, the 
use of a UV spectroscopy based assay to identify AmB resistant parasites in the 
field would pose a challenge of determining the level of ergosterol which would 
constitute that synthesised by a resistant parasite. 
 
Indeed, the results with this assay would be misleading in a situation where the 
parasites have been exposed to other drugs that are able to induce reduction of 
ergosterol content of cells. This is due to the fact that cells treated with sterol 
C14-reductase inhibitors for 24 hours also showed reduced ergosterol content. It 
would be interesting in future work to treat the wild-type parasites with the 
sterol C14-reductase inhibitors and AmB, and carry out the filipin staining assay 
to observe whether the treated cells would stain with filipin. 
 
4.8.5 Subcellular localisation of lanosterol 14α-demethylase and 
Sterol C14-reductase 
We observed strong indications of lanosterol 14α-demethylase localising to the 
mitochondria and sterol C14-reductase to the endoplasmic reticulum. The two 
enzymes may have possible interaction in the endoplasmic reticulum where 
lanosterol 14α-demethylase showed a possible low level co-localisation. 
Localisation of lanosterol 14α-demethylase in the mitochondria and endoplasmic 
reticulum is in agreement with that of lanosterol 14α-demethylase (L. donovani 
lanosterol 14α-demethylase shares 98% of its amino acid residue sequence with 
L. mexicana lanosterol 14α-demethylase) in L. donovani (Verma et al., 2011), 
although our results show much more localisation to the mitochondrion than to 
the endoplasmic reticulum in contrast to what was reported in L. donovani 
(Verma et al., 2011). An interaction of the two enzymes may also be possible in 
the endoplasmic reticulum because sterol C14-reductase also showed 
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localisation to the endoplasmic reticulum. Overall, co-localisation experiments 
of lanosterol 14α-demethylase did not indicate any apparent alteration in the 
localisation of the enzyme associated with the N176I mutation. 
 
4.8.6 Over-expression of L. mexicana lanosterol 14α-demethylase 
in E. coli. 
Our inability to express active lanosterol 14α-demethylase in E.coli may have 
been due to its being expressed as inclusion bodies. We were able to detect 
overexpression when we run crude whole cell extracts on the gel but could not 
purify the protein. Inclusion bodies result from the expression of the protein at 
rates that are over the concentration that can be protected by chaperones, that 
protect against misfolding (Wang, 2009). Many leishmania proteins are 
reportedly insoluble such that their overexpression in E. coli results in formation 
of inclusion bodies (Bhargava et al., 2010; Hargrove et al., 2011). The 
overexpression of L. donovani squalene synthase resulted in 70% of the enzyme 
being expressed as inclusion bodies at optimised conditions of bacterial culture 
growth temperature and concentration of IPTG (Bhargava et al., 2010). We used 
the His-tag for purification purposes. However, the use of the His-tag for 
purification purposes can also pose a problem of purifying proteins due a 
possibility of the His tag being masked due to misfolding of the proteins as they 
emerge from the ribosomes (Bhargava et al., 2010). Therefore, inclusion body 
formation and masking of the His-tag were possible reasons for our inability to 
purify the protein. L. infantum C lanosterol 14α-demethylase was overexpressed 
following 23 amino acid residue truncation of the N-terminus of the protein 
(Hargrove et al., 2011). We initially tried to overexpress the entire full protein 
sequence with no success. With the removal of the 23 amino acid residues 
forming part of the trans-membrane domain, the protein was overexpressed by 
Jean-Christophe. Determination and comparison of the activities of the wild-
type and mutated enzymes has been planned for our future work. 
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Chapter Five 
5 Isometamidium resistance in BSF T. b. brucei 
5.1 Introduction 
Resistance to trypanocidal drugs is of major concern in veterinary productivity in 
Africa (Geerts et al., 2001). Isometamidium is used as a prophylactic drug 
because it stays in circulation after administration for up-to 4 months (Eisler et 
al., 1996). However, concentration of the drug in circulation decreases over the 
4 months period such that infections that may occur by the end of the period, 
and means that parasites are exposed to waning concentrations of the drug. The 
declining concentration of the drug in circulation may promote the development 
of resistance to the drug (Matovu et al., 2001). Drug resistance to 
isometamidium has been reported in most parts of Africa for a long time, 
although the mode of action and mechanism of resistance is not fully known. 
However, possible targets and mechanisms of resistance to isometamidium were 
recognised as early as 1993 (Kinabo, 1993). Strides have been made to 
understand some of these processes and possible mechanisms of resistance in 
Trypanosoma species. The kinetoplast has been proposed as the target and 
reduction in mitochondrial membrane potential has been implicated in both 
isometamidium and ethidium bromide resistance (Chowdhury et al., 2010; 
Wilkes et al., 1997). Understanding modes of action and resistance mechanism 
may help delay selection and spread of resistance.  
 
We have initiated a characterization of isometamidium resistance. Our approach 
has been to elucidate differences between the wild type and selected 
isometamidium-resistant lines, with the purpose of identifying characteristics, or 
markers, that are associated with resistance development. To achieve our goal, 
we characterised isometamidium resistant T. brucei bloodstream forms in terms 
of alterations in growth phenotype, internal morphology of mitochondria, 
mitochondrial membrane potential, metabolite alterations and cross-resistance 
to other trypanocidal drugs. 
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5.2 Results 
5.2.1 Induction of isometamidium resistance in BSF T. b. brucei 
Isometamidium resistant T. brucei were selected in vitro in order to characterise 
the drug resistant parasites. The selection for isometamidium resistance in 
bloodstream forms over 134 days achieved a ten-fold increase in the EC50 value 
relative to that of the wild type. Thereafter, the selection for higher resistance 
occurred more quickly (Figure 5.1). The fold increase in isometamidium EC50 
values, over the period of isometamidium resistance induction was 2.99, 10.57 
and 94.17 for clones growing in the presence of 4 nM, 40 nM and 1 µM, 
respectively. These fold-increases in EC50 represented significant differences 
(Unpaired student t-test; P = 0.0004, P < 0.0001, P < 0.0001, respectively) 
between isometamidium resistant clones and the wild-type cells. 
 
 
Figure 5.1  Isometamidium resistance selection in T. brucei 427 bloodstream forms. 
Crosses and left y-axis show concentration of isometamidium in which the cells grew while 
the bars and the right y-axis show the EC50 values for the clones growing in the presence of 
4, 40  400 and 1, 000 nM isometamidium at various stages of the isometamidium resistance 
induction. The insert shows the induction of resistance at lower concentrations of the drug, 
from 0.01 nM of the drug on day 1 and 0.1 nM after 120 days. Resistance was selected for by 
stepwise increase of drug concentration in the growth medium.  
 
Interestingly we were unable to induce isometamidium resistance in T. brucei 
927 procyclic forms. Cells exposed to low concentrations of isometamidium 
could not survive beyond a third passage. Twenty nanomolar isometamidium was 
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the maximum dose in which procyclic T. brucei survived but these cells could 
not be grown beyond a fourth passage. Attempts were made to grow the cells 
beyond 20 nM isometamidium for the whole duration of the resistance induction 
in the bloodstream forms. 
 
5.2.2 Characterisation of isometamidium resistant strains 
5.2.2.1 Growth phenotype 
To assess whether there was an effect on the growth phenotype of the derived 
isometamidium (ISMM) resistant bloodstream T. brucei, the growth of the 
resistant lines were compared to that of the wild-type (Figure 5.2). There was a 
gradual slowing in growth of the resistant cells as the level of resistance 
increased. 
 
 
Figure 5.2 Comparison of growth of T. brucei Wt and derived ISMM resistant cells. 
The growth curves were made by growing cloned cells in HMI-9 at a starting density of 2 × 
10
4
 cells/ml and counting the cells every 24 hours using the improved Haemocytometer 
under the light microscope. The growth curve plots are of three replicates. 
 
The growth phenotype was also assessed in minimal medium (CMM) (Creek et 
al., 2013). Interestingly, CMM allowed normal growth of wild-type cells but not 
of the derived resistant cells, (especially for the clones growing in the presence 
of the higher isometamidium concentration). Clones growing in the presence of 
isometamidium in HMI-9 starting from 400 nM to 1 µM isometamidium, failed to 
grow in CMM in the absence of isometamidium. The growth phenotypes of these 
clones were even more affected when grown in CMM in the presence of ISMM.  
An attempt to replace the omitted nutrients one by one and in various 
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combinations was made but no success was achieved in identifying the missing 
ingredients that could allow the derived resistant lines to proliferate in this 
medium. The derived isometamidium resistant T. brucei showed reduced growth 
phenotype and hence reached the late log-phase after 72 hours compared to 48 
hours for the wild-type in commercial HMI-9 (Figure 5.2). It is worth noting that 
the derived resistant cells died more quickly than the wild-type cells once they 
reached the maximum density of growth. 
 
5.2.2.2 Cross-resistance of isometamidium resistant trypanosomes to other 
anti-trypanocides 
Derived isometamidium resistant clones were assessed for isometamidium cross-
resistance to other trypanocidal drugs using the modified alamar blue assay. This 
was achieved by comparing the EC50 values of various drugs tested for the wild-
type and the derived isometamidium resistant clones. Isometamidium cross-
resistance to the widely used trypanocides in AAT are shown in figure 5.3 and 
HAT trypanocidal drugs (Table 5.1). 
 
 
Figure 5.3 Isometamidium cross-resistance to ethidium bromide and diminazene aceturate. 
The EC50 values were determined using the modified Alamar blue assay. An analysis of at 
least three independent replicates was done and the significance of the difference in EC50 
expressed as Mean ± SEM between the Wt and each derived ISMM clone was determined 
using the unpaired t-test in GraphPad Prism software. * P = 0.04; ** P = 0.003; *** P < 0.0004. 
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 Wt  4 nM Clone  40 nM Clone  1 µM Clone 
EC50 (µM)  EC50 (µM) 
Fold-
change 
 EC50 (µM) 
Fold-
change 
 EC50 (µM) 
Fold-
change 
ISMM  0.044 ± 0.001  0.131 ± 0.008 3.0  0.461 ± 0.006 10.47  4.106 ± 0.092 93.31 
DA  0.156 ± 0.002  0.261 ± 0.0046 1.67  0.427 ± 0.0016 2.74  1.548 ± 0.057 9.92 
EtBr 1.23 ± 0.07  1.469 ± 0.04 1.19  1.75 ± 0.04 1.42  3.336 ± 0.11 2.71 
Pentamidine  0.007 ± 0.0001  0.014 ± 0.0004 2  0.037 ± 0.0009 5.3  0.160 ± 0.008 22.9 
Melarsoprol  0.023 ± 0.0003  0.022 ± 0.0002 0.96  0.023 ± 0.0004 1.0  0.023 ± 0.0005 1.0 
Eflornithine 109.3 ± 2.8  76.6 ± 1.7 0.7  70.4 ± 2.3 0.6  40.5 ± 0.9 0.4 
Table 5.1 Cross-resistance of isometamidium resistant trypanosomes to AAT and HAT trypanocides. 
Cross-resistance of isometamidium (ISMM) resistant trypanosomes to diminazene aceturate (DA) ethidium bromide (EtBr), pentamidine, melarsoprol and 
eflornithine was determined using the alamar blue assay over 48 hrs incubation with the drug with an additional 24 hrs incubation at 37°C after addition of 
12.5 mM resazurin in 96-well plates. Absorbance values were analysed using GraphPad Prism software. Data were collected from three independent 
experimental replicates. Results are presented as Mean ± SEM. Fold-change is the ratio of Isometamidium resistant clone EC50 value for a drug to Wild-type 
EC50 value of the same drug. 
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Fold-increase of isometamidium cross-resistance to diminazene aceturate was 
1.68, 2.74 and 9.93 for the clones growing in the presence 4 nM, 40 nM and 1 µM 
isometamidium, respectively, and for ethidium bromide was 1.20, 1.42 and 2.72 
for the clones growing in the presence of 4 nM, 40 nM and 1 µM isometamidium, 
respectively. 
  
Isometamidium cross-resistance to trypanocides used in HAT were also assessed 
(Table 5.1). Cross-resistance to pentamidine increased as the level of resistance 
to isometamidium in clones increased. However, increasing sensitivity (P = 
0.0006, P = 0.0004 and P < 0.0001 for clones at 4 nM, 40 nM and 1 µM, 
respectively) to eflornithine by the clones was observed as the level of 
resistance to isometamidium increased. There was no isometamidium cross-
resistance to melarsoprol in any of the clones, with an average EC50 value being 
determined as 0.023 µM. 
 
5.2.2.3 Monitoring mitochondrial membrane potential 
Accumulation of isometamidium and ethidium bromide in the mitochondria of 
bloodstream forms of T. congolense and T. brucei, respectively, has been 
associated with maintenance of mitochondrial membrane potential (Wilkes et 
al., 1998; Chowdhury et al., 2010). It was indicated that a reduction of the 
mitochondrial membrane potential resulted in reduced accumulation of these 
drugs. Therefore, the mitochondrial membrane potential of the selected 
isometamidium resistant T. brucei was monitored in comparison to the parental 
wild-type cells to determine whether the reported modulation of mitochondrial 
membrane potential in T. congolense was operational in our isometamidium 
resistant clones. 
 
The status of the mitochondrial membrane potential (∆Ψm) in the derived 
isometamidium resistant bloodstream forms and that of the T. brucei 427 wild-
type was monitored and compared using the fluorescent signal of the 
accumulated active-mitochondrial-specific dye TMRE and analyzed by FACS 
analysis. TMRE is a lipophilic cationic fluorescent dye that accumulates in 
polarized mitochondria. Its accumulation in mitochondria depends on the level 
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Figure 5.4 Monitoring mitochondrial membrane potential of bloodstream forms of T. brucei 427 wild-type and the derived isometamidium resistant clones. 
Mitochondrial membrane potential was monitored by fluorescence signal of the accumulated active-mitochondrial-specific dye (25 nM) TMRE by 1 × 10
6
 
cells/ml following incubation for 30 minutes and analyzed by FACS analysis. Troglitazone and valinomycin were used as controls to polarise and 
depolarise the inner mitochondrial membrane, respectively. The top row represents Wt controls for all conditions tested while the second and third rows 
are for the isometamdium resistant lines. The columns represent comparison of the three cell lines for each condition tested. At least three replicates were 
done. 
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of polarisation of the mitochondria i.e., the less polarised (less negatively 
charged) the mitochondrial matrix, the less the dye accumulates, and the more 
polarised (more negatively charged) a mitochondrial matrix the more the dye 
accumulates (Perry et al., 2011). The ∆Ψm was monitored and compared for the 
wild-type and the derived isometamidium resistant clones growing in the 
presence of 40 nM and 1 µM isometamidium (Figure 5.4; Appendix B). The ∆Ψm 
was monitored both in the presence and absence of isometamidium and it was 
observed to be reduced in both cases. There was a progressive reduction of the 
∆Ψm from the 40 nM isometamidium resistant clone to the 1 µM isometamidium 
resistant clone. The monitored ∆Ψm both in the absence and presence of 
isometamidium for the two isometamidium resistant clones was significantly (P < 
0.0001 and P = 0.0001) different from that of the wild-type. The wild type T. 
brucei showed a significant decrease in the ∆Ψm when monitored in the absence 
of the drug and then monitored after exposure to 500 nM isometamidium for 30 
minutes. However, a comparison of the monitored ∆Ψm in the absence of, and 
after exposure to, the drug for each of the clones growing in the presence of 4 
nM and 1 µM isometamidium showed decreases in ∆Ψm that were not significant 
(P = 0.0786 and P = 0.2002, respectively). This indicates maintenance of a low 
∆Ψm that cannot be reduced significantly after exposure to the drug. 
Troglitazone which polarizes the inner mitochondrial membrane and valinomycin 
an ionophore abolishes ∆Ψm by depolarising the inner mitochondrial membrane, 
were used as controls to indicate higher and lower levels of ∆Ψm (Denninger et 
al., 2007; Figarella et al., 2005). The use of these controls indicated the 
presence of a functional ∆Ψm as they were able to increase and abolish it in the 
resistant cells as was the case with the parental wild-type cells (Figure 5.4).  
 
The selected isometamidium resistant bloodstream forms of T. brucei showed 
maintenance of a low mitochondrial membrane potential as monitored by active 
mitochondrion labelling dye TMRE. Exposure of the resistant cells to 
isometamidium results in further reduced mitochondrial membrane potential as 
compared to that monitored in the absence of the drug. The higher the 
resistance level the lower the mitochondrial membrane potential. 
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5.2.2.4 Status of the kinetoplast and kDNA genes 
Loss of kinetoplast due to various trypanocides, including isometamidium, has 
been known for some time (Shapiro and Englund, 1990). We, therefore, set out 
to determine whether induced isometamidium resistance led to loss of the 
kinetoplast. To achieve this objective we used the DNA selective staining and 
fluorescent properties of DAPI. DAPI binds to the A-T rich regions of the minor 
groove of DNA and is known to show increased fluorescent properties when 
bound to kinetoplast DNA due to increased abundance of the A-T sequences 
(Kapuscinski, 1995). The isometamidium resistant clones growing in the presence 
of as low as 0.1 nM isometamidium were observed to have lost their kinetoplast 
DNA (Figure 5.5). 
 
Figure 5.5 Loss of the kinetoplast by isometamidium resistant BSF T. brucei 427 
The wild-type (A and B) and isometamidium resistant (C and D) bloodstream forms of T. 
brucei 427 were fixed in methanol at -20°C overnight and stained with 1 µg/ml 
DAPI/1%DABCO in PBS before applying to slides and viewing under the fluorescent 
microscope. The slides were observed under oil immersion. B and D show cells in 
cytokinesis. K = kinetoplast; N = Nucleus; Bar = 10 µm. 
 
The kinetoplast is known to harbour maxicircle genes that code for several genes 
including ATPase A6 subunit and six subunits of complex I or NADH 
dehydrogenase or NADH: ubiquinone oxidoreductase of the electron transport 
chain among other proteins (Schnaufer et al., 2002; Surve et al., 2012). Loss of 
the kinetoplast would then be confirmed by lack of amplification of these genes 
by PCR. The loss of the kinetoplast was confirmed by a PCR amplification of the 
genes encoded by maxicircle genes of the kinetoplast. Amplification of the actin 
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gene which is encoded by the nucleus was used as a control for the presence of 
nuclear DNA. The NADH dehydrogenase or NADH: ubiquinone oxidoreductase 
subunits ND4, ND5, and ND7 and the ATPase A6 subunit (Domingo et al., 2003; 
Lai et al., 2008) were found to be absent in our isometamidium resistant strains 
(Figure 5.6). Therefore, lack of staining of the kinetoplast and amplification of 
the kinetoplast encoded genes by PCR confirmed the loss of the kinetoplast in 
our isometamidium resistant clones. Loss of the kinetoplast seems to be 
associated with isometamidium resistance development as it was also observed 
in bloodstream forms of T. congolense (Wilkes et al., 1997). 
 
 
Figure 5.6 PCR amplification of the kinetoplast based maxicircle genes of BSF T. brucei. 
Presence of kinetoplast based maxicircle genes of wild-type and various isometamidium 
(ISMM) resistant bloodstream forms of T. brucei was compared by PCR amplification of the 
genes. The amplified DNA was separated on 1% agarose and stained with SYBR safe. 
Nucleus encoded actin gene was used as the control for the presence of nuclear DNA. In (A) 
absence of ATPase A6 subunit PCR band in clones growing in the presence of 0.1 nM ISMM 
(0.1 ISMR) and clone growing in the presence of 1 µM ISMM (1 ISMR). In (B) Absence of PCR 
bands for ND4, ND5 and ND7 genes in the resistant clone, indicated as ISMR, growing in the 
presence of 1 µM ISMM. Expected PCR bands sizes Actin = 456 bp; ND4 = 256 bp; ND5 = 
395; ND7 = 161 bp. 
 
 
5.2.2.5 ATPase F1 gamma subunit compensatory mutations 
The F1F0 ATPase is made up of the F1 and the F2 components. The F1 component, 
which projects into the mitochondrial matrix, is hydrophilic and contains the 
catalytic sites. It is attached to the hydrophobic F0 which is a membrane bound 
component through the stalk made up of the gamma, epsilon and delta subunits 
(Williams, 1994). The F0 conducts protons across the inner mitochondrial 
membrane following the hydrolysis of ATP by the F1 component during 
generation of the mitochondrial membrane potential (Dean et al., 2013; 
Williams, 1994). The loss of the kinetoplast induced by acriflavine exposure of 
trypanosomes has been reported to be compensated by mutations in the gamma 
subunit of the ATPase F1 component. This is to allow the continued generation of 
the mitochondrial membrane potential by akinetoplastic trypanosomes (Dean et 
al., 2013; Schnaufer et al., 2005). We checked for the mutations in the gamma 
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subunit of ATPase through whole genome sequence analysis data. There were no 
SNPs detected in the ATP synthase F1 subunit gamma protein (Tb427.10.180) 
which were unique to the isometamidium resistant cells. 
  
However, there were three mutations in both the isometamidium resistant 
clones and the parental wild-type cells as compared to the reference genome of 
T. brucei 427 Lister strain. Two of the three mutations were synonymous 
mutations (Table 5.2). The non-synonymous mutation was different from those 
reported in literature for T. evansi and T. equiperdum (Dean et al., 2013). 
Therefore, the occurrence of the mutations in both the parental wild-type cells 
and the derived isometamidium resistant cell lines indicated these mutations 
may have arisen due to adaptation to laboratory culture conditions.  
 
SNP Position  Mutation Amino acid 
substitution Tb427_10_v5    Non-synonymous Synonymous 
72460    gcA/gcG A31 
72561  gCc/gTc  A65V 
72688    gtC/gtT V107 
Table 5.2 ATPase gamma subunit protein mutations in Wt and ISMM resistant clones. 
 
 
5.2.2.6 Alteration of the internal morphology of the mitochondrion 
Internal mitochondrial structure of the derived isometamidium resistant clones 
was compared to that of the wild-type BSF T. brucei 427 by using the active-
mitochondria stain Mito-Tracker Red CMXRos. Mito-Tracker dyes are not only 
used to determine alterations to the internal morphology of mitochondria but 
also localisation of dyes (TMRE) used for monitoring the mitochondrial 
membrane potential. Thus Mito-Tracker dyes are employed to determine the 
influence of alteration to internal mitochondrial morphology as determined by 
localisation dyes and how this may influence the monitored ∆Ψm (Perry et al., 
2011). Therefore, our use of the Mito-Tracker Red CMXRos was not only to 
compare the internal mitochondrial morphology between the wild-type 427 and 
derived isometamidium resistant cells but also as controls for the monitored ∆Ψm 
in Section 5.2.2.3. 
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Figure 5.7 BSF T. brucei active mitochondria staining with Mito-Tracker Red CMXRos. 
The mitochondria of 2 × 107 cells/ml in 1 ml growth medium was stained with 1 nM Mito-
Tracker Red CMXRos and 0.5 µg/ml DAPI/1% DABCO in PBS and immobilised in 1% Low gelling 
temperature agarose before viewing under the fluorescent microscope using DAPI and DsRed 
filters. Images were merged using the free software, GIMP. Bar = 10 µm; K = Kinetoplast; N = 
Nucleus. 
 
None of the clones showed any apparent difference in mitochondrial internal 
morphology when compared to the wild-type bloodstream forms of T. brucei 427 
as determined by Mito-Tracker Red CMXRos staining (Figure 5.7). Therefore, the 
loss of the mitochondrial membrane potential by the isometamidium resistant 
clones was not due to changes in the internal morphology of the mitochondria 
but in line with the suggested need to maintain a low mitochondrial membrane 
potential to reduce the accumulation of the drug by the resistant cells as earlier 
reported (Wilkes et al., 1997). 
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5.2.3 Metabolic changes in isometamidium resistant BSF T. 
brucei 
The reduction of the mitochondrial membrane potential by the isometamidium 
resistant cells to reduce the accumulation of the drug is likely to have 
implications on the metabolism of the parasites. The mitochondrial membrane 
potential is generated during the energy metabolism of trypanosomes. In the 
case of bloodstream forms of T. brucei this is done by the break-down of ATP 
through the reverse function of ATPase (Brown et al., 2006; Schnaufer et al., 
2005). Further, the mitochondrial membrane potential is used for the 
importation of nuclearly encoded proteins into the mitochondrion (Schnaufer et 
al., 2002). Therefore, a reduction of the mitochondrial potential would affect 
the metabolism of the parasites. It is for this reason that we used untargeted 
metabolomics to determine the effect of reduced mitochondrial membrane 
potential on the metabolism of the parasites. We used untargeted metabolomics 
to assess alterations in global metabolite profiles that may have resulted from 
the effect of induced isometamidium by comparing derived isometamidium 
resistant clones with the parental wild-type.  
 
Metabolomes of resistant clones growing in the presence of 40 nM and 1 µM were 
compared to the parental wild-type bloodstream form T. brucei strain 427. We 
attempted to establish the anticipated energy metabolic differences with the 
view that the altered ∆Ψm could be achieved through adjustments to the energy 
metabolism which is linked to generation of ∆Ψm by the isometamidium resistant 
clones.  
 
There were no apparent metabolite differences between the wild-type and the 
derived isometamidium resistant clones with regard to the energy metabolism. 
Changes in the glycolytic pathway would have been good indicators of 
alterations in the energy metabolism of the bloodstream forms of T. brucei, but 
none were noted. Classically it was believed glucose catabolism by BSF T. brucei 
proceeded only to pyruvate. However, recent data (Creek et al., Unpublished) 
indicates that numerous other pathways exist, e.g. succinate, fumarate and 
malate are all produced and some succinate is secreted. These metabolites were 
detected in the various isometamidium resistant clones, but there were no 
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apparent differences as compared to the detected levels in the parental wild-
type cells. However, a metabolomics analysis of the clone of the highest 
resistance (1 µM) showed differences in some of the metabolites that were 
identified (Figure 5.8; Attached CD).  
 
 
Figure 5.8 Pie chart representation of all identified metabolites analysed using IDEOM.  
The summary represents all the metabolites identified in the wild-type and the 
isometamidium resistant clone growing in the presence of 1 µM isometamidium. The 
samples were extracted with methanol:chloroform:water mixture and separated and 
detected using LC/MS. The pie chart was generated using IDEOM. 
 
 
Using the built-in statistical analysis of IDEOM we generated the Principal 
Components Analysis (PCA) of all the identified metabolites to check for 
metabolite clustering according to sample source. We observed a clear 
separation of the clustered samples from wild-type and the derived-
isometamidium resistant clone, indicative of differences between the two cell 
lines or groups (Figure 5.9). It is worth noting that the quality control samples 
(QC) clearly clustered together and the medium related samples also clustered 
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together. The PCA separated the samples into clusters composed of 
experimental replicates for the wild-type and the isometamidium resistant 
clone. 
 
 
Figure 5.9 Differentiation of the wild-type from the isometamidium resistant clone by PCA. 
The wild-type T. brucei 427 differentiated from the derived isometamidium resistant clone 
growing in the presence of 1 µM isometamidium by clustering them into experimental 
replicates, three for each. The first principal exhibits the most changing variables while the 
second component depicts other possible variabilities in the data. The PCA was generated 
using IDEOM. 
 
Spingolipids have been linked to roles in growth, cytokinesis and segregation of 
the kinetoplast during cell division of T. brucei (Fridberg et al., 2008). 
Sphingolipids consisting of sphingomyelin (SM), ethanolamine 
phosphorylceramide (EPC) and inositol phosphorylceramide (IPC), make up about 
10 to 15% of the total phospholipids in T .brucei (Richmond et al., 2010). T. 
brucei bloodstream forms synthesize SM and EPC while the procyclic forms 
synthesize SM as well as IPC (Sutterwala et al., 2008). A total of 13 sphingolipids 
were identified (Figure 5.8). We observed both increased and reduced levels of 
different sphingolipids in the resistant samples as compared to the wild-type 
samples (Table 5.3). Relative abundance graphs of the detected sphingolipid 
metabolites (Figure 5.10) are superimposed on the T. brucei sphingolipid 
biosynthetic pathway (Smith and Butikofer, 2010).  
 
159 
 
Similar profiles of sphingolipid metabolite changes were observed in the clones 
growing in the presence of 4 nM and 40 nM ISMM. The two lower level resistant 
clones showed a similar pattern of depleted relative abundance level of 
spingomyelin when compared to the wild-type. The change in relative 
abundance of sphingomyelin in the resistant clone growing in the presence of 1 
µM ISMM was more pronounced as compared to the two lower resistant clones. 
 
Mass 
(m/z) 
RT Formula Putative metabolite identified 
Fold 
change 
555.52 3.695 C34H69NO4 [SP hydroxy(16:0)] N-(hexadecanoyl)-
4S-hydroxysphinganine 
5.91 
537.51 3.673 C34H67NO3 Ceramide 2.65 
565.54 3.664 C36H71NO3 [SP (18:0)] N-(octadecanoyl)-sphing-
4-enine 
2.04 
285.3 8.981 C18H39NO [SP] 1-deoxy-sphinganine 1.61 
688.55 4.07 C38H77N2O6P 
[SP (18:0/14:0)] N-(octadecanoyl)-
tetradecasphing-4-enine-1-
phosphoethanolamine 
1.30 
727.6 3.742 C42H81NO8 Glucosylceramide (d18:1/18:0) 1.23 
509.48 3.692 C32H63NO3 Dihydroceramide 1.18 
511.5 3.686 C32H65NO3 Dihydroceramide 1 
861.62 3.778 C46H87NO13 Lactosylceramide 0.84 
301.3 7.21 C18H39NO2 Sphinganine  0.72 
273.27 7.232 C16H35NO2 Hexadecasphinganine  0.30 
676.55 4.17 C37H77N2O6P Sphingomyelin 0.12 
 
Table 5.3 Sphingolipids identified in isometamidium resistant clone and the wild-type cells. 
Sphingolipids in bold font are superimposed in the pathway in figure 5.10. The metabolites 
were separated, detected and identified using LC/MS and IDEOM. RT = Retention time, fold 
change is the comparison of the metabolite level in isometamidium resistant derived 
samples to that from the wild-type. 
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Figure 5.10 Most changing T. brucei metabolites of the sphingolipid biosynthetic pathway. 
Comparison of the sphingolipid metabolite relative abundances between the wild-type T. 
brucei and the derived isometamidium resistant clone growing in the presence of 1 µM 
isometamidium and inserted in the sphingolipid biosynthetic pathway. The samples were 
extracted at 4°C using methanol:chloroform:water mixture and analysed by LC/MS and 
IDEOM. The results are for at least three replicates. 1 = Serine palmitoyltransferase; 2 = 3-
Ketosphingosine reductase; 3 = Dihydroceramide synthase; 4 = Dihydroceramide 
desaturase; 5 = Sphingosine kinase; 6 = Sphingosine-1-phosphate lyase; SLS1 = 
Sphingosine synthase 1; SLS2 = Sphingosine synthase 2; SLS3 = Sphingosine synthase 3; 
SLS4 = Sphingosine synthase 4. IPC = Inositol phosphorylceramide; EPC = Ethanolamine 
phosphorylceramide; DAG = Diacylglycerol. (Sphingolipid biosynthetic pathway adapted 
from Smith and Butikofer, 2010). 
 
The first part of the sphingolipid biosynthetic pathway (Figure 5.10) leading to 
ceramide in eukaryotic cells occurs in the endoplasmic reticulum while the 
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second part that starts from ceramide to the various sphingolipids occurs in the 
Golgi complex (Futerman and Riezman, 2005). Although the genes for all the 
enzymes of the sphingolipid pathway of T. brucei have been identified, only the 
first enzyme of the pathway, serine palmitoyltransferase, and the four 
sphingolipid synthases, TbSLS1-4, have been characterized. SLS1 and SLS2 
catalyze the synthesis of IPC and EPC, respectively while SLS3 and SLS4 are 
bifunctional and lead to synthesis of either SM or EPC from ceramide (Fridberg et 
al., 2008; Mina et al., 2009; Sevova et al., 2010; Sutterwala et al., 2008). 
 
5.2.4 Genetic status of sphingolipid pathway enzymes 
Following the alterations in the sphingolipid metabolites we determined whether 
the enzymes of the pathway were altered at the gene level from our whole 
genome sequencing by NGS of the wild-type and the resistant clones. The 
observed depletion in relative abundance levels of some of the sphingolipid 
metabolites (Figure 5.10) from metabolomics analysis led us to focus on the 
genetic status of the sphingolipid pathway’s enzymes. With the use of the 
metabolomics analysis results, a comparison of the sphingolipid pathway enzyme 
gene sequences of the parental wild-type with those of the isometamidium 
resistant clones, revealed 8 SNPs in choline phosphorylceramide synthase (SLS4) 
(Table 5.4). 
 
SLS4 on chromosome 9, whose substrate ceramide accumulated in the resistant 
cells (Figure 5.10), had 8 SNPs involving 4 synonymous mutations and 4 non-
synonymous mutations (Table 5.4). Two of the 4 non-synonymous mutations 
affected the same codon resulting in three non-conservative substitutions of 
residues in the enzyme. The wild-type and ISMM resistant sequencing reads 
aligned showed presence of the mutations in 50% of the reads from ISMM 
resistant lines implying that the mutations were heterozygous. The mutations 
were found to be outside the predicted catalytic site and they were also outside 
the four highly conserved sphingolipid synthases signature residues, D1-4, and 
outside the six trans-membrane domains, TM1-6 (Figure 5.11) (Sevova et al., 
2010; Sutterwala et al., 2008). There were no SNPs detected in the other 
enzymes of the pathway. 
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SNP Position  Mutation Amino acid 
substitution Tb427_09_v4  Non-synonymous Synonymous 
1450214 2850   Gac to Aac  D177N 
1450218 2854    tgT to tgC C175 
1450222 2858   cTg to cAg  
L174K 
1450223 2859  Ctg to Atg  
1450233 2869   gcG to gcT A170 
1450236 2872    ccG to ccT P169 
1450239 2875  ttG to ttT  L168F 
1450245 2881   acG to acA T166 
Table 5.4 Choline phosphorylceramide synthase point mutations of ISMM resistant clones. 
Genomic DNA of the wild-type T. brucei 427 bloodstream and the derived isometamidium 
resistant cells was extracted using the Phenol: chloroform: isoamyl alcohol (25:24:1). The 
genomic DNA was sequenced using NGS. The isometamidium resistant cells gDNA 
sequences were aligned to the parental wild-type gDNA and both to the reference genome 
sequence of T. brucei Lister strain 427. 
 
 
 
Figure 5.11 Non-synonymous mutations detected in choline phosphorylceramide synthase. 
The non-synonymous mutations are indicated by asterisks while the six trans-membrane 
domains (TM1-6) are boxed and the four highly conserved signature residues (D1-4) of SLSs 
are underlined with a dashed line. The predicted triad residues found in the catalytic site of 
the enzyme are circled. Alignment of the wild-type (Wt) and the mutated protein sequences 
of choline phosphorylceramide synthase (SLS4) downloaded from Tritryp websites was 
done using CLC Genomics Workbench 6.0.4. Enzyme features adapted from Sutterwala et 
al., 2008. 
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5.2.5 Comparison of endocytosis between the wild-type and ISMM 
resistant T. brucei through uptake of Lucifer yellow CH dye 
Perturbation of the sphingolipid from the committed step catalysed by serine 
palmitoyltransferase has been linked with reduced endocytosis in T. brucei 
(Sutterwala et al., 2007). Depletion of dihyrosphingosine or sphinganine in S. 
cerevisiae has been shown to reduce the internalisation step of endocytosis 
(Zanolari et al., 2000). Following the noted perturbation of the sphingolipid 
biosynthetic pathway in our isometamidium resistant cells we investigated 
whether there were differences in endocytosis by the resistant cells in 
comparison to the parental wild-type cells through monitoring the uptake of 
Lucifer yellow CH fluorescent dye (Zanolari et al., 2000). Dr. Federica Giordani 
showed that there was no appreciable difference in the fluorescence given off 
by Lucifer yellow CH in the endosomes located between the kinetoplast and the 
nucleus of the two cell lines with both cell lines showing similar fluorescence 
(Figure 5.12). 
 
 
Figure 5.12 Comparison of the internalisation of lucifer yellow CH fluorescent dye. 
The stained endosomes located between the nucleus and the kinetoplast in the posterior 
region of the cells are clearly seen in both the wild-type and ISMM resistant (ISMM-R) cells. 
The two cell lines were mixed and stained stained with 4.4 mM Lucifer yellow CH (LY-CH) in 
growth medium for 1 hour at 37°C and washed in PBS before addition of 20 µM DAPI. The 
cells were immobilised in 1% low melting temperature agarose before application to glass 
slides. The cells were viewed under oil immersion on a ZEISS Axioplan 2 Imaging 
fluorescent microscope after applying the cover slips using the GFP filters. K = kinetoplast; 
N = nucleus; Bar = 10 µm. The top row images are for the wild-type while the bottom role 
images are for the ISMM resistant cell line. (Data generated by Federica Giordani). Images 
were merged using GIMP free software. 
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Our untargeted metabolomics comparison of the wild-type and the ISMM 
resistant cell lines showed peptides which represented the largest number of 
identifications as a group compared to the other groupings of the identified 
metabolites (Figure 5.8). The peptides, dipeptides, tripeptides and 
tetrapeptides were found to show marked differences in abundance level 
between the wild-type and the resistant cells. However, we were unable to 
identify any of the most changing peptides. 
 
5.3 Discussion 
Resistance to trypanocidal drugs is of major concern in veterinary productivity in 
Africa. Understanding modes of action and resistance mechanism can help delay 
selection and spread of resistance. Here we have initiated a characterization of 
isometamidium resistance.  
 
5.3.1 Isometamidium resistance selection 
It took 9 months involving 115 passages to generate clones of the higher level (1 
M) isometamidium resistance in T. brucei 427 bloodsteam forms in vitro and 
about 4.5 months to move from the lower level resistance (4 nM) to reach the 
higher level of resistance (1 M). This is comparable to 11 months it took to 
induce higher isometamidium resistance in T. congolense in vivo (Peregrine et 
al., 1997). Isometamidum seems to have a cumulative effect on T. brucei 
bloodstream forms as at low concentrations of the drug the wild-type cells died 
at about the third or fourth passage. It was noticed that past the fifth passage 
the cells would continue to survive and grow at a given concentration indicating 
that the cells were able to tolerate the drug at that given concentration in the 
growth medium.  
 
It took 19, 23 and 28 weeks to attain 3.0 -, 10.6 -, and 94.2 – fold increases in 
the isometamidium EC50 values for the clones growing in the presence of 4 nM, 
40 nM and 1 µM isometamidium. The associated cross-resistance to diminazene 
aceturate was 1.6 -, 2.7 - , and 9.9 – fold increase, and 1.20 -, 1.42 -, and 2.72 – 
fold increase for ethidium bromide, repectively. The modest cross-resistance to 
diminazene aceturate by the clone growing in the presence of 40 nM is 
consistent with the results of Peregrine et al. (1997) and therefore diminazene 
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could be used as a sanative drug for these isometamidium resistant clones. At 
this stage ethidium bromide could also be used for the same purpose for this 
particular clone. However, our results indicate a loss of sanative use of 
isometamidium and diminazene aceturate at higher isometamidium resistance, 
due to increased isometamidium cross-resistance to diminazene aceturate. 
 
5.3.2 Isometamidium cross-resistance to diminazene aceturate 
and ethidium bromide 
Diminazene and ethidium are two compounds that contribute to the overall 
structure of isometamidium (Kinabo, 1993) and therefore all three drugs share 
similarities of certain parts of their structures (Figure 1.10 and Figure 1.11). 
Ethidium bromide appears to target the free minicrcles of the kinetoplast and 
prevents the initiation of their replication. It also inhibits nuclear DNA 
replication in cells that have no kinetoplast (Chowdhury et al., 2010). 
Diminazene is not an intercalating agent like ethidium but it binds specifically to 
the adenine – thymine pairs of the minor groove of DNA (Peregrine and Mamman, 
1993). However, resistance to diminazene has been linked to loss of the drug’s 
transporters in trypanosomes (de Koning et al., 2004; Witola et al., 2004). The 
susceptibility of the derived resistant clones, especially the clone growing in the 
presence of less than 40 nM isometamidium, to these two drugs then could be 
attributed to ethidium’s ability to kill cells that have no kinetoplast through 
inhibition of the nuclear DNA and probably the presence of the diminazene 
transporters in these cells. The presence of these transporters could lead to the 
accumulation of the drug in the cells and hence their killing. The fact that the 
kinetoplast is lost by the ISMM resistant clone of lower resistance and yet they 
showed a modest cross resistance to diminazene aceturate and ethidium 
bromide indicates a modest participation of the kinetoplast in ISMM cross-
resistance to these drugs although they are known to interact with the 
kinetoplast. 
 
It was long reported that cross-resistance between drugs that belong to different 
groups of chemical compounds can result from sharing the route of uptake or 
drug efflux mechanism or indeed having the same target or a combination of 
these themes (Barrett and Fairlamb, 1999). Cross resistance between arsenicals 
and diamidines in T. brucei has been a perplexing problem for a long time 
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because these two drugs belong to two different chemical compound groupings 
(Barrett and Fairlamb, 1999). However, it has now been shown as earlier 
reported that cross-resistance between the two drugs was possible in the cells 
whose both alleles of aquaglyceroporin 2 gene were knocked out (Baker et al., 
2012; Munday et al., 2014). This confirmed the earlier reported notion of drugs 
belonging to different chemical groupings sharing the mode of entry into the cell 
would have cross-resistance between them in the absence of their shared 
transporter. However, we observed isometamidium cross-resistance to 
pentamidine with a 21.9 fold-increase in EC50 although there was no cross 
resistance to melarsoprol in all our isometamidium resistant clones as would be 
expected. This would indicate non-participation of aquaglyceroporin 2 
transporter's participation in isometamidium cross-resistance to pentamidine. 
Pentamidine is known to induce loss of the kinetoplast in Trypanosoma species 
(Shapiro and Englund, 1995) and it is also known to interact with the minicircles 
of L. donovani and L. amazonensis (Basselin et al., 1998). This implies that the 
kinetoplast contributes to the accumulation of the drug in the cells. The loss of 
the kinetoplast by our ISMM resistant cells means the cells retain less 
pentamidine than the progenitor wild-type cells. Indeed, the loss of the 
kinetoplast was observed in low resistant cell lines growing in the presence of 
the 4 nM ISMM. This may explain the 2-fold increase in ISMM cross-resistance to 
pentamidine by these cells as they had lost the means to retain the drug. The 
continued increase in cross-resistance to pentamidine by the clones of higher 
ISMM resistance could then have been due to other contributing factors. 
 
5.3.3 Susceptibility of ISMM resistant BSF T. brucei to eflornithine 
Eflornithine is used for treatment of HAT and is more effective against T. b. 
gambiense than against T. b. rhodesiense (Brun et al., 2011). It is an amino acid 
analogue of ornithine, a non-proteinogenic amino acid. Eflornithine is an 
irreversible inhibitor of ornithine decarboxylase of the polyamine pathway and 
thus exerts its inhibitory effect on the growth of T. brucei by blockage of this 
pathway (Bacchi et al., 1980). Resistance to eflornithine is due to the deletion 
of the amino acid transporter TbAAT6 gene which leads to reduced accumulation 
of the drug in the resistant cells (Vincent et al., 2010). Our isometamidium 
resistant clones showed progressive increase in susceptibility to eflornithine as 
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the level of isometamidium resistance increased. This happened despite there 
being no difference in levels of arginine, ornithine, putrescine, spermidine, N1-
acetylspermidine and N-acetylputrescine of the polyamine pathway determined 
by metabolomics analysis of the resistant cells as compared to the wild-type 
cells. The increased sensitivity of the resistance cells to eflornithine when 
compared to the wild-type cells must be therefore attributed to other factors 
other than changes in the polyamine pathway. These remain elusive. 
 
5.3.4 Maintenance of a low ΔΨm by ISMM resistant BSF T. brucei 
Use of a diminished ΔΨm to reduce the accumulation of the drug in the 
mitochondria, thereby reducing the concentration of the drug reaching its 
target, has been reported to be a strategy utilised by isometamidium and 
ethidium bromide resistant Trypanosoma parasites (Chowdhury et al., 2010; 
Wilkes et al., 1997). Thus the accumulation of ethidium and isometamidium into 
the mitochondrion has been reported to be decreased by the reduction in the 
ΔΨm expressed by T. brucei and T. congolense, respectively (Chowdhury et al., 
2010; Wilkes et al., 1997). However, the ΔΨm is required for the importation of 
proteins encoded by the nuclear DNA into the mitochondrial matrix where they 
perform various functions (Schnaufer et al., 2005). In this study, the derived 
resistant clones showed a much reduced ΔΨm as monitored by the actively 
accumulating mitochondrial dependent dye, TMRE, compared to the wild type 
cells. The reduction in the ΔΨm would have implications on the transport 
processes between the cytosol and mitochondrial matrix (Schnaufer et al., 
2005). This may have been responsible for the reduced growth phenotype of the 
derived resistant cells, especially clones of higher isometamidium resistance as 
they exhibited a much reduced ΔΨm. The fact that kDNA encodes many proteins 
that contribute to ΔΨm could underlie this loss. Specific point mutations in the γ 
subunit, which is encoded in the nucleus, of ATPase have been shown to 
compensate for the loss of the kDNA, hence rendering essential kDNA encoded 
proteins dispensable, in acriflavine resistant bloodstream forms of T. brucei. The 
mutations have been suggested to lead to uncoupling of the F0 and F1 
components of the ATPase complex (Dean et al., 2013). The uncoupling of F0 and 
F1 components result in the shift of generation of ΔΨm from the hydrolysis of 
ATP by ATPase complex to the use of the proposed ADP/ATP carrier (AAC) which 
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works in conjunction with only the F1 component of ATPase complex (Dean et 
al., 2013; Schnaufer et al., 2005). Our isometamidium resistant cell lines showed 
none of the reported compensatory mutation or any mutations unique to them as 
compared to the parental wild-type cells. 
 
Our failure to select PCF trypanosomes resistant to ISMM might relate to the 
essentiality of the kinetoplast and dependence on the electron transport chain 
for the generation of the ΔΨm in these cells (Schnaufer et al., 2002). Further, 
loss of the kinetoplast has been suggested to lock the trypanosomes in the 
bloodstream form and their transmission becomes mechanical because they 
cannot survive in the insect host (Schnaufer et al., 2002).  
 
Kinetoplastids including T. brucei, Leishmania species and T. cruzi have had 
most of the genes for putative enzymes involved in de novo metabolism of the 
major phospholipids identified and some of these have already been 
characterised (Serricchio and Buetikofer, 2011; Smith and Butikofer, 2010). 
Bloodstream forms of T. brucei require de novo biosynthesis of sphingolipids for 
their viability (Sutterwala et al., 2007). Probably the essentiality of this pathway 
in bloodstream forms of T. brucei resulted in failure to generate serine 
palmitoyltransferase RNAi cell lines (Fridberg et al., 2008). 
  
The roles of sphingolipids in most eukaryotic cells are known to range from cell 
signalling, mediation in heat stress to protein targeting (Cowart and Obeid, 
2007). Little is known about the role of sphingolipids in protozoan cells apart 
from being components of the cell membranes as in other eukaryotic cells 
(Futerman and Riezman, 2005; Zhang et al., 2010). However, functions of 
sphingolipids in trypanosomatids have started to emerge and are essential for T. 
brucei cell viability (Fridberg et al., 2008; Sutterwala et al., 2007). 
 
5.3.5 Perturbation of the sphingolipid biosynthetic pathway 
The reduction in de novo synthesis of sphingolipids was reported during RNAi and 
myriocin inhibition of the first enzyme, serine palmitoyltransferase, of the 
sphingolipid biosynthetic pathway (Figure 5.10) in procyclic and bloodstream 
forms of T. brucei (Fridberg et al., 2008; Sutterwala et al., 2007). The cells 
exhibited a reduced growth phenotype, abnormal cytokinesis and failure to 
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segregate the kinetoplast during cell division. This led to the suggestion that 
sphingolipids could be essential in cell proliferation signalling, although these 
characteristics could not be attributed to changes in levels of either a particular 
end product or an intermediate of the sphingolipid biosynthetic pathway but the 
perturbation of the pathway in its entirety (Fridberg et al., 2008). Therefore, 
our akinetoplastic isometamidium resistant cells’ perturbed sphingolipid 
synthesis may have been a response to reduced requirement of these 
metabolites for kinetoplast segregation. Our akinetoplastic isometamidium 
resistant clones of higher resistance exhibited a reduced growth phenotype 
which may have been due to the perturbations in the sphingolipid biosynthetic 
pathway that were detected in metabolomics analysis of these cells. In 
particular they showed an accumulation of ceramide and depleted levels of 
sphingomyelin, a metabolite that has been shown to be more abundant in 
bloodstream forms than the procyclic forms of T. brucei (Richmond et al., 2010). 
The depleted sphingomyelin in the isometamidium resistant cells may be 
attributed to the four heterozygous non-synonymous mutations that were found 
in the resistant line’s SLS4, although none of these mutations form part of the 
predicted catalytic site of the enzyme. But all the mutations were outside the 
various predicted trans-membrane domains of the enzyme and conserved 
signatures of the SLSs. T. brucei SLS4 has six trans-membrane domains and has 
been shown to localise to the Golgi (Sutterwala et al., 2008). The accumulated 
levels of ceramide (2.65 fold difference with the wild-type) in our resistant cells 
is consistent with the 3.5 fold increase in accumulated ceramide in T. brucei 
whose SLSs were silenced by RNAi (Sutterwala et al., 2008). In our case the 
elevated levels of ceramide in the resistant cells could be attributed to point 
mutations in SLS4. Amino acid residues in the catalytic site of the SLSs have 
been indicated to specify the products of the enzymes and an alteration of these 
residues lead to altered enzyme product specificity (Sutterwala et al., 2008). 
This would suggest that mutations in the active site are rare as these enzymes 
are developmentally regulated to maintain synthesis of particular sphingolipids 
at particular stages of life cycle of trypanosomes (Sutterwala et al., 2008). 
 
Prolonged blockage of the sphingolipid biosynthetic pathway from the rate 
determining step catalyzed by serine palmitoyltransferase has a mild effect of 
reduced endocytosis processes of bloodstream T. brucei (Sutterwala et al., 
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2007). Participation of sphingolipids in endocytosis has been reported in S. 
cerevisiae. The internalisation step of endocytosis in S. cerevisiae was shown to 
be facilitated by dihyrosphingosine (DHS) or sphinganine (Figure 5.10) (Zanolari 
et al., 2000). It was later shown that sphingolipids with fatty acyl groups 
consisting of 26 carbon atoms were required for synthesis of a functional V1 unit 
of the V1V0-ATPase assembly in yeast (Chung et al., 2003). Blockage of DHS 
synthesis and lack of availability of C26 acyl groups in sphingolipids of yeast 
resulted in fragmented vacuoles (Chung et al., 2003; Zanolari et al., 2000).Yeast 
V-ATPases are located in the vacuole membranes where the V1 component 
hydrolyzes ATP to power the pumping of proton by the V0 component into the 
vacuoles to create a proton gradient. The proton gradient is used for 
transportation of ions, small molecules including drugs, metabolites and amino 
acids into the vacuole (Graham et al., 2000). Exposure of T. brucei to 
isometamidium and use of RIT-seq approach (Alsford et al., 2012) to seek genes 
whose loss of function can underlie resistance has revealed the up-regulation of 
various components of the acidic compartments like vacuolar ATPase system and 
the adaptins (Appendix C)(Baker et al., 2014). A corroboration of these data and 
perturbation of the sphingolipid biosynthetic pathway resulting in depleted 
levels of sphingoid bases (i.e. sphinganine and hexadecasphinganine) and 
sphingomyelin in our isometamidium resistant cell lines suggest a likelihood of 
involvement of endocytosis in the uptake of isometamidium. However, we have 
been unable to show an appreciable difference in internalisation of Lucifer 
yellow dye between the parental wild-type and the ISMM resistant cells. This 
result is consistent with the unaltered uptake of isometamidium in cells whose 
V-ATPase subunits were knocked-out (Baker et al., 2014). However, It has 
already been demonstrated that isometamidium resistant T. congolense take up 
and accumulate less isometamidium than the wild-type cells (Sutherland et al., 
1992; Sutherland et al., 1991).
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Chapter Six 
6 General Discussion 
6.1 Amphotericin B resistance 
The importance of AmB in leishmaniasis treatment cannot be overemphasised 
especially that no documented resistance to the drug has been reported. There 
have been views that resistance to the drug is possible due to the fact that 
resistance can be induced in vitro (Croft et al., 2006). The absence of resistance 
to the drug in the field and the capability of the parasites to develop resistance 
in vitro offers a timely opportunity to study AmB resistance as this will offer 
ways and means of countering resistance to the drug and prolong the use of the 
drug should resistance develop in future. 
 
The effect of AmB on perturbation of the parasites ergosterol biosynthetic 
pathway is well known. However, most of the studies have highlighted the 
metabolite changes in the resistant cells with no indication of how this 
perturbation comes about in Leishmania. Absence of the active S-adenosyl-L-
methionine: C-24-Δ-sterol methyltransferase A (SCMT-A) and over expression of 
copies of SCMT-B has been reported in L. donovani resistant to AmB with a 
corresponding absence of ergosterol in these cells (Pourshafie et al., 2004; 
Purkait et al., 2012). These results suggested that the absence of ergosterol was 
due to absence of SCMT-A in the AmB resistant cells. Although ergosterol was not 
detected in these cells it was thought to be replaced by Cholesta-5,7,24-trien-
3β-ol, a metabolite that was detected in the resistant cells due to loss of C24 
transmethylation (Purkait et al., 2012). We did not observe any results that 
could be connected with SCMT. In our study we have identified a non-
synonymous mutation (N176I) in lanosterol 14α-demethylase which was outside 
the catalytic site. We observed a modest but statistically significant cross 
resistance to ketoconazole with a 1.7 fold increase in EC50 value. Ketoconazole is 
a specific inhibitor of lanosterol 14α-demethylase. Associated with this mutation 
was the accumulation of the product of lanosterol 14α-demethylase, 4, 4-
dimethylcholesta-8, 14, 24-trien-3β-ol and depleted levels of ergosterol. We 
have speculated the accumulation of the reaction product of the mutated 
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lanosterol 14α-demethylase to be due to a probable loss of lanosterol 14α-
demethylase’s interaction to a different protein. 
 
Extra-chromosomal expression of the wild-type lanosterol 14α-demethylase in 
AmB resistant cells restored the levels of ergosterol in the re-expresser cells. 
Restoration of ergosterol was accompanied by reversal of the AmB resistance 
and cross resistance to ketoconazole. This indicated a difference between the 
wild-type and the mutated lanosterol 14α-demethylase. It is for this reason that 
we hope to test for differences in activity of the two enzymes following our 
successful over-expression of the two enzymes in E. coli. We also observed loss 
of susceptibility to pentamidine by AmB resistant cells following expression of 
the wild-type lanosterol 14α-demethylase in these cells. AmB resistant cells 
were found to be highly sensitive to pentamidine (Chapter 4). These results 
taken together indicate that ergosterol is an important determining factor in 
AmB resistance as has already been reported. Further, our expression of the 
wild-type lanosterol 14α-demethylase in AmB resistant cells and the 
accompanying reversal of characteristics of AmB resistant cells suggest that 
N176I mutation underlies AmB resistance in L. mexicana. Thus for the first time, 
to our knowledge, we have identified the role of lanosterol 14α-demethylase in 
AmB resistance. It would be interesting to check for the presence of N176I in 
AmB resistant species of Leishmania in other studies (Al-Mohammed et al., 2005; 
Mbongo et al., 1998; Purkait et al., 2012) to confirm that this mutation underlies 
AmB resistance in other species of Leishmania. The relevance of this mutation is 
further supported by the fact that lanosterol 14α-demethylase is essential to 
these parasites as double knock of the gene was not possible (Verma et al., 
2011). Therefore, a homozygous mutation in this gene has resulted in depleted 
levels of ergosterol, reducing the drug’s target, while a heterozygous mutation 
we speculate would render the parasites susceptible to AmB due to continued 
synthesis of ergosterol albeit at reduced level. This would not make parasites 
with a heterozygous mutation in lanosterol 14α-demethylase resistant but of 
reduced susceptibility to AmB, since AmB has been reported to kill cells by a 
mere binding to ergosterol in yeast (Gray et al., 2012). 
  
Susceptibility to oxidative stress is enhanced with inhibition of the sterol 
biosynthetic pathway from episterol (Figure 1.8) as the metabolites after this 
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point contain a conjugated double bond in ring B that is important in protection 
against ROS attack through their proximity to the hydroxyl group in ring A 
(Figure 3.14) (Dupont et al., 2012). Therefore perturbation of the pathway at an 
even earlier point such as from lanosterol 14α-demethylase would render the 
parasites susceptible to oxidative stress. Indeed our AmB resistant parasites 
were more susceptible to oxidative stress than the parental wild-type. Exposure 
of yeast to AmB has been reported to either up-regulate or down-regulated the 
expression of membrane transporter proteins to counter the loss of ions and 
nutrients through membrane pores formed by AmB in yeast. Among the induced 
transport proteins were the drug resistance protein, MDR protein and ABC 
transporter protein (Zhang et al., 2002). In line with the up-regulation of 
membrane transport proteins, the multidrug resistance protein 1 (MDR1) was 
found to be up-regulated in AmB resistant L. donovani and this was linked to 
increased drug efflux than in the wild-type cells (Purkait et al., 2012). 
Natamycin, a related polyene antibiotic has been shown to inhibit membrane 
proteins in a general way as different types of transporters were affected by the 
exposure of yeast and fungi to the drug. It was suggested that the inhibition of 
these proteins is brought about by the drug’s ability to bind to ergosterol in the 
membranes (te Welscher et al., 2012). Indeed we found that the AmB resistant 
cells showed cross resistance to miltefosine which was reversed in re-expressor 
cells. Chemical withdrawal of sterols from membranes was shown to reduce 
sensitivity to miltefosine by both wild-type and miltefosine resistant cells (Saint-
Pierre-Chazalet et al., 2009). Against the background of susceptibility to 
oxidative stress and anticipated disturbances in membrane transport proteins 
and increased uptake of pentamidine by the AmB resistant cells, we observed a 
very significant sensitisation of the AmB resistant parasites to pentamidine. It is 
worth noting that AmB resistant Leishmania highly sensitized towards 
pentamidine was not reported in studies by Mbongo et al., (1998) and Garcia-
Hernandez et al., (2012). Pentamidine is able to induce ROS production and has 
been suggested to kill leishmania by oxidative stress (Mehta and Shaha, 2004; 
Moreira et al., 2011). In view of all this, our results taken together suggest a 
possible use of this drug to counter AmB resistance. The reversal of sensitivity to 
pentamidine by the re-expressor cells following restoration of ergosterol 
synthesis suggested a key role of ergosterol levels in sensitivity to pentamidine 
by the AmB resistant cells. Pentamidine and paromomycin may hold promise to 
174 
 
counter AmB resistant leishmania due to their increased toxicity towards AmB 
resistant cells we observed, therefore part of the future work will aim at 
determining how pentamidine enters the AmB resistant cells as this may suggest 
other ways that can be utilised to tackle the resistant cells. 
Leishmania amastigotes are clinically relevant but we used the promastigotes 
that are found in insect vectors. AmB resistant promastigotes were shown to 
infect mice and the isolated amastigotes from such mice were found to maintain 
the AmB resistance trait albeit with altered morphology of promastigotes, i.e., 
promastigotes without flagella (Al-Mohammed et al., 2005). Our AmB resistant 
promastigotes were able to infect macrophages. To further explore the 
relevance of AmB resistant parasites carrying the N176I mutation, it would be 
interesting to pass these parasites in insects to find out whether the mutation 
compromises their fitness of survival in insects. This would also provide 
information on the possible transmission of these parasites to humans especially 
where the disease in anthroponotic. 
  
The identification of mutated lanosterol 14α-demethylase could not have 
happened without other compensatory mutations that would have occurred in 
response to the altered ergosterol levels in the parasites and the general process 
of resistance induction. Indeed there were a lot of SNPs that were observed in 
our resistant cells. It is important to appreciate that our analysis of the gDNA 
analysis was guided by the metabolomics and partly proteomics results. 
Therefore there could have been other genetic changes that could be relevant to 
AmB resistance that may have been missed by our analysis possibly because they 
operate in the background. 
  
6.2 Isometamidium resistance 
African animal trypanosomiasis is a major impediment to the realisation of the 
potential contribution of livestock to economic development in rural Africa 
where livestock is a source of livelihood through provision of draught power, 
transportation, food, etc., (Welburn et al., 2006). The situation is further 
exacerbated by the presence of parasites resistant to the few commonly used 
drugs. ISMM is mostly used for prophylactic purposes but also for treatment of 
animals against trypanosomiasis caused by T. congolense (Delespaux et al., 
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2008; Geerts et al., 2001). However, little is known about the mode of action 
and mechanism of resistance to ISMM. Various possible targets of ISMM were 
reported earlier (Kinabo, 1993) although lately reports have reiterated the 
involvement of processes in the mitochondrion of the parasites. Thus, reduction 
of the mitochondrial membrane potential and accumulation of the drug in the 
mitochondrion, with a specific association with the kinetoplast, have been linked 
with ISMM resistance (Wilkes et al., 1997). Characterisation of the ISMM resistant 
parasites will offer an opportunity to prolong the use of the current drugs in the 
absence of a vaccine as this would open up ways and means of handling the 
resistant parasites and hence informed drug policy formulation regarding drug 
treatment regimens. 
 
ISMM resistant T. congolense has been shown to take up and accumulate less 
ISMM than the wild-type (Sutherland et al., 1992; Sutherland et al., 1991). It was 
shown by fluorescence properties of ISMM that it associates with the kinetoplast 
in the mitochondrion (Wilkes et al., 1997). Isometamidium is said to promote 
kDNA – protein complex formation which can be easily cleaved by topoisomerase 
II leading to linearization of the minicircles and generation of free minicircles in 
T. equiperdum (Shapiro and Englund, 1990). Loss of isometamidium fluorescence 
by resistant parasites in the region of the kinetoplast was reported (Wilkes et 
al., 1997). We have shown loss of the kinetoplast by ISMM resistant T. brucei 
BSF. We showed the loss of the kinetoplast by use of the DNA specific stain DAPI 
and confirmed by absence of NADH dehydrogenase subunit genes that are found 
in the maxicircles that form part of the kDNA using PCR. The loss of the 
kinetoplast was possible even at very low isometamidium resistance level as 
exhibited by resistant clones growing in the presence of 0.01 nM ISMM. Although 
ISMM resistance is accompanied by loss of the kinetoplast, it does not easily 
happen as was deduced from the length of time it took us to generate the 
resistant parasites. It took us 9 months to generate parasites of the highest ISMM 
resistance, 1 µM with a 94-fold increase in EC50. A result consistent with that 
done in vivo and took 11 months to achieve a 94-fold increase in resistance 
involving a CD50 (CD50 is the concentration of the drug required to eliminate the 
symptoms in 50% of the animals tested) change from 0.018 mg/kg body weight to 
1.7 mg/kg bodyweight in T congolense (Peregrine et al., 1997). Indeed it has 
been reported that it is not easy to generate dyskinetoplastic parasites either in 
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vivo or in vitro (Timms et al., 2002). Perhaps the difficulty associated with 
generation of isometamidium resistant parasites involving loss of the kinetoplast 
could be the determining factor in resistance to this drug as it involves the loss 
of the maxicircles that harbour the genes that are required for the transmission 
of the parasites in the insect without which they are incapable of surviving in 
the insect due to failure to switch their energy metabolism involving the 
electron transport chain and hence failure to transform into procyclic forms 
(Schnaufer et al., 2002; Timms et al., 2002). Acriflavine induced loss of the 
kinetoplast hence the maxicircle genes has been reported to be compensated by 
mutations in Ɣ subunit of the ATPase that allows the resistant parasite to shift 
the generation of the mitochondrial membrane potential from breakdown of the 
ATP by F1 which allows translocation of protons through the F0 during the reverse 
function of the ATPase to use of ADP/ATP carrier (AAC) which works in 
conjunction with only the F1 component of ATPase complex to generate the 
mitochondrial membrane potential (Dean et al., 2013; Schnaufer et al., 2005). 
Our isometamidium resistant cells did not show presence of mutations in the Ɣ 
subunit of the ATPase that were unique to these cells. Therefore, kinetoplast 
loss is most likely the key to isometamidium resistance and therefore this would 
suggest a possible use of the loss of the kinetoplast as a marker of ISMM 
resistance. 
 
The loss of the kinetoplast which has been suggested to be the target of the drug 
would seem to reduce the accumulation of the drug in the mitochondrion. 
Another strategy used by the parasites to reduce the accumulation of the drug in 
mitochondria is the maintenance of a reduced mitochondrial membrane 
potential. The mitochondrial membrane potential has been suggested to lead to 
accumulation of isometamidium and ethidium bromide in the mitochondrion 
(Chowdhury et al., 2010; Wilkes et al., 1997), while a reduced mitochondrial 
membrane potential was thought to lead to reduced accumulation of the drugs. 
We have showed a much reduced mitochondrial membrane potential by our ISMM 
resistant cells as compared to the parental wild-type cells. Because the 
mitochondrial membrane potential is generated during the energy metabolism of 
trypanosomes, we hypothesised that the reduced mitochondrial membrane 
potential would have pronounced changes in energy metabolite profile of the 
parasites. However we observed no apparent changes in metabolite profiles 
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connected with energy metabolism in resistant parasites as compared to the 
parental wild-type. However, we observed changes in the sphingolipid 
metabolites. 
 
The differences in uptake and accumulation of isometamidium by the wild-type 
and the resistant parasites did not provide information on how the drug enters 
the parasites. The perturbation of the sphingolipid biosynthesis has been shown 
to induce reduced growth phenotype, abnormal cytokinesis and failure to 
segregate the kinetoplast (Fridberg et al., 2008). Sphingolipid depletion has also 
been reported to reduce endocytosis processes of bloodstream T. brucei 
(Sutterwala et al., 2008). A similar effect has also been shown to affect the 
internalisation step of endocytosis in yeast (Zanolari et al., 2000) where 
sphingolipids with fatty acyls made up of specific number of carbon atoms are 
required for the synthesis of functional V1 components of V1V0-ATPase are 
required (Chung et al., 2003). Exposure of T. brucei to ISMM induces 
overexpression of the various elements of the acidic vacuole system including V-
ATPases and adaptins (see appendix C) (Baker et al., 2014). Our ISMM resistant 
parasites have shown alterations in the sphingolipid biosynthetic pathway 
although there was no appreciable difference in internalisation of Lucifer yellow 
and hence endocytosis. 
 
The fact that we found an association between the appearance of heterozygous 
mutations in SLS4 and isometamidium resistance suggests an important 
experiment that time constraints have not allowed in this thesis. Specifically the 
mutant allele should be expressed in wild-type parasites, to determine whether 
this expression can yield isometamidium resistance; either immediately or at an 
increased rate should it be a predisposition to kinetoplast loss that underlies the 
effect. 
 
With very few drugs available for treatment of AAT, occurrence of ISMM cross 
resistance to other AAT drugs poses the challenge of limited alternative 
treatment drugs should resistance develop to one of the drugs. We have shown 
increasing ISMM cross resistance to DA with increasing level of resistance to 
ISMM. T. brucei of lower ISMM resistance, i.e. those growing in the presence of 
400 nM or less, show modest ISMM cross resistance to diminazene aceturate and 
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ethidium bromide. This is in agreement with earlier reports in T congolense 
(Peregrine et al., 1997), although our ISMM resistant clones achieved this in 
about 8 months compared to 11 months by Peregrine and co-workers (1997). 
ISMM cross resistance to ethidium bromide in our resistant clones was 2.7 fold in 
contrast with that reported earlier for T. congolense standing at 34-fold increase 
in 50% inhibitory concentration of the drug. ISMM is normally used as a 
prophylactic drug while diminazene aceturate is recommended for treatment of 
AAT cases. Therefore treatment with diminazene aceturate where higher ISMM 
resistance exists would result in more treatment failures. 
  
Several methods are employed to elucidate drug resistance mechanisms (Berg et 
al., 2013a; Horn and Duraisingh, 2014), here we show that polyomics can be 
used to decipher drug resistance mechanisms. Complementary use of untargeted 
metabolomics and gDNA sequencing is a worthwhile combination of techniques 
that can be used, especially that the cost of sequencing has continued to go 
down and the technique has continued to be developed (Liu et al., 2012). On the 
other hand metabolomics has also continued to evolve resulting in improved 
LC/MS methods and improved data analysis platforms that are applicable to 
study of mode of action and mechanisms of resistance to anti-protozoal drugs 
(Creek and Barrett, 2014). Metabolomics involves minimal sample handling 
thereby ruling out degradation of samples during sample extraction. While 
proteomics has also continued to evolve perhaps it has one disadvantage of 
multistep sample handling which predisposes protein samples to degradation.  
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Appendices 
Appendix A: Reagent recipes 
A1 NTE buffer 
10 mM Tris-HCl pH 8.0  
100 mM NaCl   
5 mM EDTA  
 
A2 Tb BSF buffer 
90 mM Na-PO4 pH7.3  1.8 mL 
5 mM KCL    166.6 uL 
50 mM HEPES pH7.3   1 mL 
0.15 mM CaCl2   30uL 
dd H2O    7 mL 
Store at 4°C 
 
A3 TAE (1×) 
40 mM Tris acetate (pH 8.5)  
1 mM EDTA 
 
A4 Assay Buffer 
33 mM  HEPES    
98 mM NaCl     
4.6 mM KCl     
0.55 mM CaCl2    
0.07 mM MgSO4    
5.8 mM NaH2PO4. 2H2O   
0.3 mM MgCl2    
23 mM NaHCO3    
14 mM Glucose   
Adjust pH to 7.3 
 
A5 Lysis buffer: 
6 M urea 
2 M thiourea 
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4% CHAPS 
25 mM tris base 
 
A6 DiGE Rehydration buffer 
6 M Urea 
4% CHAPS 
2 M Thiourea 
65 mM DTT 
0.5% IPG buffer 
Trace bromophenol blue 
 
A7 DiGE Equilibration Buffer I 
2 % SDS 
50 mM Tris-HCl pH 8.8 
6 M urea 
30 % (v/v) glycerol 
0.002% bromophenol blue 
1% DTT 
 
A8 DiGE Equilibration Buffer II 
2 % SDS 
50 mM Tris-HCl pH 8.8 
6 M urea 
30 % (v/v) glycerol 
0.002% bromophenol blue 
2.5 Idoacetamide 
 
A9 Coomassie blue stain solution 
10 ml Acetic acid  
45 ml water 
0.1 g Coomassie blue stain 
 
A10 Destaining solution 
40% methanol 
10% acetic acid 
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A11 SDS Running buffer (5X) 
Tris     30.3 g 
Glycine    144.0g 
SDS     10.0 g 
Made up to 2000 ml with dH2O
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Appendix B: Monitoring mitochondrial membrane 
potential 
 
 
 
 
Monitoring of the mitochondrial membrane potential by accumulation of TMRE 
by the parental wild-type and derived isometamidium resistant clones 
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Appendix C: Ritseq result of the T. b. brucei 927 exposed to isometamidium 
 
Alterations in the various components of the acidic compartments following exposure of wild-type T. brucei to isometamidium 
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Appendix D: S. cerevisiae sterol biosynthetic pathway enzymes and L. mexicana 
orthologs 
S. cerevisea gene and enzyme 
sequence Blasted 
Sequences producing 
High-scoring Segment 
Pairs 
L. Mexicana Enzyme ID 
High 
score 
Smallest sum 
probability EC # 
P(N) N 
ERG1(squalene monooxygenase) LmxM.13.1620.1..pep squalene monooxygenase-like 
protein 
471 2.0e-46 1 1.14.13.132 
ERG2 (C-5 sterol desaturase) LmxM.08_29.2140.1..pep C-8 sterol isomerase-like protein 442 2.4e-43 1  
ERG3 (C-5 sterol desaturase) LmxM.23.1300.1..pep lathosterol oxidase-like protein 480 2.2e-47 1 1.14.21.6 
LmxM.30.0590.1..pep C-5 sterol desaturase, putatative 127 3.3e-07 1  
ERG4 (C-24 sterol reductase) LmxM.32.0680.1..pep sterol C-24 reductase, putative 704 4.1e-71 1 1.3.1.71 
LmxM.31.2320.1..pep C-14 sterol reductase, putative 232 1.9e-18 1  
ERG5 (C-22 sterol desaturase) LmxM.29.3550.1..pep cytochrome p450-like protein 442 2.4e-43 1 1.14.14.1 
LmxM.33.3330.1..pep cytochrome p450-like protein 169 6.0e-11 1  
LmxM.11.1100.1..pep lanosterol 14-alpha-demethylase, 
putative 
147 1.2e-08 1 1.14.13.70 
ERG 6 (SAM:C-24 sterol 
methyltransferase) 
LmxM.36.2390.1..pep sterol 24-c-methyltransferase, 
putative 
673 7.9e-68 1  
LmxM.36.2380.1..pep sterol 24-c-methyltransferase, 
putative 
672 1.0e-67 1  
ERG 7 (2,3-oxidosqualene-
lanosterol cyclase) 
LmxM.06.0650.1..pep lanosterol synthase, putative 1017 3.7e-111 2 5.4.99.8 
LmxM.33.4030.1..pep geranylgeranyltransferase, 
putative 
74 0.63 1 2.5.1- 
ERG 8 (phosphomevalonate kinase) LmxM.15.1460.1..pep phosphomevalonate kinase-like 
protein 
373 4.9e-36 1 2.7.4.2 
LmxM.30.0560.1..pep mevalonate kinase, putative 69 0.64 2  
ERG9 (squalene synthetase) LmxM.30.2940.1..pep farnesyltransferase, putative 673 7.9e-68 1 2.5.1.21 
ERG10 (acetoacetyl CoA thiolase) LmxM.30.1640.1..pep thiolase protein-like protein 365 3.4e-35 1 2.3.1.16        
LmxM.30.1640.1..pep 3-ketoacyl-CoA thiolase-like 
protein, putative 
306 6.1e-29 1 2.3.1.16 
LmxM.23.0690.1..pep 3-ketoacyl-CoA thiolase-like 
protein 
92 4.1e-07 3 2.3.1.16 
ERG 11 (cytochrome P450 LmxM.11.1100.1..pep lanosterol 14-alpha-demethylase, 475 6.5e-54 2 1.14.13.70 
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lanosterol 14a-demethylase) putative 
LmxM.29.3550.1..pep cytochrome p450-like protein 165 1.1e-14 2 1.14.14.- 
LmxM.33.3330.1..pep cytochrome p450-like protein 178 6.0e-12 1  
ERG12 (mevalonate kinase)* LmxM.30.0560.1..pep mevalonate kinase, putative 120 1.7e-09 3  
ERG13 (3-hydroxy-3-methylglutaryl 
coenzyme A synthase) * 
LmxM.24.2110.1..pep hypothetical protein, conserved 190 7.8e-17 2  
ERG 20 (farnesyl diphosphate 
synthetase) 
LmxM.22.1360.1..pep farnesyl pyrophosphate synthase, 
putative 
545 2.9e-54 1 2.5.1.10 
LmxM.15.1020.1..pep farnesyl synthetase, putative 107 9.9e-05 1  
ERG24 (C-14 sterol reductase) LmxM.31.2320.1..pep  C-14 sterol reductase, putative  674 6.2e-68 1  
LmxM.32.0680.1..pep sterol C-24 reductase, putative 231 2.9e-35 2 1.3.1.71 
ERG25 (C-4 sterol methyl oxidase)* LmxM.36.2540.1..pep hypothetical protein, unknown 
function 
143 7.0e-09 2  
LmxM.23.1300.1..pep lathosterol oxidase-like protein 136 2.8e-08 1 1.3.3.2 
LmxM.30.0590.1..pep C-5 sterol desaturase, putative 120 1.5e-06 1  
ERG26 (C-3 sterol dehydrogenase)* LmxM.06.0350.1..pep NAD(p)-dependent steroid 
dehydrogenase-like protein 
263 2.2e-24 1  
ERG27 (3-keto sterol reductase)* LmxM.34.1230.1..pep short chain dehydrogenase, 
putative 
82 0.028 2  
LmxM.34.2150.1..pep hypothetical protein, conserved 63 0.69 2  
ERG28(Polypeptide: subunit of C-4 
demethylation complex)* 
(Subunit composition of C-4 
demethylation - 
ERG25;ERG26;ERG27ERG28)  
LmxM.08_29.1970.1..pep hypothetical protein, unknown 
function 
51 0.14 1  
LmxM.29.1625.1..pep hypothetical protein, conserved 60 0.62 1  
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Appendix E: Ergosterol pathway enzyme wise SNP and CNV annotations for Wt and 
AmB-R cell lines 
Ergosterol Pathway Enzyme wise SNP and CNV annotations for WT and AmpB-R 
                  
1. Thiolase protein-like (most likely trifunctional protein Beta subunit) LmxM.30.1640 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
n
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_131200 GeneDB|Lm
xM.30 
4 2 765531 7686
19 
7.145 170.712 507793 1.79 7.1 LmxM.30.16
30, 
LmxM.30.16
40 
Thiolase protein-
like protein, 3-
ketoacyl-CoA 
thiolase-like 
protein, putative 
341.423 1015
586 
110.56 2 8 
AmpB-R               
OG5_131200 GeneDB|Lm
xM.30 
4 2 765531 7686
19 
6.5 155.922 510457 1.62 6.5 LmxM.30.16
30, 
LmxM.30.16
40 
Thiolase protein-
like protein, 3-
ketoacyl-CoA 
thiolase-like 
protein, putative 
311.843 1020
914 
100.99 2 8 
                  
2. Hydroxy-3-methylglutaryl coenzyme a reductase LmxM.29.3190 
No SNPs in WT                  
No SNPs in 
AmpB-R 
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OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_127955 GeneDB|Lm
xM.29 
2 1 1144534 1145
839 
1.984 44.626 138831 0.99 2 LmxM.29.31
90 
3-hydroxy-3-
methylglutaryl-
CoA reductase, 
putative 
44.6258 1388
31 
34.2 1 2 
AmpB-R               
OG5_127955 GeneDB|Lm
xM.29 
2 1 1144534 1145
839 
2.123 45.709 157109 1.06 2.1 LmxM.29.31
90 
3-hydroxy-3-
methylglutaryl-
CoA reductase, 
putative 
45.7086 1571
09 
35.03 1 2 
                  
                  
3. Mevalonate kinase LmxM.30.0560 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_128331 GeneDB|Lm
xM.30 
4 1 214235 2152
94 
2.902 138.565 412434 0.73 2.9 LmxM.30.05
60 
Mevalonate 
kinase, putative 
138.565 4124
34 
130.85 1 4 
AmpB-R               
OG5_128331 GeneDB|Lm
xM.30 
4 1 214235 2152
94 
2.64 127.166 414612 0.66 2.6 LmxM.30.05
60 
Mevalonate 
kinase, putative 
127.166 4146
12 
120.08 1 4 
                  
4. Phosphomevalonate kinase LmxM.15.1460 
No SNPs in WT                  
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No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_131773 GeneDB|Lm
xM.15 
2 1 532092 5334
69 
1.834 31.345 104123 0.92 1.8 LmxM.15.14
60 
Phosphomevalo
nate kinase-like 
protein 
31.3452 1041
23 
22.76 1 2 
AmpB-R               
OG5_131773 GeneDB|Lm
xM.15 
2 1 532092 5334
69 
1.932 34.099 123345 0.97 1.9 LmxM.15.14
60 
Phosphomevalo
nate kinase-like 
protein 
34.0989 1233
45 
24.76 1 2 
                  
5. Diphosphomevalonate decarboxylase LmxM.18.0020 
Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
St
ra
n
d
 s
en
se
 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.18 
5569 N Intro
nic 
783 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
5691 N Intro
nic 
661 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
6333 N Intro
nic 
19 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
6466 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 TT[T/C] [F/F] Y     
GENEDB|LMXM
.18 
7025 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 A[A/G]C [N/S] N     
GENEDB|LMXM
.18 
7072 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 GG[C/T] [G/G] Y***     
AmpB-R               
GENEDB|LMXM 5445 N Intro 907 6352 7503 LmxM.18 - NA NA NA NA NA     
189 
 
.18 nic .0020 
GENEDB|LMXM
.18 
5569 N Intro
nic 
783 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
5691 N Intro
nic 
661 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
6197 N Intro
nic 
155 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
6333 N Intro
nic 
19 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
GENEDB|LMXM
.18 
6466 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 TT[T/C] [F/F] Y     
GENEDB|LMXM
.18 
7025 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 A[A/G]C [N/S] N     
GENEDB|LMXM
.18 
7072 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 GG[C/T] [G/G] Y***     
GENEDB|LMXM
.18 
7330 Y Exon
ic 
NA 6352 7503 LmxM.18
.0020 
- -1 ^0 GT[C/T] [V/V] Y***     
GENEDB|LMXM
.18 
7627 N Intro
nic 
124 6352 7503 LmxM.18
.0020 
- NA NA NA NA NA     
                  
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_128252 GeneDB|Lm
xM.18 
2 1 6351 7503 2.573 53.331 166002 1.29 2.6 LmxM.18.
0020 
Diphosphomeval
onate 
decarboxylase, 
putative 
53.3315 1660
02 
46.29 1 2 
AmpB-R               
OG5_128252 GeneDB|Lm
xM.18 
2 1 6351 7503 2.163 44.266 152238 1.08 2.2 LmxM.18.
0020 
Diphosphomeval
onate 
decarboxylase, 
putative 
44.2661 1522
38 
38.43 1 2 
                  
6. Isopentenyl-diphosphate delta-isomerase LmxM.34.5330 
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Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
St
ra
n
d
 s
en
se
 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
C
o
d
o
n
 
Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.34 
1930162 N Intro
nic 
298 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931192 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 [G/C]CT [A/P] N     
GENEDB|LMXM
.34 
1931194 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 GC[T/G] [A/A] Y***     
GENEDB|LMXM
.34 
1931272 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 CT[G/A] [L/L] Y***     
GENEDB|LMXM
.34 
1931368 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 AC[A/G] [T/T] Y***     
GENEDB|LMXM
.34 
1931437 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 AT[C/G] [I/M] N     
GENEDB|LMXM
.34 
1931567 N Intro
nic 
37 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931605 N Intro
nic 
75 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931615 N Intro
nic 
85 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931818 N Intro
nic 
288 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931908 N Intro
nic 
378 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931974 N Intro
nic 
444 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
AmpB-R               
GENEDB|LMXM
.34 
1930162 N Intro
nic 
298 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1930424 N Intro
nic 
36 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931192 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 [G/C]CT [A/P] N     
GENEDB|LMXM
.34 
1931194 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 GC[T/G] [A/A] Y***     
GENEDB|LMXM
.34 
1931272 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 CT[G/A] [L/L] Y***     
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GENEDB|LMXM
.34 
1931368 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 AC[A/G] [T/T] Y***     
GENEDB|LMXM
.34 
1931437 Y Exon
ic 
NA 1930
460 
1931
530 
LmxM.34
.5330 
+ 2 1 AT[C/G] [I/M] N     
GENEDB|LMXM
.34 
1931567 N Intro
nic 
37 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931605 N Intro
nic 
75 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931615 N Intro
nic 
85 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931818 N Intro
nic 
288 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931908 N Intro
nic 
378 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
GENEDB|LMXM
.34 
1931974 N Intro
nic 
444 1930
460 
1931
530 
LmxM.34
.5330 
+ NA NA NA NA NA     
                  
OrthomclID Chromosom
e 
Chro
moso
me 
Ploidy 
# 
Gene
s in 
Ref 
Region 
Start 
Regio
n End 
CN 
total 
mean 
coverage 
mean 
fpkm 
Haploid 
Numbe
r 
Gene 
Dose 
Gene 
List 
Description total 
coverage 
total 
fpkm 
covera
ge per 
kb 
Rou
nded 
Hapl
oid 
Roun
ded 
Gene 
Dose 
WT               
OG5_131452 GeneDB|Lm
xM.34 
2 1 1930459 1931
530 
1.937 45.672 141239 0.97 1.9 LmxM.3
4.5330 
Isomerase, 
putative,isopent
enyl-
diphosphate 
delta-isomerase, 
putative 
45.6724 1412
39 
42.64 1 2 
AmpB-R               
OG5_131452 GeneDB|Lm
xM.34 
2 1 1930459 1931
530 
2.225 49.84 170316 1.11 2.2 LmxM.3
4.5330 
Isomerase, 
putative,isopent
enyl-
diphosphate 
delta-isomerase, 
putative 
49.8402 1703
16 
46.54 1 2 
                  
7. Farnesyl pyrophosphate synthase FPPS LmxM.22.1360 
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Chromsome 
Number 
SNP Position Withi
n CDS 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
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o
f 
cu
rr
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t 
C
D
S 
En
d
 o
f 
cu
rr
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t 
C
D
S 
G
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e 
ID
 
co
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rr
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t 
C
D
S 
St
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n
d
 s
en
se
 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.22 
563569 N Intro
nic 
1342 5649
11 
5659
99 
LmxM.22
.1360 
- NA NA NA NA NA     
GENEDB|LMXM
.22 
566244 N Intro
nic 
245 5649
11 
5659
99 
LmxM.22
.1360 
- NA NA NA NA NA     
AmpB-R               
GENEDB|LMXM
.22 
566244 N Intro
nic 
245 5649
11 
5659
99 
LmxM.22
.1360 
- NA NA NA NA NA     
                  
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_127590 GeneDB|Lm
xM.22 
2 1 564910 5659
99 
2.497 49.995 157763 1.25 2.5 LmxM.22.
1360 
Farnesyl 
pyrophosphate 
synthase, 
putative 
49.9953 1577
63 
45.91 1 2 
AmpB-R               
OG5_127590 GeneDB|Lm
xM.22 
3 1 564910 5659
99 
2.604 77.471 267691 0.87 2.6 LmxM.22.
1360 
Farnesyl 
pyrophosphate 
synthase, 
putative 
77.4711 2676
91 
71.14 1 3 
                  
8. Prenyltransferase, putative LmxM.28.1320 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
193 
 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_127332 GeneDB|Lm
xM.28 
2 1 481248 4827
18 
2.319 52.357 161148 1.16 2.3 LmxM.28.13
20 
Prenyltransferas
e, putative 
52.357 1611
48 
35.62 1 2 
AmpB-R               
OG5_127332 GeneDB|Lm
xM.28 
2 1 481248 4827
18 
2.399 52.484 178820 1.2 2.4 LmxM.28.13
20 
Prenyltransferas
e, putative 
52.484 1788
20 
35.7 1 2 
                  
9. Farnesyl pyrophosphate synthetase|solanesyl diphosphate synthase LmxM.15.1020 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_126937 GeneDB|Lm
xM.15 
2 1 402341 4034
21 
1.864 32.516 105814 0.93 1.9 LmxM.15.10
20 
Farnesyl 
synthetase, 
putative 
32.5158 1058
14 
30.11 1 2 
AmpB-R               
OG5_126937 GeneDB|Lm
xM.15 
2 1 402341 4034
21 
1.791 31.791 114328 0.9 1.8 LmxM.15.10
20 
Farnesyl 
synthetase, 
putative 
31.791 1143
28 
29.44 1 2 
                  
10. Geranylgeranyl transferase type II beta subunit, putative LmxM.33.4030 
No SNPs in WT                  
No SNPs in 
AmpB-R 
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OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_127744 GeneDB|Lm
xM.33 
2 1 1526900 1527
893 
1.674 39.131 124080 0.84 1.7 LmxM.33.40
30 
Geranylgeranyltr
ansferase, 
putative 
39.1313 1240
80 
39.41 1 2 
AmpB-R               
OG5_127744 GeneDB|Lm
xM.33 
2 1 1526900 1527
893 
1.768 38.364 135228 0.88 1.8 LmxM.33.40
30 
Geranylgeranyltr
ansferase, 
putative 
38.3642 1352
28 
38.63 1 2 
                  
11. Squalene synthase | farnesyl transferase LmxM.30.2940 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_129470 GeneDB|Lm
xM.30 
4 1 1342726 1343
971 
2.669 125.114 379380 0.67 2.7 LmxM.30.29
40 
Farnesyltransfer
ase, putative 
125.114 3793
80 
100.49 1 4 
AmpB-R               
OG5_129470 GeneDB|Lm
xM.30 
4 1 1342726 1343
971 
2.859 134.369 449052 0.71 2.9 LmxM.30.29
40 
Farnesyltransfer
ase, putative 
134.369 4490
52 
107.93 1 4 
                  
12. Squalene monooxygenase LmxM.13.1620 
No SNPs in WT                  
No SNPs in 
AmpB-R 
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OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_129832 GeneDB|Lm
xM.13 
3 1 571618 5733
28 
2.806 96.015 297034 0.94 2.8 LmxM.13.16
20 
Squalene 
monooxygenase-
like protein 
96.0149 2970
34 
56.15 1 3 
AmpB-R               
OG5_129832 GeneDB|Lm
xM.13 
3 1 571618 5733
28 
2.715 78.298 268588 0.91 2.7 LmxM.13.16
20 
Squalene 
monooxygenase-
like protein 
78.298 2685
88 
45.79 1 3 
                  
13. Lanosterol synthase LmxM.06.0650 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_127966 GeneDB|Lm
xM.06 
2 1 230609 2336
18 
1.806 40.944 136592 0.9 1.8 LmxM.06.06
50 
Lanosterol 
synthase, 
putative 
40.9442 1365
92 
13.61 1 2 
AmpB-R               
OG5_127966 GeneDB|Lm
xM.06 
2 1 230609 2336
18 
1.787 28.007 103714 0.89 1.8 LmxM.06.06
50 
Lanosterol 
synthase, 
putative 
28.0074 1037
14 
9.31 1 2 
                  
14. Sterol 14-alpha (lanosterol) demethylase (CP51) LmxM.11.1100 
196 
 
Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
Strand 
sense 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.11 
441733 N Intro
nic 
1040 4427
73 
4442
12 
LmxM.11
.1100 
+ NA NA NA NA NA     
GENEDB|LMXM
.11 
441733 N Intro
nic 
1040 4427
73 
4442
12 
LmxM.11
.1100 
+ NA NA NA NA NA     
AmpB-R               
GENEDB|LMXM
.11 
441733 N Intro
nic 
1040 4427
73 
4442
12 
LmxM.11
.1100 
+ NA NA NA NA NA     
GENEDB|LMXM
.11 
443299 Y Exon
ic 
NA 4427
73 
4442
12 
LmxM.11
.1100 
+ 2 0 A[A/T]C [N/I] N     
                  
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_129288 GeneDB|Lm
xM.11 
2 1 442772 4442
12 
2.468 53.446 168137 1.23 2.5 LmxM.11.
1100 
Lanosterol 14-
alpha-
demethylase, 
putative 
53.4463 1681
37 
37.12 1 2 
AmpB-R               
OG5_129288 GeneDB|Lm
xM.11 
2 1 442772 4442
12 
2.006 44.519 152519 1 2 LmxM.11.
1100 
Lanosterol 14-
alpha-
demethylase, 
putative 
44.5185 1525
19 
30.92 1 2 
                  
15. C-14 sterol reductase, putative LmxM.31.2320 
197 
 
Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
Strand 
sense 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.31 
906599 N Intro
nic 
39 9066
38 
9079
51 
LmxM.31
.2320 
- NA NA NA NA NA     
AmpB-R               
GENEDB|LMXM
.31 
906599 N Intro
nic 
39 9066
38 
9079
51 
LmxM.31
.2320 
- NA NA NA NA NA     
                  
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
C
N
 t
o
ta
l 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_128488 GeneDB|Lm
xM.31 
2 1 906637 9079
51 
2.12 47.956 150211 1.06 2.1 LmxM.31.
2320 
C-14 sterol 
reductase, 
putative 
47.9563 1502
11 
36.5 1 2 
AmpB-R               
OG5_128488 GeneDB|Lm
xM.31 
2 1 906637 9079
51 
1.927 42.383 146660 0.96 1.9 LmxM.31.
2320 
C-14 sterol 
reductase, 
putative 
42.383 1466
60 
32.25 1 2 
                  
16. NAD(p)-dependent steroid dehydrogenase-like protein LmxM.06.0350 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
198 
 
WT               
OG5_128811 GeneDB|Lm
xM.06 
2 1 118081 1191
73 
5.48 139.392 414527 2.74 5.5 LmxM.06.03
50 
NAD(p)-
dependent 
steroid 
dehydrogenase-
like protein 
139.392 4145
27 
127.65 3 6 
AmpB-R               
OG5_128811 GeneDB|Lm
xM.06 
2 1 118081 1191
73 
3.909 69.779 226937 1.95 3.9 LmxM.06.03
50 
NAD(p)-
dependent 
steroid 
dehydrogenase-
like protein 
69.7792 2269
37 
63.9 2 4 
                  
17. Sterol 24-c-methyltransferase LmxM.36.2380 | LmxM.36.2390 
Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
Region 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
Strand 
sense 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.20 
951390 Y Exonic NA 9504
30 
9514
91 
LmxM.36
.2380 
+ 3 1 [G/A]TT [V/I] N     
GENEDB|LMXM
.20 
951814 N Intronic 323 9504
30 
9514
91 
LmxM.36
.2380 
+ NA NA NA NA NA     
GENEDB|LMXM
.20 
955152 Y Exonic NA 9541
92 
9552
53 
LmxM.36
.2390 
+ 3 1 [G/A]TT [V/I] N     
AmpB-R               
GENEDB|LMXM
.20 
950820 Y Exonic NA 9504
30 
9514
91 
LmxM.36
.2380 
+ 3 1 [G/A]TC [V/I] N     
GENEDB|LMXM
.20 
951390 Y Exonic NA 9504
30 
9514
91 
LmxM.36
.2380 
+ 3 1 [G/A]TT [V/I] N     
GENEDB|LMXM
.20 
951793 N Intronic 302 9504
30 
9514
91 
LmxM.36
.2380 
+ NA NA NA NA NA     
GENEDB|LMXM
.20 
951814 N Intronic 323 9504
30 
9514
91 
LmxM.36
.2380 
+ NA NA NA NA NA     
GENEDB|LMXM
.20 
955152 Y Exonic NA 9541
92 
9552
53 
LmxM.36
.2390 
+ 3 1 [G/A]TT [V/I] N     
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OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_129172 GeneDB|Lm
xM.20 
2 2 950429 9552
53 
3.133 36.467 114546 1.57 3.1 LmxM.36.
2380, 
LmxM.36.
2390 
Sterol 24-c-
methyltransferas
e, putative 
72.934 2290
92 
15.12 2 4 
AmpB-R               
OG5_129172 GeneDB|Lm
xM.20 
2 2 950429 9552
53 
3.541 39.295 135564.5 1.77 3.5 LmxM.36.
2380, 
LmxM.36.
2390 
Sterol 24-c-
methyltransferas
e, putative 
78.5893 2711
29 
16.29 2 4 
                  
18. C8-sterol isomerase LmxM.08_29.2140 
Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
Strand 
sense 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.08 
256270 N Intronic 2872 2591
42 
2598
13 
LmxM.08
_29.2140 
+ NA NA NA NA NA     
GENEDB|LMXM
.08 
260427 N Intronic 614 2591
42 
2598
13 
LmxM.08
_29.2140 
+ NA NA NA NA NA     
AmpB-R               
GENEDB|LMXM
.08 
256270 N Introni
c 
2872 2591
42 
2598
13 
LmxM.08
_29.2140 
+ NA NA NA NA NA     
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OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_131051 GeneDB|Lm
xM.08 
2 1 259141 2598
13 
1.931 43.822 132965 0.97 1.9 LmxM.08_
29.2140 
C-8 sterol 
isomerase-like 
protein 
43.8216 1329
65 
65.21 1 2 
AmpB-R               
OG5_131051 GeneDB|Lm
xM.08 
2 1 259141 2598
13 
2.276 51.72 171371 1.14 2.3 LmxM.08_
29.2140 
C-8 sterol 
isomerase-like 
protein 
51.7203 1713
71 
76.96 1 2 
                  
19. Lathosterol oxidase-like protein |C5 sterol desaturase LmxM.23.1300 
Chromsome 
Number 
SNP Position 
W
it
h
in
 C
D
S 
R
eg
io
n
 
D
is
ta
n
ce
 t
o
 
th
e 
n
ea
re
st
 
C
D
S 
St
ar
t 
o
f 
cu
rr
en
t 
C
D
S 
En
d
 o
f 
cu
rr
en
t 
C
D
S 
G
en
e 
ID
 
co
n
ta
in
in
g 
 
cu
rr
en
t 
C
D
S 
Strand 
sense 
Es
ti
m
at
ed
 
R
ea
d
in
g 
Fr
am
e 
Es
ti
m
at
ed
 
N
u
m
b
er
 o
f 
St
o
p
 C
o
d
o
n
s 
Codon Amino Acid 
sy
n
o
n
ym
o
u
s 
    
WT               
GENEDB|LMXM
.23 
598377 N Intro
nic 
1175 5962
94 
5972
02 
LmxM.23
.1300 
+ NA NA NA NA NA     
AmpB-R               
GENEDB|LMXM
.23 
598377 N Intro
nic 
1175 5962
94 
5972
02 
LmxM.23
.1300 
+ NA NA NA NA NA     
                  
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_129040 GeneDB|Lm
xM.23 
2 1 596293 5972
02 
3.324 75.912 226314 1.66 3.3 LmxM.23.
1300 
Lathosterol 
oxidase-like 
75.9121 2263
14 
83.51 2 4 
201 
 
protein 
AmpB-R               
OG5_129040 GeneDB|Lm
xM.23 
2 1 596293 5972
02 
3.22 71.364 234356 1.61 3.2 LmxM.23.
1300 
Lathosterol 
oxidase-like 
protein 
71.3637 2343
56 
78.51 2 4 
                  
                  
20. C-22 sterol desaturase|cytochrome p450-like protein LmxM.29.3550 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
                  
OrthomclID 
C
h
ro
m
o
so
m
e 
C
h
ro
m
o
so
m
e 
P
lo
id
y 
# 
G
en
es
 in
 
R
ef
 
R
eg
io
n
 S
ta
rt
 
R
eg
io
n
 E
n
d
 
CN 
total 
mean 
coverage 
mean 
fpkm 
H
ap
lo
id
 
N
u
m
b
er
 
Gene 
Dose 
Gene List Description total 
coverage 
total 
fpkm 
co
ve
ra
ge
 p
er
 
kb
 
R
o
u
n
d
ed
 
H
ap
lo
id
 
R
o
u
n
d
ed
 
G
en
e 
D
o
se
 
WT               
OG5_131167 GeneDB|Lm
xM.29 
2 1 1268313 1269
843 
2.401 54.542 168044 1.2 2.4 LmxM.29.35
50 
Cytochrome 
p450-like protein 
54.5424 1680
44 
35.65 1 2 
AmpB-R               
OG5_131167 GeneDB|Lm
xM.29 
2 1 1268313 1269
843 
2.528 55.445 187039 1.26 2.5 LmxM.29.35
50 
Cytochrome 
p450-like protein 
55.4446 1870
39 
36.24 1 2 
                  
                  
21. C-24 sterol desaturase LmxM.32.0680 
No SNPs in WT                  
No SNPs in 
AmpB-R 
                 
WT               
OG5_132400 GeneDB|Lm
xM.32 
2 1 228539 2300
30 
3.303 80.178 240526 1.65 3.3 LmxM.32.06
80 
Sterol C-24 
reductase, 
putative 
80.1776 2405
26 
53.77 2 4 
202 
 
AmpB-R               
OG5_132400 GeneDB|Lm
xM.32 
2 1 228539 2300
30 
3.106 71.831 236890 1.55 3.1 LmxM.32.06
80 
Sterol C-24 
reductase, 
putative 
71.8314 2368
90 
48.18 2 4 
Data analysis by Dr. Manikhandan Mudaliar - Glasgow Polyomics. 
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Appendix F: L. mexicana lanosterol 14α-
demethylase gene and enzyme sequences 
LmxM.11.1100, A to T non-synonymous mutation, Forward strand. 
ATGATCGGCGAGCTTCTCCTTCTCCTGACCGCCGGTCTGGCGCTGTACGGCTGGTACTTC 
TGCAAGTCCTTCAACACAACCCGTCCGACCGATCCGCCGGTCATTCACTGCACGACGCCT 
TTTGTGGGTCACATCATCCAGTTCGGCAAGGATCCCCTGGGCTTTATGTTGAGTGCGAAG 
AAGAAGTACGGCGGCATATTCACCATGAACATCTGCGGCAACCGCATCACTATTGTTGGT 
GACGTTCACCAGCACAGCAAGTTCTTCACCCCGCGTAACGAGATTCTCTCCCCGCGTGAG 
GTCTACAGCTTCATGGTGCCCGTCTTTGGCGAGGGCGTCGCCTACGCCGCGCCGTACCCG 
CGCATGCGCGAGCAGCTCAACTTCCTGGCCGAGGAGCTGACTGTGGCCAAGTTCCAGAAC 
TTCGCTCCATCGATCCAGCACGAGGTGCGCAAGTTTATGAAGGCGAACTGGGACAAGGAC 
GAAGGCGAGATCAACATCCTCGACGACTGCAGCGCCATGATCATCAACACCGCTTGCCAG  
TGCCTCTTCGGCGAGGACCTGCGCAGGCGCCTGGACGCGCGCCAGTTCGCACAGCTGCTG 
GCCAAGATGGAGACCTGCCTCATCCCCGCCGCTGTCTTCCTGCCGTGGATCCTGAAACTG 
CCGCTGCCTCAGTCCTACCGCTGCCGCGACGCCCGCGCTGAGCTGCAGGAAATCCTCAGC 
GAGATTATCATCGCTCGCGAGAAGGAGGAAGCTCAGAAGGACAGCAACACGTCGGACCTG 
CTCGCCGGTCTGCTGGGCGCCGTGTACCGCGATGGCACCCGCATGTCTCAGCACGAGGTG 
TGCGGAATGATCGTTGCCGCCATGTTTGCTGGCCAGCACACCTCCACTATTACCACCACC 
TGGTCCCTCCTGCATCTGATGGATCCTCGCAACAAGAGGCACCTCGCGAAACTGCATCAG 
GAGATCGACGAGTTCCCGGCGCAGCTGAACTACGACAACGTCATGGAGGAGATGCCGTTT 
GCGGAGCAGTGCGCGCGCGAGTCGATTCGCCGCGACCCGCCGCTCGTTATGCTCATGCGA 
AAGGTGCTGAAGCCGGTCCAGGTGGGCAAGTACGTCGTGCCAGAGGGCGACATCATCGCC 
TGCTCGCCGCTCCTCTCGCACCAGGATGAGGAGGCATTTCCGAATCCGCGTGAGTGGAAC 
CCAGAGCGCAACATGAAGCTCGTCGACGGTGCCTTCTGCGGCTTTGGTGCCGGCGTCCAC 
AAGTGCATCGGTGAGAAGTTCGGCCTCCTTCAGGTCAAGACGGTGCTGGCGACGGTCTTG 
CGCGACTACGACTTTGAGCTCCTCGGCCCACTGCCGGAACCGAACTACCACACCATGGTG 
GTGGGCCCGACGGCCAGCCAGTGCCGCGTGAAGTACATCAAGAAGAAGGCGGCGGCTTAG 
 
Affected codon by the non-synonymous mutation is underlined and the affected  
nucleotide is shown in bold. 
 
 
 
Lanosterol 14α-demethylase amino acid residue sequence, N176I point mutation 
MIGELLLLLTAGLALYGWYFCKSFNTTRPTDPPVIHCTTPFVGHIIQFGKDPLGFMLSAK 
KKYGGIFTMNICGNRITIVGDVHQHSKFFTPRNEILSPREVYSFMVPVFGEGVAYAAPYP 
RMREQLNFLAEELTVAKFQNFAPSIQHEVRKFMKANWDKDEGEINILDDCSAMIINTACQ 
CLFGEDLRRRLDARQFAQLLAKMETCLIPAAVFLPWILKLPLPQSYRCRDARAELQEILS 
EIIIAREKEEAQKDSNTSDLLAGLLGAVYRDGTRMSQHEVCGMIVAAMFAGQHTSTITTT 
WSLLHLMDPRNKRHLAKLHQEIDEFPAQLNYDNVMEEMPFAEQCARESIRRDPPLVMLMR 
KVLKPVQVGKYVVPEGDIIACSPLLSHQDEEAFPNPREWNPERNMKLVDGAFCGFGAGVH 
KCIGEKFGLLQVKTVLATVLRDYDFELLGPLPEPNYHTMVVGPTASQCRVKYIKKKAAA 
 
The residue affected by the point mutation is shown in bold font and underlined 
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Appendix G: Comparison of lanosterol 14α-
demethylase sequences of trypanosomatids, S. 
cerevisiae and H. sapiens 
 
205 
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The conflicts in sequences are indicated by an asterisk. 
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Appendix H: Two-Dimentional electrophoresis gels 
showing differences in proteins from L. mexicana 
wild-type and AmB resistant cell lines. 
 
Some of the analysed gel spots are shown by a red circle and number of the spot 
corresponding to gel spot numbers in the possible identifications table in 
appendix I. 
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Appendix I: Possible identifications of the gel 2-DE spots from L. mexicana wild-type 
and the derived AmB resistant cell lines. 
Gel 
spot 
# 
Possible protein IDs 
Gene 
accession 
number 
Mascot 
score 
% 
Coverage/
Match 
Nominal 
mass 
Calc 
pI 
Vol. 
Ratio 
R1 hypothetical protein, conserved 
hypothetical protein, conserved 
mitochondrial carrier protein-like protein 
LmxM.34.4470 
LmxM.30.1000 
LmxM.29.1050 
67 
30 
22 
17 
0 
3 
21880 
121698 
37338 
4.20 
4.92 
9.63 
-2.66 
R3 unspecified product 
alpha tubulin 
RNA helicase, putative 
thiol-dependent reductase 1 
hypothetical protein, conserved 
S-adenosylhomocysteine hydrolase 
udp-glc 4'-epimerase, putative 
hypothetical protein, conserved 
peptidase t, putative,peptidase T, putative, metallo-
peptidase, ClanMH, family M20B 
LmxM.08.1171 
LmxM.13.0280 
LmxM.21.1552 
LmxM.32.0240 
LmxM.31.0950 
LmxM.36.3910 
LmxM.32.2300 
LmxM.09.0520 
LmxM.17.0140 
 
307 
119 
85 
49 
31 
29 
25 
22 
22 
 
22 
13 
14 
13 
8 
5 
3 
2 
2 
50319 
61058 
49723 
45700 
102299 
48525 
43972 
87324 
47457 
 
4.71 
5.45 
5.95 
5.65 
5.95 
5.66 
5.68 
6.82 
5.87 
 
2.50 
R4 N-acyl-L-amino acid amidohydrolase 
S-adenosylhomocysteine hydrolase 
udp-glc 4'-epimerase 
RNA helicase 
HSP70-like protein 
LmxM.20.1550 
LmxM.36.3910 
LmxM.32.2300 
LmxM.21.1552 
LmxM.01.0640 
190 
141 
51 
30 
28 
12 
14 
8 
4 
1 
43957 
48525 
43972 
49723 
1302 
5.73 
5.66 
5.68 
5.95 
6.94 
2.55 
R7 hypothetical protein, conserved 
3-oxo-5-alpha-steroid 4-dehydrogenase, putative 
kinesin K39, putative 
hypothetical protein, conserved 
hypothetical protein, conserved 
LmxM.33.2030 
LmxM.25.1770 
LmxM.14.1120 
LmxM.23.1240 
LmxM.36.4790 
28 
27 
20 
17 
16 
2 
3 
1 
0 
1 
131098 
34286 
298624 
79509 
103151 
9.87 
9.62 
4.52 
7.70 
9.56 
3.62 
R8 peptidyl-prolyl cis-trans isomerase, putative 
glutamine synthetase, putative 
hypothetical protein, conserved 
fructose-1,6-bisphosphate aldolase 
hypothetical protein, conserved 
alpha tubulin 
LmxM.34.4770 
LmxM.06.0370 
LmxM.29.3090 
LmxM.36.1260 
LmxM.25.1220 
LmxM.13.0280 
316 
86 
57 
40 
27 
21 
42 
9 
5 
4 
1 
1 
39005 
42893 
35504 
41150 
884 
61058 
5.57 
5.71 
5.72 
8.97 
8.27 
5.45 
4.18 
209 
 
R9 actin 
axoneme central apparatus protein 
hypothetical protein, conserved 
hypothetical protein, conserved 
farnesyl pyrophosphate synthase, putative 
alpha tubulin 
fructose-1,6-bisphosphate aldolase 
hypothetical protein, conserved 
LmxM.04.1230 
LmxM.20.1400 
LmxM.07.0640 
LmxM.29.0560 
LmxM.22.1360 
LmxM.13.0280 
LmxM.36.1260 
LmxM.20.0970 
105 
146 
128 
46 
32 
29 
28 
17 
36 
8 
17 
2 
4 
1 
11 
2 
40685 
55699 
55699 
38162 
41460 
61058 
41150 
39482 
5.83 
5.49 
5.42 
5.58 
5.42 
5.45 
8.97 
5.46 
2.36 
R10 hypothetical protein, conserved 
adenosine kinase, putative 
heat shock protein 83-1 
alanyl-tRNA synthetase, putative 
3'-nucleotidase/nuclease, putative 
hypothetical protein, conserved 
unspecified product 
helicase-like protein 
cis-prenyltransferase-like protein 
hypothetical protein, conserved 
LmxM.10.1280 
LmxM.29.0880 
LmxM.32.0312 
LmxM.22.1540 
LmxM.12.0400 
LmxM.25.2290 
LmxM.08.1171 
LmxM.28.1600 
LmxM.13.0020 
LmxM.30.1000 
388 
149 
33 
33 
32 
27 
26 
25 
25 
23 
46 
20 
1 
1 
9 
4 
8 
0 
2 
0 
35957 
37766 
81035 
106668 
41121 
33755 
50319 
123221 
44180 
121698 
5.31 
5.21 
5.04 
5.52 
5.24 
8.68 
4.71 
8.94 
8.47 
4.92 
2.32 
R11 pyruvate dehydrogenase E1 beta subunit, putative 
glyceraldehyde 3-phosphate dehydrogenase, glycosomal 
eukaryotic translation initiation factor 3 subunit, putative 
hypothetical protein, conserved 
hypothetical protein, conserved 
LmxM.25.1710 
LmxM.29.2980 
LmxM.36.3880 
LmxM.24.0960 
LmxM.30.1000 
216 
123 
56 
30 
26 
37 
27 
2 
0 
2 
38476 
39326 
38805 
108178 
121698 
5.42 
9.1 
5.21 
9.27 
4.92 
4.08 
R16 hypothetical protein, conserved 
glutamate dehydrogenase 
LmxM.30.2990 
LmxM.15.1010 
40 
36 
0 
2 
214988 
115208 
6.25 
7.88 
2.34 
R19 hypothetical protein, conserved 
hypothetical protein, conserved 
hypothetical protein, unknown function 
LmxM.22.0800 
LmxM.30.1000 
LmxM.11.0940 
61 
24 
18 
10 
0 
0 
24068 
121698 
154771 
5.57 
4.92 
9.58 
2.39 
R21 heat shock protein, putative 
elongation factor 2 
hypothetical protein, unknown function 
 
hypothetical protein, conserved 
aconitase, putative 
LmxM.18.1370 
LmxM.36.0180 
LmxM.08_29.12
40 
LmxM.07.0310 
LmxM.18.0510 
246 
160 
93 
 
60 
62 
18 
15 
3 
 
3 
3 
92808  
94852 
80327 
 
90007 
98265 
5.09 
5.77 
5.32 
 
5.54 
6.75 
-3.02 
Wt2 protein kinase, putative 
aldo/keto reductase, putative,aldo/keto reductase family-like 
protein 
LmxM.08.0930 
LmxM.26.1210 
22 
16 
0 
3 
122349 
45466 
7.80 
7.28 
3.59 
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Wt3 alpha tubulin 
aconitase, putativehypothetical protein, conserved 
hypothetical protein, conserved 
hypothetical protein, conserved 
calpain-like cysteine peptidase, putative,cysteine peptidase, 
Clan CA, family C2, putative 
LmxM.13.0280 
LmxM.18.0510 
LmxM.31.0950 
LmxM.24.0960 
LmxM.31.0970 
473 
240 
34 
27 
22 
35 
1 
4 
0 
0 
61058 
98265 
102299 
108178 
202700 
5.45 
6.75 
5.95 
9.27 
6.24 
2.50 
Wt4 alpha tubulin 
unspecified product 
thiol-dependent reductase 1 
3'-nucleotidase/nuclease RNA helicase, putative 
hypothetical protein, unknown function 
hypothetical protein, conserved 
hypothetical protein, conserved 
LmxM.13.0280 
LmxM.08.1171 
LmxM.32.0240 
LmxM.36.3910 
LmxM.26.2680 
LmxM.25.2290 
LmxM.09.0520 
268 
182 
61 
60 
26 
25 
21 
28 
15 
4 
2 
2 
4 
5 
61058 
50319 
45700 
48525 
41239 
33755 
87324 
5.45 
4.71 
5.65 
5.66 
5.26 
8.68 
6.82 
2.55 
Wt5 unspecified product 
beta tubulin 
alpha tubulin 
40S ribosomal protein S4, putative 
14-3-3 protein, putative 
hypothetical protein, conserved 
60S ribosomal protein L2, putative 
LmxM.08.1171 
LmxM.21.1860 
LmxM.13.0280 
LmxM.13.1220 
LmxM.11.0350 
LmxM.36.4230 
LmxM.31.3900 
597 
467 
271 
161 
73 
55 
35 
38 
32 
21 
21 
10 
1 
12 
50319 
50394 
61058 
48291 
29414 
119323 
28597 
4.71 
4.74 
5.45 
9.97 
5.19 
4.91 
10.7 
2.55 
Wt6 unspecified product 
alpha tubulin 
40S ribosomal protein S4, putative 
40S ribosomal protein S6, putative 
LmxM.08.1171 
LmxM.13.0280 
LmxM.13.1220 
LmxM.21.1780 
244 
97 
55 
30 
23 
7 
5 
6 
50319 
61058 
48291 
28302 
4.71 
5.45 
9.97 
11.4 
2.27 
Wt9 Actin 
axoneme central apparatus protein, putative 
40S ribosomal protein S4, putative 
elongation factor 1-alpha 
cysteinyl-tRNA synthetase, putative 
cysteine conjugate beta-lyase, aminotransferase- like 
protein 
minchromosome maintenance (MCM) complex subunit, 
putative 
LmxM.04.1230 
LmxM.20.1400 
LmxM.13.1220 
LmxM.17.0080 
LmxM.12.0250 
LmxM.32.1330 
 
LmxM.24.0910 
 
220 
91 
53 
52 
38 
33 
 
27 
38 
5 
4 
1 
11 
8 
 
0 
40685 
55699 
48291 
49575 
88814 
46836 
 
87400 
 
5.83 
5.49 
9.97 
9.03 
5.55 
5.70 
 
8.93 
2.36 
Wt10 alpha tubulin 
dihydroorotate dehydrogenase, putative 
succinyl-CoA ligase [GDP-forming] beta-chain, putative 
elongation factor 2 
LmxM.13.0280 
LmxM.16.0530 
LmxM.36.2950 
LmxM.36.0180 
337 
71 
49 
41 
16 
6 
10 
5 
61058 
34287 
44526 
94852 
5.45 
5.48 
6.77 
5.77 
2.32 
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hypothetical protein, conserved 
protein phosphatase 2C-like protein 
pyruvate dehydrogenase E1 beta subunit, putative 
hypothetical protein, conserved 
LmxM.34.5340 
LmxM.36.0530 
LmxM.25.1710 
LmxM.31.1700 
39 
37 
29 
18 
6 
4 
3 
0 
39265 
33468 
38476 
90069 
5.31 
5.30 
5.42 
9.08 
Wt11 mannose-1-phosphate guanyltransferase 
unspecified product 
elongation factor 2 
S-adenosylmethionine synthetase 
heat-shock protein hsp70, putative 
alpha tubulin 
hypothetical protein, conserved 
glyceraldehyde 3-phosphate dehydrogenase, glycosomal 
pyruvate dehydrogenase E1 beta subunit, putative 
glutamine synthetase, putative 
hypothetical protein, conserved 
LmxM.23.0110 
LmxM.08.1171 
LmxM.36.0180 
LmxM.29.3500 
LmxM.28.2770 
LmxM.13.0280 
LmxM.24.0960 
LmxM.29.2980 
LmxM.25.1710 
LmxM.06.0370 
LmxM.33.2920 
984 
234 
68 
38 
35 
32 
31 
31 
28 
25 
15 
53 
14 
5 
7 
2 
6 
0 
1 
8 
6 
8 
41849 
50319 
94852 
43558 
71482 
61058 
108178 
39326 
38476 
42893 
10474 
5.29 
4.71 
5.77 
5.42 
5.34 
5.45 
9.27 
9.18 
5.42 
5.71 
9.71 
4.8 
Wt12 mannose-1-phosphate guanyltransferase 
heat shock 70-related protein 1, mitochondrial precursor, 
putative 
40S ribosomal protein S3A, putative 
unspecified product 
isocitrate dehydrogenase, putative 
elongation factor 1-beta 
hypothetical protein, conserved 
ATP synthase F1 subunit gamma protein, putative 
alpha tubulin 
hypothetical protein, conserved 
LmxM.23.0110 
LmxM.29.2490 
 
LmxM.34.0400 
 
LmxM.32.2550 
LmxM.33.0820 
LmxM.24.0960 
LmxM.21.1770 
LmxM.13.0280 
LmxM.02.0460 
134 
69 
 
46 
 
39 
30 
30 
30 
27 
24 
10 
7 
 
6 
 
6 
15 
0 
10 
6 
3 
41849 
72990 
 
30245 
 
46754 
26061 
108178 
34671 
61058 
32685 
5.29 
5.68 
 
10.3 
 
5.51 
5.00 
9.27 
9.29 
5.45 
8.87 
2.06 
Wt13 alpha tubulin 
heat-shock protein hsp70, putative 
hs1vu complex proteolytic subunit-like,hs1vu complex 
proteolytic subunit-like, threonine peptidase, Clan T(1), 
family T1B 
Malic enzyme 
40S ribosomal protein S8, putative 
hypothetical protein, conserved 
LmxM.13.0280 
LmxM.28.2770 
 
 
LmxM.36.3990 
LmxM.24.0761 
LmxM.24.2070 
LmxM.33.2580 
308 
120 
 
 
70 
67 
33 
32 
16 
12 
 
 
9 
8 
5 
5 
61058 
71482 
 
 
24793 
62922 
24729 
22615 
5.45 
5.34 
 
 
6.09 
5.79 
11.4 
9.90 
4.64 
Wt14 alpha tublin 
hypothetical protein, conserved 
hypothetical protein, conserved 
LmxM.13.0280 
LmxM.34.5340 
LmxM.24.0960 
102 
64 
27 
12 
9 
0 
61058 
39265 
108178 
5.45 
5.31 
9.27 
4.23 
212 
 
calpain-like protein, putative,cysteine peptidase, Clan CA, 
family C2, putative 
cytochrome c oxidase assembly factor, putative 
hypothetical protein, conserved 
LmxM.30.0400 
LmxM.04.1130 
LmxM.34.3720 
25 
24 
23 
0 
3 
3 
104139 
33701 
50938 
7.07 
5.61 
5.93 
Wt15 1. eukaryotic translation initiation factor 6 (eIF-6), putative 
2. hypothetical protein, conserved 
3. unspecified product 
4. acyl-coenzyme a dehydrogenase, putative 
LmxM.36.0890 
LmxM.36.6760 
LmxM.08.1171 
LmxM.06.0880 
281 
80 
70 
44 
57 
29 
8 
3 
27454 
29148 
50319 
45641 
5.05 
5.37 
4.71 
7.97 
4.27 
Wt16 1. cystathione gamma lyase, putative 
2. vacuolar ATP synthase subunit b, putative 
3. seryl-tRNA synthetase, putative 
4. hypothetical protein, conserved 
5. hypothetical protein, conserved 
6. eukaryotic translation initiation factor 6 (eIF-6), putative 
LmxM.34.3230 
LmxM.28.2430 
LmxM.11.0100 
LmxM.30.1000 
LmxM.31.1700 
LmxM.36.0890 
 
158 
52 
49 
27 
21 
18 
 
12 
4 
4 
2 
0 
6 
45102 
55837 
53671 
121698 
90069 
27454 
 
6.05 
5.72 
5.29 
4.92 
9.08 
5.05 
 
2.34 
Wt17 coatomer epsilon subunit, putative 
alpha tubulin 
unspecified product 
elongation factor 1-alpha 
LmxM.31.1730 
LmxM.13.0280 
LmxM.08.1171 
LmxM.17.0080 
578 
298 
185 
91 
56 
22 
18 
13 
35083 
61058 
50319 
49575 
5.11 
5.45 
4.71 
9.03 
2.68 
Wt18 1. unspecified product 
2. alpha tubulin 
3. peptidase m20/m25/m40 family-like protein 
4. mannose-1-phosphate guanyltransferase 
5. hypothetical protein, conserved 
6. phosphodiesterase, putative 
LmxM.08.1171 
LmxM.13.0280 
LmxM.30.1890 
LmxM.23.0110 
LmxM.30.1000 
LmxM.18.1090 
217 
97 
34 
22 
20 
18 
17 
14 
15 
8 
0 
1 
50319 
61058 
37608 
41849 
121698 
71449 
4.71 
5.45 
5.10 
5.29 
4.92 
5.48 
4.33 
Wt20 alpha tubulin 
hypothetical protein, conserved 
dihydroorotate dehydrogenase, putative 
hypothetical protein, conserved 
40S ribosomal protein S3A, putative 
unspecified product 
LmxM.13.0280 
LmxM.33.0230 
LmxM.16.0530 
LmxM.26.0870 
LmxM.34.0400 
LmxM.08.1171 
446 
74 
38 
28 
20 
19 
20 
2 
3 
1 
5 
4 
61058 
81890 
34287 
80727 
30245 
50319 
5.45 
5.42 
5.48 
9.48 
10.3 
4.71 
3.30 
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Appendix J: Chromatograms of the sterol 
metabolites detected in wild-type AmB resistant 
and re-expressor L. mexicana cell lines. 
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The chromatographic resolution using hydrophilic interaction liquid 
chromatography (HILIC) and is poor. However, the changes in abundance remain 
clear. Chromatography using a C-18 reverse-phase column should now be 
performed to obtain more quantitive information. Absence of a 4α-formyl-4β-
methyl-5α-cholesta-8-24-dien-3β-ol chromatogram for the wild-type means it 
was not detected in the samples derived from the wild-type cells. 
Chromatograms of intensity against retention time of the most changing 
metabolites were constructed using PeakML Viewer 1.0.0 (Scheltema et al., 
2011).   
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